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Abstract 
A major obstacle of many active pharmaceutical compounds is their low ability to cross body 
barriers, especially cell membranes. Cell permeability of a drug is therefore considered as a 
key step for therapeutic efficacy. Over the last decades, different approaches to overcome this 
limitation have been studied intensively. Among these are so-called cell-penetrating peptides 
(CPPs). CPPs are able to autonomously internalize into cells without the need for auxiliary 
proteins. However, not only the cellular uptake is important but also cell selectivity has to be 
addressed. Over the past two decades, cancer research has dramatically evolved, particularly 
with the appearance of targeted molecular therapies and advances in antibody engineering 
that allowed the discovery and validation of innovative molecules, more effective and less 
harmful than conventional chemotherapy. Especially small molecule-drug conjugates, like 
peptide-drug conjugates, became of particular interest since they combine several advantages 
as deep tissue penetration, possibility of cell organelle targeting and relatively easy access by 
chemical synthesis.  
This work focuses on the design and synthesis of an array of tumor-targeting peptide-drug 
conjugates combining known tumor-homing peptides with a well-described CPP and potent 
cytotoxic drugs. The development of these hybrids was followed by a validation of the model 
via in vitro studies where their selectivity towards different cell lines was evaluated. Two 
targeting ligands (GnRH-III and c[DKPf3RGD]) were employed for the conjugation to the CPP 
sC18 and a very straightforward synthesis could be developed in both cases. The conjugates 
maintained a remarkable binding affinity in low nanomolar range towards GnRH and αvβ3 
integrin receptors, respectively, and for further in vitro experiments, the expression of the 
receptors in different cell lines was explored. For the investigation of the final compounds, a 
new in vitro model based on a short contact time with the cells was established in order to 
emphasize the role of the fast CPP-mediated internalization after reversible binding to the 
receptors. While for the GnRH-III-conjugates a selectivity was difficult to detect, the 
c[DKPf3RGD] was identified as very effective targeting moiety for the synthesis of an efficient 
drug delivery system. Different drugs were attached to the CPP and daunorubicin turned out 
to be the most advantageous in terms of simple synthesis and stability. Fluorescence analysis 
demonstrated that the internalization was mainly mediated by the CPP but that the ligand had 
an important role in targeting the surface of the cells overexpressing the receptor. The 
selectivity could also be proved by anti-proliferative assays providing another demonstration 
that with this approach it would be possible to overcome the drawbacks of CPP-mediated drug 
transport leading to higher target selectivity and better bioavailability.  
In the second part of the thesis, cyclic CPPs with peculiar diketopiperazine scaffolds (trans 
DKP3 and cis DKP1) were synthesized starting from the sequence of a truncated variant of 
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sC18. An optimized cyclization strategy could be developed and the secondary structure of 
these peptides was analyzed and compared with the linear counterparts by different 
techniques. The biological activity of these compounds was also evaluated in cell systems 
where the ability to transport cytotoxic drugs inside the cells was explored by using both a 
non-covalent as well as covalent drug coupling approach. Notably, the cycle actually showed 
a higher ability to increase the activity of daunorubicin than the linear CPP, proving that 
cyclization via a diketopiperazine scaffold is a promising strategy to improve CPP-mediated 
drug delivery.  
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Zusammenfassung 
Viele aktive pharmazeutische Verbindungen sind nicht in der Lage Barrieren, insbesondere 
Zellmembranen, ohne Hilfe zu überwinden, um ihren spezifischen Wirkort zu erreichen. Aus 
diesem Grund gilt diese Zellpermeabilität eines Arzneimittels als Schlüsselschritt für die 
therapeutische Wirksamkeit. Um diese Verbindungen zu transportieren, wurden bereits 
verschiedene Strategien etabliert, unter denen sich auch sogenannte zellpenetrierenden 
Peptide (CPP, cell-penetrating peptides) einreihen. CPPs sind in der Lage von einer Vielzahl 
von Zellen aufgenommen zu werden, ohne dabei auf Hilfe von Transportproteinen angewiesen 
zu sein. Aber nicht nur die zelluläre Aufnahme steht im Fokus der Forschung, insbesondere 
die Zellselektivität ist von großem Interesse. In den letzten zwei Jahrzehnten hat sich die 
Krebsforschung stark weiterentwickelt, vor allem durch gezielte molekulare Therapien und 
Fortschritte in der Antikörperentwicklung, die die Entdeckung und Validierung innovativer 
Moleküle ermöglichten, die dadurch sowohl wirksamer als auch weniger schädlich als 
konventionelle Chemotherapien sind. Besonders kleine Molekül-Wirkstoff Konjugate, wie zum 
Beispiel Peptid-Wirkstoff Konjugate, sind vielversprechend, da sie sich durch tiefe 
Gewebepenetration und mögliches Ansteuern verschiedenster Zellkompartimente 
auszeichnen. Desweitern sind diese Konjugate relativ einfach herzustellen und so einfach 
zugänglich. 
Diese Arbeit konzentriert sich auf das Design und die Synthese von Krebs spezifischen Peptid-
Wirkstoff-Konjugaten, bei der ein Peptidfragment, das in der Lage ist ein bestimmte Tumorart 
anzusteuern, mit einem bekannten CPP und einem Zytostatikum kombiniert wird. Nach der 
Herstellung dieser Hybride folgte eine Validierung ihrer Aktivität durch verschiedenste in vitro 
Studien. Zwei spezifische Ziel-Liganden (GnRH-III und c[DKPf3RGD]) wurden für die 
Konjugation an das CPP sC18 verwendet, und in beiden Fällen konnte eine optimierte 
Syntheseroute entwickelt werden. Die Konjugate zeigten eine bemerkenswerte 
Bindungsaffinität im niedrigen nanomolaren Bereich zu GnRH bzw. αvβ3 Integrin-Rezeptoren. 
Für weitere in vitro Experimente wurde außerdem die Expression der Rezeptoren in 
verschiedenen Zelllinien untersucht. Für die Analyse der Verbindungen wurde ein neues in 
vitro Modell etabliert, das auf einer kurzen Kontaktzeit mit den Zellen basiert, um die Rolle der 
schnellen Internalisierung durch das CPP nach der Bindung zu den Rezeptoren zu 
untersuchen. Während für die GnRH-III-Konjugate eine Selektivität schwer nachzuweisen war, 
wurde c[DKPf3RGD] als sehr wirksame Zielgruppe für die Synthese eines effizienten 
Transportsystems identifiziert. Verschiedene Toxine wurden an das CPP gebunden, wobei 
sich Daunorubicin im Hinblick auf die einfache Synthese und Stabilität als das 
vielversprechendste erwies. Aufnahmestudien zeigten, dass die Internalisierung hauptsächlich 
durch das CPP vermittelt wurde, der Ligand jedoch möglicherweise eine wichtige Rolle beim 
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Binden an die Oberfläche der Zellen hatte, die den Rezeptor überexprimieren. Die Selektivität 
konnte auch durch antiproliferative Versuche nachgewiesen werden. Somit liefert der hier 
vorgestellte Ansatz eine mögliche Lösung CPPs mit einer Zellselektivität auszustatten.  
Im zweiten Teil dieser Doktorarbeit wurden verschiedene zyklische CPPs synthetisiert. Dafür 
wurden spezielle Bausteine, basierend auf Diketopiperazinen (trans DKP3 und cis DKP1), 
verwendet. Es konnte eine optimierte Zyklisierungsstrategie entwickelt werden und die 
Sekundärstruktur dieser neuen Peptide wurde durch verschiedene Techniken analysiert und 
mit den linearen Versionen verglichen. Die biologische Aktivität dieser Verbindungen wurde in 
Zellen getestet, dabei stand besonders im Vordergrund, zytotoxische Wirkstoffe in Zellen zu 
schleusen. Die Wirkstoffe wurden dabei sowohl nicht-kovalent als auch kovalent an das Peptid 
gekuppelt. Das zyklische Peptid war in der Lage die Aktivität von Daunorubicin deutlich zu 
verbessern im Vergleich zum linearen Peptid. Dieses Ergebnis unterstreicht, dass die 
Zyklisierung mittels eines Diketopiperazingerüstes zu neuen CPPs mit sehr 
vielversprechenden Aktivitäten führt. 
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1. Introduction 
Over the last year, 18.1 million new cases of cancer have been reported worldwide. In other 
words, one in five men and one in six women is diagnosed with cancer and these numbers 
increase constantly. These data from the Globocan report have been published in the journal 
CA: A Cancer Journal for Clinicians and represent a "photograph" of the diagnoses of cancer 
registered globally. The statistics show an increase in cancer diagnosis, which may be due to 
several factors from the aging of the population to the precarious conditions of social and 
economic development that are recorded in different areas of the planet. This second aspect 
also affects cancer-caused mortality, which in 2018 should be almost about ten million, while 
over 43 million people are expected to live within the five-year prevalence. [1] In fact, research 
has led to increasingly effective therapies with fewer side effects, which in many cases are 
able to reduce mortality. The progresses made in the last century are highlighted in Figure 1. 
The main treatments of tumors are represented by surgical resection, [2] chemotherapy, [3-4] 
radiation therapy [5-6] but also by the more innovative hormone therapies, [7-9] targeted 
therapies, [10-11] immuno-oncology and gene therapy, used individually or in combination. [12-13]  
 
Figure 1. Timeline: milestones in cancer therapy. From traditional to targeted therapies. Adapted from DeVita 
et al. and Chabner et al. [14-15]  
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1.1. Traditional chemotherapy versus targeted chemotherapeutics 
Conventional chemotherapy is still widely applied in cancer treatment. 5-fluorouracil/leucovorin 
and oxaliplatin, for example, are still the gold standard for colorectal cancer, [16] while a regimen 
of cisplatin or carboplatin combined with paclitaxel, gemcitabine or docetaxel is currently used 
for the treatment of non-small cell liver cancer at stage IV. [17] However, the compounds used 
as chemotherapeutic agents localize with low efficiency in solid tumors. This unfavorable 
biodistribution profile, exemplified in Figure 2, combined with a mechanism of non-selective 
action, causes serious side effects and prevents a dose increase at therapeutically active 
regimens. [18]  
 
Figure 2. Unfavorable biodistribution profile of traditional chemotherapeutic drugs. A: Tissue distribution of 
5-Fluorouracil (5-FU) in ascitic hepatoma bearing rats. B: Tissue distribution of 3H-Paclitaxel in Balb/c nude mice 
bearing MDA-MB-435 tumors (melanoma). Adapted from Abe et al. and Cao et al. [19-20]  
Two main approaches have been followed to reach the final goal of widening the therapeutic 
window: the combination of two or more cancer drugs without overlapping mechanism and/or 
toxicity [21] and the introduction of more potent drugs administrated at lower dosage. [22] Both 
strategies could lead to encouraging results in terms of efficacy, although an absolutely positive 
safety profile could not be achieved. Researchers understood that the unique key to completely 
avoid a systemic toxicity was the enhancement of selectivity. Targeted therapies, for instance, 
are interfering in a much more directed way with a molecule or a specific process of cell growth, 
not causing damage to healthy tissues, thus reducing side effects. [23-24] In fact, they selectively 
act on specific cell receptors, hence improving the tolerability of the treatment, to the benefit 
of the patient and his quality of life. [25]  
Targeted therapies represent one of the most important tools of personalized medicine, since 
the treatment is no longer chosen only based on the development of the tumor, but also in 
relation to its molecular characteristics and expression of biomarkers, which can be different 
from patient to patient. [26-30] Many efforts have been made in this field and the results obtained 
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in the last few years are exciting. Even if novel targeted therapies are pioneering and reserved 
for particular types of cancer, they already display an important role in the fight against this 
disease. In fact, many data show that they have prolonged survival and improved the quality 
of life of many patients. [31-33] Over the years a number of directed agents have been used and 
these therapies are able to: 
- manipulate the endocrine system through external administration of precise hormones 
or drugs that inhibit their production (hormone therapy for hormone-dependent 
tumors, e.g. anti-estrogens, [34-36] aromatase inhibitors, [37] GnRH agonists, [38-39] anti-
androgens [40-41]); 
- stimulate the immune system to identify and destroy cancer cells (immuno-oncology); 
[42-43] 
- hinder angiogenesis, [44-45] inhibit tumor-related kinases [46] and other oncoproteins 
(targeted therapy);  
- selectively release toxic substances that act on cancer cells through different ways, e.g 
promoting apoptosis or decreasing their uncontrolled ability to grow and divide 
(targeted delivery). [47-48] 
The last example, in particular, has been proposed as an alternative method to overcome the 
limits of classic chemotherapy, carrying powerful cytotoxic compounds at the tumor site after 
conjugation to ligands that are specific towards tumor-associated targets. [24] The conjugation 
of these pharmacodelivery vehicles with a cytotoxic drug realizes the concept of "magic bullet" 
as it was conceived more than a century ago by Paul Ehrlich (1854-1915), who was awarded 
the Nobel Prize for Medicine in 1908. [49-50] In Figure 3 the peculiar and advantageous 
characteristic of these new compounds is illustrated with a schematic representation of their 
mode of action. The selectivity of these drug-delivery systems is driven by the high binding 
affinity towards particular tumor cell substrates resulting in a moderate occurrence of 
undesirable effects since the healthy cell lines should not be affected. 
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Figure 3. Traditional chemotherapy vs targeted delivery of chemotherapeutics. A: General strategy of 
traditional chemotherapy; B: The “magic bullet” concept. 
Antibody-drug conjugates (ADCs) and small molecule-drug conjugates (SMDCs) represent 
two innovative classes of biopharmaceutical products, designed to selectively bring cytotoxic 
agents to the tumor tissue. They combine the best features of two therapeutic modalities. In 
particular, antibodies and small ligands that display target specificity but limited antitumor 
activity are conjugated to cytotoxic agents, very potent but with poor safety and pharmaceutical 
profiles. The following sections will first focus on three commonly used drugs, which were also 
employed in this work, and will further highlight two novel delivery strategies. 
 
 
 
 
 
 Introduction 
5 
 
1.2. Cytotoxic payloads 
1.2.1. Daunorubicin 
Daunorubicin and doxorubicin are the parent compounds of the anthracycline antibiotics. 
Mostly isolated from natural sources (Streptomyces peucetius), [51] they are extensively used 
for the treatment of cancer alone or in combination and widely investigated as cytotoxic 
payloads in conjugation with tumor homing peptides [52-54] or antibodies. [55-56] In fact, they are 
very effective but also very toxic, as they do not discriminate between malignant and healthy 
cells, leading in particular to cardio-toxicity [57-58] and myelosuppression. From the structural 
point of view, anthracycline antibiotics are characterized by a planar tetracyclic portion, 
glycosidically linked to an aminosugar (daunosamine). The molecular structures of 
daunorubicin and doxorubicin differ only in one of the terminal substituents, as it is shown in 
Figure 4.  
 
Figure 4. Structures of the two anthracycline parent compounds: daunorubicin and doxorubicin. Red box: 
planar tetracyclic portion; blue box: daunosamine; green: hydroxyl group substituent in doxorubicin that is missing 
in daunorubicin. 
Although small, this structural difference has important consequences on the activity spectrum 
of the two cytotoxic antibiotics. Doxorubicin, in fact, has significant clinical applications 
especially in solid tumors, [59-62] while the main indication of daunorubicin is acute leukemia. [63] 
The current tendency is to consider the DNA intercalation as necessary but not sufficient for 
anti-tumor action. [64] In fact, numerous results have indicated topoisomerase II as the main 
anthracycline target. This nuclear enzyme relaxes the supercoiled DNA by the formation of a 
phosphodiester bond between the OH group of its active-site tyrosyl residue and the 
phosphoric group of DNA. This allows the free end of the nucleic acid to rotate, solving the 
supercoiling. At this point the OH group at the free end of the DNA can restore the continuity 
of the helix by attacking the activated phosphate. [65] At present, it is known that anthracyclines, 
after intercalating in the double helix, stabilize a ternary cleavage complex between the DNA, 
tied to the enzyme, and the drug. Therefore the action of the drug leads to irreversible cuts in 
DNA that open the way to the programmed cell death in cancer cells. [66] Two further 
mechanisms were identified as responsible for toxicity, notably the production of free oxygen 
radicals through an enzymatic reduction process [67] and induction of histone eviction from open 
chromatin. [68] 
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1.2.2. Chlorambucil 
Chlorambucil is a chemotherapeutic agent belonging to the class of the so-called alkylating 
drugs, in particular deriving from nitrogen mustards.  
 
Figure 5. Structure of chlorambucil. 
At physiological pH, chlorambucil forms a very reactive cyclic intermediate (aziridinium ion) 
which attacks the nitrogen in position 7 of a guanine, present in the DNA chain, building a 
covalent bond. The same process takes place on the other chain (ClCH2CH2N-) of the 
chlorambucil, which in turn will interact with a new guanine, present in the same or in the other 
DNA helix. Inter or intra helix bridges do not allow anymore DNA to perform its biological 
functions (duplication and transcription). [69-70] The alteration that the chlorambucil induces in 
the DNA prevents the cancer cell from dividing, forcing it to undergo apoptosis. [71] It is mainly 
used for the treatment of chronic lymphocytic leukemia, [72-73] normally in combination with other 
chemotherapeutic agents. As previously described in the case of daunorubicin, chlorambucil 
provokes the common side effects of the non-targeted therapies; hence, its conjugation to 
targeting moieties has been studied and researched intensively. [74-77] 
1.2.3. Cryptophycin 
Cryptophycins are 16-membered macrocycles with bacterial origin composed by four units, [78] 
having potent activity towards cancer cells and MDR (multi-drug resistant) cancer cells (IC50 in 
the pM range), as the human cervical carcinoma cell line KB-V1. [79-80] They are able to 
coordinate to β-tubulin interacting with the vinca domain. In particular, they inhibit tubulin 
polymerization, inflicting a conformational change on tubulin dimers and depolymerize 
microtubules in vitro, reducing microtubule dynamics. [81] This leads to mitotic arrest and 
apoptosis.  
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Figure 6. Structure of cryptophycin-52 and derivatives of cryptophycin-55 glycinate conjugated to a 
targeting peptide and a mAb. Blue: unit A; black: unit B; yellow: unit C; pink: unit D. Adapted from Weiss et al. [82] 
 
Cryptophycin-52 is the lead compound within this class and was tested in clinical Phase II, 
where it unfortunately showed a lack of in vivo efficacy and high toxicity (in particular 
neurotoxicity since neurons are the main tubulin producers for the transport of 
neurotransmitters). Cryptophycin-55 (the chlorohydrin of Cry-52) and its glycinate 
correspondent derivative were described as highly active in vivo in preclinical models, 
displaying a better pharmacokinetic profile. [83-84] Under physiological conditions the 
chlorohydrins are converted to the original epoxides, hence they are considered as prodrugs 
of the epoxides. After esterification with the glycine, improvement in water solubility and 
stability was also reached and this most importantly allowed the conjugation to homing 
peptides, like octreotide, but also antibodies [82, 85] and other ligands, e.g. acetazolamide [86] 
(Figure 6). 
1.3. Antibody-drug conjugates (ADCs) 
An antibody-drug conjugate (ADC) is the unique combination of a monoclonal antibody, a linker 
and a potent cytotoxic agent. It is designed to provide therapeutic potency to the antibody and 
specificity to the anti-cancer agents, which can be directed to the tumor cell in a targeted way 
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to limit systemic exposure. [87] This idea dates back to the early eighties. However, the first 
products did not obtain the desired results due to a series of technological limits, inadequate 
knowledge of the receptor target, use of insufficiently potent drugs and instability of the linker 
in biological fluids. [88] Notable improvements in the conjugation technology associated with a 
greater understanding of the biology of the system led to the discovery of a second generation 
of ADCs. These new therapeutic agents have better stability in biological fluids and allow an 
appropriate release of the toxic agent to the target cell. [89] ADCs include some of the most 
promising molecules in the oncology pipeline of large pharmaceutical companies. The 
peculiarity of ADCs is their long half-life (over a week), no systemic toxicity in circulation and 
activity only upon binding to tumors. All these characteristics lead to a maximum efficiency in 
administering the cytotoxic substance to the tumor cells in a perfectly selective way. [90] To 
date, there are four ADCs approved by the FDA: Adcetris ® for the treatment of refractory 
Hodgkin's lymphoma [91] and anaplastic large cell lymphoma, [92-94] Kadcyla ® for the treatment 
of HER2-positive metastatic breast cancer, [95-96] Mylotarg ® for adulte acute myeloid leukemia 
[97-98] and Besponsa ® for adult acute lymphoblastic leukemia, [99-100] as represented in Figure 
7. Auristatin (MMAE), maytansine (DM1) and N-acetyl-gamma-calicheamicin (CCM) are used 
as cytotoxic agents, respectively. On average, two to four toxins are conjugated to the mAb. 
In addition to the four commercial ADCs, nearly forty are under investigation in many different 
types of cancer. [101] 
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Figure 7. FDA approved ADCs. Drug-to-Antibody ratio is different, dependently from the conjugation strategy. n=4 
(Adcetris ®), n=3.5 (Kadcyla ®), n=2.5 (Besponsa ® and Mylotarg ®).  
Despite their growing success, the clinical advances of ADC products may be restricted by 
some limitations. Among these, heterogeneity is a crucial drawback leading to analytical and 
process challenges [102] and difficulties in administrating these compounds to patients. [103-104] 
The optimal design to obtain homogeneous compounds with the same average and distribution 
of payloads is a key point to achieve product safety and it is being addressed by researchers 
with new methods involving site-specific conjugation like engineering of the antibody 
sequence, [105] site-selective conjugation strategies [106] or modular approaches. [107] A high 
Drug-to-Antibody Ratio (DAR) is also affecting the propensity of the ADCs to aggregate, 
especially after being conjugated to very hydrophobic linker-drugs, so that the introduction of 
hydrophilic molecules could help to solve this major problem. [108] Besides that, increased 
stability against extracellular proteases needs to be reached to avoid dangerous off-site toxicity 
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after administration if the linker is not stable enough to prevent the premature release of the 
drug in the circulation before being introduced in the tumor cell. [109] Last but not least, the slow 
extravasation that characterizes immunoglobulins (IgG) is hindering their activity against solid 
tumors leading to the need of optimizing the format of the targeting moiety like for example by 
the introduction of small immune proteins (SIP) distinguished by a fast clearance, good 
extravasation and very good tumor/blood and tumor/organ ratio. [110] 
1.4. Small-molecule drug conjugates (SMDC) 
SMDC products, in particular peptide-drug conjugates, have been proposed to overcome some 
typical limits of antibodies. [111] In fact, small organic ligands can penetrate into depth of solid 
organs and tumors within a few minutes after administration, conveying the drug to the tumor 
with greater efficiency, and are typically characterized by rapid excretion from circulation. [112] 
In addition, they are easily developed, obtainable with inexpensive production and are easy to 
manipulate. However, they are often less selective than the correspondent antibodies. [47, 113] 
Some of the prerequisites for a peptide to become a receptor-mediated carrier are: 
- overexpression of the receptors on the surface of tumor cells; 
- knowledge of SAR to efficiently synthesize peptide analogues; 
- high affinity for the target; 
- efficient internalization (to provide the introduction of the drug). 
Two examples of receptor targeting moieties are gonadotropin-releasing hormone (GnRH) 
agonists and integrin ligands, whose biological background is introduced in the following 
paragraphs.  
1.4.1. GnRH receptors 
GnRH and its analogs have been widely used in clinical medicine since they were identified 
and synthesized in 1971 by Schally’s group. [114] The native GnRH-I, also called luteinizing 
hormone-releasing hormone (LHRH), is a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-
Pro-Gly-NH2), produced and released in a pulsatile manner by the hypothalamus. After binding 
to specific receptors (GnRH-I R) on the plasma membrane of the gonadotrophs (Figure 8), it 
stimulates them to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH) 
with a consequent gonadal response. [115] A second form of GnRH (GnRH II) is ubiquitous and 
maintained in its structure throughout different species. Nevertheless, the GnRH-II receptor 
has not been identified yet in humans, even if there is strong evidence that this receptor exists. 
[116] GnRH receptors are highly expressed on various cancer cells and apart from pituitary cells 
and reproductive organs, they are present in a very limited number in healthy tissues. They 
are for this reason a good target for selective cancer chemotherapy. [117-118]  
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Figure 8. Binding of GnRH to its receptor. [119] IC: intracellular; EC: extracellular 
In order to increase the power and duration of action of the GnRH-I, through modifications of 
the molecular structure of this decapeptide, many analogs have been synthesized, and are 
available for clinical use. The substitution with D-amino acids in position 6 (involved in the 
enzymatic cleavage) or 10 (important for the tridimensional structure) resulted in analogs with 
agonist activity with a greater potency and a longer half-life than the native GnRH-I. These 
produce an initial stimulation of the pituitary cells followed by the down-regulation and inhibition 
of the hypophysis-gonadal axis. GnRH-I analogs are powerful therapeutic agents, proved to 
be very useful in various clinical indications, including the therapy of some hormone-dependent 
tumors, like prostate or breast cancer. In this context, doxorubicin was conjugated by an ester 
bond to a GnRH-I agonist called zoptarelin. [120-121] The final conjugate AEZS-108 was tested 
till Phase III of clinical trials on endometrial cancer but failed to extend survival in the advanced 
disease. [122] 
Taking advantage of these findings, some researchers are paying a special attention on the 
improvement of GnRH-based drug delivery systems, by starting from the sequence of a third 
form of GnRH (GnRH-III) discovered in sea lamprey, able to selectively bind to GnRH receptors 
but with a lower endocrine effect compared to GnRH-I agonists. [123-127] In the group of Prof. 
Mező (ELTE University, Budapest) the native sequence was modified in order to obtain a 
higher stability and allow drug-conjugation and many strategies have been pursued. [128-130] In 
particular Ser4 was substituted with a butyrylated lysine, Lys(Bu), while Lys8, functionalized 
with an aminooxyacetic acid linker, was conjugated to daunorubicin by an oxime linkage, in 
order to prevent the enzymatic cleavage of the ester bond by carboxylesterases (Figure 9). [131] 
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Figure 9. Optimization of the GnRH sequence. Pink: changes in the sequence; Green circle: conjugation point 
for the attachment of the drug. Bu: butyryl. 
The conjugates are very stable in human serum from the chemical and enzymatic point of view 
but in presence of lysosomal homogenate they are degraded with subsequent release of 
different metabolites. H-Lys(Dau=Aoa)-OH was recognized as the smallest drug containing 
metabolite which is still able to bind to DNA in vitro. [132] The stability and selectivity of the 
conjugate have been favored at the expense of the cytotoxicity that is in fact lower than the 
free drug. The introduced peptide was chosen in this work for further studies. 
1.4.2. Integrin receptors and integrin ligands 
Adhesive contacts with neighboring cells and with the extracellular matrix (ECM) control cell 
behavior and development. These interactions are mediated by proteins of the cell surface, 
called cell adhesion receptors, divided in four groups: cadherins, selectins, immunoglobulin 
superfamily and integrins. [133] 
Integrins form the largest and most versatile receptor family, being implied in both cell-ECM 
and cell-cell interactions. They are transmembrane heterodimeric glycoprotein receptors found 
in mammals in 24 combinations, constituted from 18 different α- and β-subunits. [134] The 
subunits are not covalently linked and consist of an ectodomain, a transmembrane region and 
a short unstructured cytoplasmic tail (Figure 10). [135] The N-terminal regions of all α subunits 
contain seven repeating sections, folded in the form of a seven-bladed β-propeller, supported 
by a thigh and two calves. The β-chains of αv integrins present a domain I for the interaction 
with the matrix followed by a hybrid and a PSI (plexin-semaphorin-integrin) domain, four 
cysteine-rich EGF-like repeats and a β-tail. [136] A conserved region called MIDAS (metal ion-
dependent adhesion site) in the β-I domain, is particularly important for the sequence 
recognition, because it binds divalent cations (e.g., Ca2+, Mg2+, Mn2+) that can possibly 
coordinate a carboxylic acid residue of the ligand, e.g., aspartic acid residue of the RGD 
pattern. [137] 
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Figure 10. Integrin structure and activation. A: α and β subunits of an integrin receptor. B: Outside-in and inside-
out signaling pathways. Adapted from Shattil et al. [138] EC: extracellular; IC: intracellular. 
The connection between ECM and cytoskeleton provided by integrins is highly dynamic and 
involves a bidirectional transfer of information: while the cytoskeleton regulates the affinity of 
the integrin extracellular domain, the binding of ECM proteins or cell-surface ligands to 
integrins alter the arrangement of the cytoskeletal system. [139] 
In the pathway of signal transduction from the cell interior to outside (inside-out signaling), the 
integrin ectodomain initially adopts a collapsed configuration stabilized by a salt bridge 
between the cytoplasmic domains of the two subunits. This arrangement is susceptible to 
unfold after the recruitment of certain cytosolic proteins, especially talin and kindlin that bind 
to the β-subunit, stimulating the integrin to assume an activated form. [135, 140] Subsequently, 
interaction sites with the extracellular matrix are revealed allowing the interaction with the 
appropriated ligand. At the same time, the interaction of integrins with their extracellular ligands 
changes the conformation of the integrin generating signals in the inside of the cell (outside-in 
signaling). The formation of integrin clusters stimulated by multimeric ligands causes an 
increased ligand-receptor interaction inducing the formation of focal adhesion complexes and 
causing a transfer of stronger signals. [135] The two processes are reciprocally influencing each 
other: while the integrin activation can promote ligand binding, concurrently interaction with the 
ligand can generate intracellular signals. [138] The activation of these receptors can control the 
change of the cell shape, migration and tissue organization playing a crucial role in many 
physiological but also pathological processes like cancer development because of their role 
on the one hand in tumor cells (development of metastases) and, on the other hand, in 
endothelial cells (neo-angiogenesis). For this reason, the pharmacological targeting of these 
receptors for these indications has been the subject of numerous studies. [141]  
In this work, the integrin αvβ3, will serve as a target in the development of tumor therapeutics, 
therefore this class of integrins will be characterized here in more detail. The αvβ3 integrin is 
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overexpressed on tumor cells rather than on healthy tissues, e.g. melanoma, breast cancer 
and glioblastoma cells, which is why it is also used as an indicator of the invasive phase of 
tumors. [141] Ligand oriented design was the starting point for the synthesis of new selective 
compounds: each integrin is able to recognize well-defined ligands at the level of extracellular 
matrix and the integrin αvβ3 recognizes the motive Arg-Gly-Asp (RGD) on fibronectin and some 
other proteins. Pierschbacher and Ruoslathi found the tripeptide sequence RGD in fibronectin 
in 1984. [142] This was identified as the minimal fragment for stimulating cell adhesion and called 
'universal' cell recognition motif, as it is present in about half of the matrix proteins and it is 
recognized by eight members of the 24 membered integrin family. [143] Starting from this natural 
binding sequence, a variety of peptidic and non-peptidic integrin ligands were developed, 
resulting in different receptor affinity, selectivity and bioavailability, partly superior to the natural 
ligand. [144] Conformational restriction is a way to achieve superactivity and selectivity of 
sub-type recognition; in peptides, cyclization and peptidomimetic constraints help to pin-down 
the active conformation. [145] It could be shown for example that flanking amino acids of the 
recognition sequence and their conformation are essential for the integrin-ligand interaction, 
the ligand affinity and selectivity. In the research group of Prof. Kessler, the incorporation of 
D-amino acids [146] and N-methylation [147-148] resulted in the first synthetic, metabolically stable 
αvβ3-selective ligand c[RGDf(N-Me)V], called cilengitide. [149] Unfortunately, it failed in Phase 
III of clinical trial because it did not meet its primary endpoint of significantly increasing overall 
survival when added to the current standard chemoradiotherapy regimen. [150] NMR 
spectroscopic studies combined with molecular dynamics simulations revealed that this 
particular conformational restriction was crucial to achieve maximal binding affinity and this 
was finally confirmed by the crystal structure of the αvβ3 integrin in complex with cilengitide, 
reported by Arnaout and coworkers. [151] As schematically illustrated in Figure 11 and 13, the 
side chains of arginine and aspartic acid come thereby in an optimal orientation for interaction 
with the αvβ3 integrin receptor (with Asp218/Asp150 and with the metal ion in the MIDAS region, 
respectively) and have been identified as essential groups. The aromatic residue, adjacent to 
the carboxylic group, increases binding affinity by π-interaction with the receptor (Tyr122). The 
role of the glycine imposing steric restrictions in the relatively flat binding pocket is also 
fundamental, thus analogous RAD peptides possess a much lower affinity and can be used as 
controls. On the contrary, the valine residue does not interact with the receptor, which is why 
it can be replaced through different amino acids without loss of integrin affinity and selectivity.  
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Figure 11. Interactions of cilengitide with the RGD binding pocket. Red circle: π-interaction; blue circle: ionic 
interactions; yellow circle: steric restriction; green arrow: no interaction. Adapted from Mas-Moruno et al.  [149] 
After the structure of the complex between receptors and ligands has been analyzed in detail, 
further optimization could be done via rational structure oriented design. This is what they tried 
to study and efficiently succeeded in the research groups of Prof. Gennari and Prof. Piarulli. In 
this case, important peptidomimetic variations, helping to optimize biological activity and 
selectivity between subtypes, were introduced in the new developed constrained peptides 
containing the RGD motif. They understood that to prepare effective compounds they had to 
work on the conformation; for this reason, various ligands were screened, which differed from 
each other because of the peculiar DKP (diketopiperazine) scaffold used to close the ring, 
each functionalized with a carboxylic acid and a Boc-protected amino group as showed in 
Figure 12 and obtained with good overall yields. [152-154]  
 
Figure 12. DKP library developed in the research groups of Prof. Gennari and Prof. Piarulli. Red box: elected 
DKP scaffold for the synthesis of a DKP-RGD ligand with high affinity and selectivity towards the receptor sub-type 
αvβ3. 
Binding affinity studies on the purified αvβ3 and αvβ5 integrin receptors showed very promising 
results: the affinity rate was in general in nM range a part from the DKP1-containing ligand, 
characterized by a non-extended arrangement. DKP3RGD was chosen for further studies, 
since it showed a high affinity in low nanomolar range, comparable to cilengitide but contrarily 
to the latter, a much higher selectivity for αvβ3 (for the binding to αvβ5 IC50 values in micromolar 
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range were measured). These results were confirmed also by the investigation of ligand-
integrin interactions. The best pose of the ligand into the crystal structure of αvβ3 binding site 
was overlaid on cilengitide during docking studies and showed that all the important 
interactions of the X-ray complex were conserved, in particular the distance between Arg and 
Asp was maintained (Figure 13). [153] 
 
Figure 13. Docking into αvβ3 binding site. All the important interactions are conserved. The metal ion in the 
MIDAS region is represented by a blue sphere. Green: cilengitide. Grey: c[DKP3RGD]. [155] 
 
Since 2012 a functionalized version of the integrin ligand c[DKP3RGD] was employed as 
tumor-homing device for site-directed delivery of paclitaxel, [156-157] SMAC (second 
mitochondrial-derived activator of caspases) mimetic proapoptotic compounds [158] and 
antiangiogenic helical peptides targeting VEGF receptors. [159] In in vivo tumor-targeting 
experiments the paclitaxel conjugate exhibited a superior activity than the free drug despite 
the lower molar dosage used. [156] These results could demonstrate that the position of the 
functionalization was ideal not to interfere with the binding to the integrins and that very likely 
integrin-mediated endocytosis occurred.  
1.5. Receptor-mediated uptake 
Receptor-mediated uptake is a type of endocytosis where specific ligands are combined with 
receptor proteins of the cell membrane and subsequently internalized. These receptors are 
localized and concentrated in particular areas of the membrane called coated pits or migrate 
in these zones after binding to the molecule, which should be transported. The coated pits are 
characterized by the presence of a layer of peripheral membrane proteins known as clathrins. 
Once the receptors are bound to specific molecules, the dimple folds back into the cell and 
forms a vesicle covered by the clathrin layer and containing the substance of interest. 
Subsequently the vesicle loses the clathrin becoming an endosome, which then forms two 
vesicles: one containing the receptors and the other containing the ligand. The receptors are 
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recycled and return to the plasma membrane while the ligand-containing vesicle merges with 
the lysosome to form a secondary lysosome whose content, once digested, is released into 
the cell (Figure 14). [160] 
 
Figure 14. Receptor mediated uptake of SMDCs. After internalization, the linker is cleaved in the lysosome, the 
free drug is released from the ligand and it can express the activity on the particular target (tubulin, DNA, 
neighbouring cells). Adapted from Khalil et al. [160] 
 
An integrin heterodimer can follow more than one internalization route. Both proteins caveolin 
and clathrin are able to interact with the tails of αvβ3 integrin and trigger the vesicles formation. 
[161-163] In this context, Coll and coworkers investigated the integrin mediated-internalization 
pathway of a multimeric cRGD ligand showing that this was able to bind to two integrins at the 
same time favoring clustering and subsequent internalization via clathrin coated vesicles. [164] 
However, issues concerning the respective contributions made by integrin dependent vs 
independent endocytosis remain largely unresolved. [165-166]  
For the GnRH receptors, it has been demonstrated that ligand binding induces receptor 
dimerization and the formation of small receptor groups, which are internalized. Following the 
internalization, the hormone-receptor complex undergoes degradation in the lysosomes and a 
fraction of the receptors is recovered on the plasma membrane, thus participating in a recycling 
process strongly related to the up-regulation of receptors after GnRH stimulation. The agonists 
are internalized very fast: after 15 minutes, the complexes are already transferred to the 
lysosomes and after 30 minutes the shift is completed. [167] 
1.6. CPPs as carrier molecules and their role in cancer therapy 
The bioavailability and efficiency of many biological therapeutic molecules is frequently 
restricted by their chemical features, in particular their large size and hydrophilicity, which 
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contrast with the ability to passively diffuse through the membrane and internalize in the cell 
reaching their site of action. This issue consequently leads to a diminished therapeutic effect 
or even complete loss of activity. The conception of an efficient drug delivery in living cells is 
therefore an essential challenge in the development of new drugs. [168] To overcome this 
problem, during the last years, many research groups have been working on new transport 
vectors called cell-penetrating peptides (CPP). These are short peptides, up to 30 amino acids, 
with low cytotoxicity and exceptional translocation properties being able to pass cell 
membranes without destroying membrane integrity. [169-170]  
Since the discovery of TAT in 1988, originated from a transactivating regulatory protein in HIV, 
[171-172] and penetratin a few years later, derived from the Drosophila antennapedia 
homeodomain, [173-174] the development of innovative CPPs has rapidly expanded. [175] Other 
members included in the class of natural CPPs were identified later, as for example VP22 from 
virus Herpes simplex [176] and pVEC, [177] a peptide of 18 amino acids derived from the cadherin 
of murine vascular endothelium. Based on these discoveries and on SAR studies showing that 
the amino acid arginine plays a fundamental role in the uptake, various synthetic CPPs have 
been also developed and comparable results in cell internalization were obtained. The most 
known representatives of this group are the synthetic oligopeptides R8/9 consisting in poly-
arginine sequences displaying maximum translocation efficiency. [178-179] In our research group 
the CPP sC18 was developed. [180] It derives from the C-terminal domain of the cationic 
antimicrobial protein CAP18, consists of 16 amino acids and belongs to the group of 
amphipathic CPPs. Its internalization is time- and concentration- dependent and mainly occurs 
through endosomal pathways, when cargoes are attached. [180-182] Furthermore, the C-terminal 
truncated fragment sC18*, lacking the last four amino acids, also shows a cell-penetrating 
ability, although weaker than sC18, probably due to the two missing positive charged lysine 
residues. [183-184] These two CPP variants have been used in this work. In Table 1, important 
members of the CPP family are listed with their correspondent amino acid sequences and 
origin. 
Table 1. Name, sequence and source of some important CPPs. 
Name Sequence Origin Reference 
TAT GRKKRRQRRRPPQ HIV-1 [171-172]  
polyarginine Rn Synthetic [178, 185] 
pVEC LLIILRRRIRKQAHAHSK VE-cadherin [177, 186]  
Penetratin RQIKIWFQNRRMKWKK Drosophila antennapedia [173-174]  
VP22 NAATATRGRSAASRPTQR VHS [176] 
sC18 GLRKRLRKFRNKIKEK CAP18 
 
[180-181, 187]  
sC18* GLRKRLRKFRNK [183] 
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Notably, even if the sequence and secondary structure of these peptides are divergent, the 
mechanism of transfer within the cells seems to be quite similar. Thanks to the favorable 
attributes of these peptides, they can transport inside the cell covalently or electrostatically 
bound cargoes, from small therapeutic molecules to plasmid or nanoparticles that otherwise 
could not pass through the cell membrane. [188-189] In order to ensure an efficient drug delivery 
into the target cell, it is fundamental to understand the uptake mechanism. So far, the exact 
process has not been definitively disclosed yet and contrasting data are described even if it is 
believed that the internalization always starts by interacting with the components on the surface 
of the plasma membrane (proteoglycan, phospholipids). The main uptake route for CPPs 
occurs via energy-dependent endocytosis, although direct translocation also exists under 
certain conditions and it cannot be excluded that the different internalization mechanisms are 
concomitantly used (Figure 15). In particular, the type of internalization depends on a variety 
of factors such as the type of CPP, the peptide concentration, the type of cargo molecule, the 
cell type, and the lipid composition. [190] 
 
Figure 15. Cellular uptake mechanisms of CPPs. Adapted from Mickan et al. [191] 
The internalization of CPPs via endocytosis is divided into different subclasses, including 
clathrin, caveolae, lipid-raft mediated endocytosis and macropinocytosis. [192-193] Differently, the 
uptake via direct translocation involves several models, primarily based on the interaction of 
the negatively charged membrane and the positively charged CPP sequence. The inverted 
micelle model, originally proposed for penetratin, describes the uptake of CPPs caused by the 
strong attractive potential between positive residues, in particular arginine, and the anionic 
phospholipids. After merging with the membrane, a subsequent interaction of the hydrophobic 
amino acids with the hydrophobic tails of the phospholipids occurs, resulting in the 
reorganization of the bilayer and formation of inverse micelles that release the CPPs into the 
intracellular space. The pore formation model describes the generation of transient pores 
resulting from the bundles originated from the amphipathic α-helical structure of CPPs, where 
the hydrophobic residues interact with the lipid tails of the phospholipids while the hydrophilic 
side chains are directed towards the lumen of the pore. Differently, in the carpet model, the 
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entry into the cell is facilitated by the parallel alignment of the CPP sequence on the membrane 
surface in a carpet-like manner until a maximal concentration is reached. This provokes the 
rotation of the peptide with the subsequent interaction with the hydrophobic core of the 
membrane leading to its destabilization and the subsequent penetration of the CPP. [194-198] 
The indisputable efficiency of this drug delivery system in cancer therapy is hindered by the 
lack of selectivity so that many researchers had to deal with some new strategies in order to 
overcome this disadvantage, which could lead to unwanted toxicity and side effects on healthy 
cell lines. [197] One approach is to combine CPPs with homing peptides targeting particular 
receptors overexpressed on the surface of cancer cells. This strategy is depicted in Figure 16 
where some examples of active targeted CPPs are exemplified. 
 
 
Figure 16. Different approaches to develop selective CPPs. A: Conjugation of a homing peptide to the CPP 
sequence; B: The CPP is masked by a negatively charged sequence and the construct is selectively directed 
towards tumor cells by the homing peptide. In the tumor environment, the linker will be cleaved by MMP-2 and the 
CPP will restore its penetration ability. C: The targeting moiety is represented by a mAb, conjugated to a molecule 
of heparin, which is electrostatically interacting with the CPP. Adapted from Martin et al. and Kurrikoff et al. [199-200]  
For example, Langel and coworkers conjugated the two homing peptides PEGA and CREKA 
to the CPP pVEC to carry the cytotoxic payload chlorambucil in breast tumor cells. In both 
cases the system improved the cytotoxicity of the drug and the selectivity of the first compound 
could be even demonstrated in vivo. [74, 201] CPP-drug conjugates with monomethylauristatin E 
have been designed by Crisp et al. to selectively target tumor cells overexpressing integrin 
receptors, by adding the ligand cRGD. [202] This strategy involved the preparation of an 
activatable CPP attached to a negatively charged sequence that should prevent the anticipated 
internalization of the construct on healthy cell lines. These two elements are in fact combined 
via a MMP-2 cleavable linker that would be selectively cleaved in the tumor environment where 
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these enzymes are overexpressed. Also in this case, in vivo studies could demonstrate an 
improved tumor targeting. However, not only homing peptides could be used as targeting 
moieties. An example is the employment of a mAb conjugated to heparin and further 
complexed with a TAT-gelonin construct as described by Shin et al., which was also validated 
in several in vivo models. [203] 
A part from selectivity, blood stability is also a very important attribute that a drug should 
possess in order to reach the target without being degraded by blood proteases before arriving 
to the tissue. [204] This obstacle can be circumvented applying different shielding strategies in 
order to protect the structure of the CPPs till reaching the desired tissue and utilizing for 
instance more stable D-amino acid configurations or [205] backbone cyclization. [183, 206-207] 
Further development of CPPs through cyclization strategies will be highlighted in the following 
section. 
1.7. Rational for cyclic peptides 
Cyclic peptides are an unusual class of compounds, first discovered in microorganisms, [208] 
and subsequently object of great interest from the scientific community due to their attractive 
biological activities. [209] Among them are antibiotics, such as bacitracin [210] and polymyxin B, 
[211] immunosuppressive agents as cyclosporine A, [212] or also toxins such as α-amanitin, the 
poison of the mushroom Amanita phalloides. [213] All of these compounds have been very 
actively investigated as potential sources for new drugs and antibiotics. The three-dimensional 
conformation of these peptides is more rigid than that of their linear analogues, which could 
partly explain the observed increase in receptor selectivity and biological activity. [214] 
Moreover, one of their most interesting features is the enhanced resistance to proteolytic 
enzymes in comparison to correspondent linear peptide chains, reaching a higher stability in 
the human body.[215-219] In addition, such cyclic peptides often include unusual amino acids, 
further enhancing their resistance against proteolytic degradation and improving their 
bioavailability. [220-222]  
The concept of cyclization has been found wide acceptance with respect to modulate the 
biological activity of peptides including peptide carriers, such as CPPs. Their cyclization has 
been demonstrated to be an effective strategy for enhancing their proteolytic stability, cellular 
uptake rates and promoting endosomal escape, thus cytoplasmic distribution. [223-224] Indeed, 
endosomal escape is a decisive concern, since for many CPPs the main entry pathways 
proceed via endocytic mechanisms. In fact, the CPP construct must be internalized by cells, 
but more importantly, cargoes have to be released and reach their extra-endosomal targets in 
the cytosol or in the nucleus. 
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1.7.1. Previous work 
Recently, triazole-bridged cyclic peptides were synthesized and characterized in our research 
group. [206] In more detail, a fragment of the cell penetrating peptide sC18 (GLRKRLRKFRNK, 
namely sC18*) was cyclized via chemoselective copper-catalyzed azide-alkyne cycloaddition 
(CuAAC) in three different ways, yielding three different ring sizes.  
  
Figure 17.Structures of the sC18*-derived cyclic peptides synthesized in our group. [184] 
These cyclic CPPs were evaluated regarding cellular uptake, toxicity and interaction with lipid 
systems. It has been observed that the internalization rate was strongly associated with the 
number of arginine residues included in the cycle. The peptides contain respectively one, three 
or five arginine residues and show an improved cell internalization in this order. The rigid 
presentation of guanidinium groups leading to the enhancement of the internalization efficiency 
has been already described by Lättig-Tünnemann et al. in 2011: when guanidinium groups 
were forced into maximally distant positions by peptide cyclization higher uptake rates have 
been registered. [225] Also in this case, the improved interaction with negatively charged 
constituents of the membrane played an important role in cell entry. A certain cancer selectivity 
was demonstrated too, since the internalization pattern in MCF-7 breast cancer cells was 
mainly cytosolic and nuclear, speaking for a direct penetration and good membrane 
permeability, differently from the endosomal distribution observed in HEK-293 (human 
embryonic kidney) healthy cells. Our results let conclude that particularly cyc-3 benefited from 
cyclization, since it demonstrated improved lipid-peptide interaction and thus, cellular uptake 
properties. 
1.7.2. DKP scaffolds 
Peptide cyclization can be achieved in different ways, commonly divided into two groups: head-
to-tail (C-terminus to N-terminus) and side chain-to-side chain cyclization, the latter involving 
various strategies, like thioether and disulfide bond formation, lactone/lactame formation, ring 
closing metathesis and the previously mentioned CuAAC. [226-227] Encouraged by the previously 
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described results, we planned to replace the triazole bridge with a more spatially oriented and 
rigid scaffold such as the bifunctional diketopiperazine scaffold (DKP). 
From the DKP library developed in the group of Prof. Piarulli and Gennari, the cis (DKP1) and 
trans (DKP3) diketopiperazine rigid scaffolds, previously depicted in Figure 12, were chosen 
for the synthesis of cyclic compounds. These two DKP scaffolds showed completely different 
characteristics in the conformation of small cyclic peptide sequences evaluated in previous 
studies. While DKP1 acted as a reverse turn inducer, DKP3 promoted the formation of an 
extended structure. [152-153] Therefore, the comparison of cyclic peptides containing different 
DKP scaffolds would be of great interest. 
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2. Aims of the thesis 
2.1. Receptor-targeted CPPs for selective delivery of anticancer 
therapeutics 
Insufficient cellular uptake of new therapeutic drug candidates often limits their clinical use. A 
promising strategy to solve this permeability obstacle is represented by CPPs, conveniently 
used as appropriate vectors for these applications. They appear to be very advantageous and 
versatile tools to deliver anticancer molecules which otherwise would not be able to cross the 
plasma membrane barrier by their own and the safety of these devices was demonstrated in 
many works, allowing their extensive use for in vitro or in vivo studies. However, their entry 
mechanisms appear to vary with experimental conditions, cargo, types and the details of the 
various uptake ways are poorly understood. Furthermore, none of the studied internalization 
pathways indicated certain selectivity towards cancer cells and this is in total contrast with the 
outstanding development in the course of the last years of selective strategies to limit side 
effects. Trying to fill this gap in the research, the first part of this work will be dedicated to the 
synthesis of novel drug delivery systems constituted by a CPP (sC18) bearing a cytotoxic 
warhead and attached to a targeting ligand (GnRH-R or integrin ligand) by a PEG spacer. By 
this way, we wanted to overcome the selectivity issue in CPP delivery, trying to study which 
entry mechanism would prevail when this construct came in contact with different cell lines 
expressing the receptor of interest at a different level. For this purpose, we wanted to find an 
optimal strategy for the successful synthesis of these conjugates and subsequently biologically 
test them in different cell systems. In particular, we wanted to analyze which role would play 
the receptor-mediated uptake compared to the traditional entry mechanisms previously 
described for CPPs, including endocytosis and direct penetration through the membrane. We 
tried to evaluate this tendency by choosing ideal cell models, which would permit the 
comparison of the different uptake behaviors in presence or absence of the receptors of 
interest.  
2.2. Cyclic CPPs for cargo delivery  
A part from the difficulties encountered in designing selective molecules, the use of CPPs is 
often severely restricted because of their low proteolytic stability in biological fluids and rapid 
degradation in the organism after administration. By cyclization of the peptide backbone, the 
linear truncated version of sC18 has recently displayed an increased internalization rate and 
stability. In the second part of this work, the focus was on the synthesis and characterization 
of analogues of the cyclized sC18* derivatives recently synthesized by Florian Reichart during 
his PhD thesis. Therefore, the triazole bridge obtained by CuAAC reaction should be 
substituted with a DKP scaffold and different conditions should be attempted to obtain a final 
optimization of the cyclization reaction. Afterwards, the secondary structure of the obtained 
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molecules should be investigated in details by CD and NMR spectroscopy and compared to 
the linear peptides. Furthermore, their potential for drug delivery should be determined by 
generating non-covalent and covalent complexes with cytotoxic drugs. To measure the efficacy 
of the drug transport through the membrane and of the effect on cell viability, cytotoxicity 
assays and cellular uptake studies should be performed and the results compared to those of 
the linear counterparts. 
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3. Novel CPP-drug conjugates bearing a targeting moiety 
3.1. GnRH-III as targeting moiety and daunorubicin as cytotoxic payload 
Since GnRH receptors are expressed in different types of tumors but not in healthy cells, they 
could represent an interesting target in the context of tumor selectivity. For this reason, many 
GnRH-drug conjugates have been synthesized and investigated. In this work, the GnRH-III 
derivative developed by Mező and co-workers, where Lys4 was butyrylated, has been used as 
targeting moiety in our drug delivery system, while daunorubicin (Dau) served as cytotoxic 
payload. [131] To simplify the nomenclature of the synthesized conjugates, from now on the 
sequence <EHWK(Bu)HDWKPG-NH2 will be indicated with the name GnRH-III. Any further 
conjugation to the GnRH-III sequence always occurred at Lys8, since it was often confirmed to 
be a good conjugation site, not invalidating the selectivity and activity of the conjugate (Figure 
9). [228-229]  
Considering that small variations at the sugar moiety of daunorubicin caused a drastical 
decrease in activity, it could be deduced that the daunosamine is involved in the interaction 
with DNA; [126, 230] for this reason, to easily conjugate the drug to the peptide, the amide bond 
formation with the amino group of the sugar was not possible without the contemporary drastic 
loss of activity. Due to its structural properties, daunorubicin cannot be conjugated to the 
targeting moiety by ester bond like doxorubicin but the ketone group allows the formation of 
oxime bonds originating conjugates with high stability under physiological conditions. In some 
works an enzymatic cleavable linker, the commonly used tetrapeptide GFLG, was added to 
allow the release of the drug after cleavage by cathepsin B, which is known to be 
overexpressed in tumor cells. [231-232] It has been demonstrated that the release of the free drug 
is not necessary for the antitumor activity of the conjugate since the amino acid-Dau metabolite 
is also able to intercalate with the DNA with sufficient efficiency. [132] Through this approach, it 
was possible to obtain selectivity with a small decrease in activity compared to the free drug. 
[131]  
To further investigate the intracellular drug release and the effect on multi-drug resistant cancer 
cells, we decided to add another important portion to the construct resulting in a new hybrid 
conjugate composed by a targeting moiety (GnRH-III), a carrier moiety (CPP) and the drug. 
Two different variants, with and without cleavable linker were designed and synthesized. The 
synthetic strategy will be discussed and most importantly, the binding affinity of these 
conjugates will be analyzed in detail comparing two overexpressing cell lines (healthy pituitary 
gland and prostate cancer cells). Moreover, cytotoxicity of the novel conjugates on receptor 
positive and negative cell lines will be shown. 
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3.1.1. Synthetic strategy 
The peptide sC18 served as starting point for the conjugation of daunorubicin. As illustrated in 
Figure 18, one first modification was introduced at the side chain of lysine at position 8 within 
the peptide sequence, whereby coupling of daunorubicin was performed via oxime ligation by 
insertion of an aminooxyacetic acid spacer yielding the two CPP-drug conjugates sC18(Dau) 
and sC18(GFLG-Dau), the latter containing the enzymatic cleavage site GFLG. These two 
conjugates were used as control peptides for further investigation of the selectivity in 
comparison with the targeting constructs. Drug conjugation by oxime bond was successfully 
performed but particular care had to be taken to increase the yields and facilitate the 
purification of the final product. Notably, as already described by Mező et al., [233] 10 eq. of Boc-
aminooxyacetic acid were added to the cleavage cocktail and in general use of acetone and 
plastic consumables was limited in order to prevent the formation of the acetone and 
formaldehyde adducts with delta mass +40 and +12. [228, 234] In addition, the temperature for 
every reaction step was maintained under 40 °C to avoid the release of the sugar moiety and 
the subsequent decrease of the cytotoxicity. For the conjugation of the two elements, the 
glycine at the N-terminus of the CPP sequence was replaced by propargylglycine, while, in 
collaboration with the PhD student Sabine Schuster (ELTE University, group of Prof. Mező, 
Budapest), the GnRH-III ligand was synthesized and the side chain of Lys8 within the GnRH-
III sequence was functionalized by incorporation of 2-azidoacetic acid. This allowed the “click” 
reaction (CuAAC) within the two moieties. 
Nevertheless, the conjugation to the functionalized GnRH-III was the yield-limiting factor. The 
reaction was carried out as described by Raposo Moreira Dias et al. [235] and the azido-
functionalized ligand was used in excess (1.3 eq.). The reaction worked very well and no 
limiting reactant was detectable after completion but some difficulties occurred with the 
purification of the crude product, leading to very low yields (20-30%). Furthermore, the 
recovered mixed fractions could not be separated even by changing the gradient or using 
columns with different polarity. This problem could be solved by modifying the reaction 
conditions. This time an excess of the more hydrophilic alkyne-functionalized sC18 (1.3 eq.) 
was added, by means of which the starting GnRH-III was completely converted in the product 
and the CPP could be easily separated from the final conjugate due to their different retention 
time, reaching 91% yield (see Table 20 in the attachment).  
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Figure 18. Synthetic strategy of the full conjugates GnRH-III-sC18(Dau) and GnRH-III-sC18(GFLG-Dau). A: 
Synthesis of the peptide sequence by SPPS, followed by conjugation of daunorubicin. B: “Click” reaction between 
the azido group of GnRH-III and the alkyne group at the N-terminus of the CPP. Reagents and conditions: a: 5 eq. 
Fmoc-L-Pra-OH (B), 5 eq. Oxyma, 5 eq. DIC in DMF, overnight; b: 30% piperidine in DMF (20 min x 2); c: 10 eq. 
Boc2O, 1 eq. DIPEA in DCM for 2 h (2x); d: 2% hydrazine in DMF (10x); e: 5 eq. Bis-Boc aminooxyacetic acid, 5 
eq. Oxyma, 5 eq. DIC in DMF, overnight; f: TFA/TIS/H2O (95:2,5:2,5), 3 h; g: 30% excess daunorubicin, 0.2 M 
NH4OAc, pH 5, 10 mg/ml; h: 1 eq. GnRH-III(N3), 1.5 eq. I or II, 0.5 eq. CuSO4 • 5H2O, 0.6 eq. Na ascorbate, 
H2O:DMF 1:1, 10 mM, 40 °C, N2, 24 h 
Three different conjugates were synthesized (see Table 2). GnRH-III-sC18, not bearing the 
drug, served as a control conjugate in order to investigate the selectivity in presence of the 
large and hydrophilic CPP. The additional GFLG linker in GnRH-III-sC18(GFLG-Dau) was 
introduced between the drug and the CPP to evaluate if the activity could be enhanced in 
respect to GnRH-III-sC18(Dau). 
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Table 2. List of the synthesized GnRH-III conjugates and controls with their names, structures and 
molecular weights (calculated and experimental).  
Conjugate Structure 
MW 
[g/mol] 
MWexp 
[g/mol] 
GnRH-III-
sC18 
 
3561.2 3560.7 
GnRH-III-
sC18(Dau) 
 
4144.3 4145.2 
GnRH-III-
sC18(GFLG-
Dau) 
 
4518.7 4519.7 
sC18(Dau)  2652.2 2653.2 
sC18(GFLG-
Dau) 
 3027.0 3027.9 
 
3.1.2. Triptorelin binding assay 
The affinity of the novel GnRH-III conjugates to GnRH-Rs was investigated by means of a 
radioligand binding study, performed at the Department of Biopharmacy (Faculty of Pharmacy) 
at the University of Debrecen, as previously described. [131] Radioiodinated triptorelin was used 
for this purpose, since it provides a high binding affinity to GnRH-I receptors. In the present 
study, the in vitro competition assay was executed on human pituitary and human prostate 
cancer cells, both overexpressing the receptors, and the displacement of the radiolabeled 
triptorelin was evaluated to characterize the binding affinity of the novel conjugates. It has been 
confirmed by many studies that the receptors in cancer cells are exactly the same as the 
pituitary receptors [236] but, at the same time, it has been also speculated about the presence 
of distinct receptor conformations in different tissues leading to selective binding to specific 
ligands and various intracellular signaling pathways (antagonist or agonist action). [237-238] 
Furthermore, high affinity/low capacity and low-affinity/high capacity receptors have been 
found from the investigation of different research groups. [239] To prove that our conjugates 
could bind with high affinity also on cancer cells, both tissues were analyzed. 
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Table 3. IC50 values corresponding to the ability of the GnRH-III conjugates to replace [125I]-triptorelin. K2 
was also analyzed and served as reference. 
Conjugate 
IC50 (nM) 
Human pituitary gland 
IC50 (nM) 
Human prostate cancer 
GnRH-III-sC18 14.7 ± 2.3 17.8 ± 2.2 
GnRH-III-sC18(Dau) 24.5 ± 0.8 20.9 ± 2.7 
GnRH-III-sC18(GFLG-Dau) 27.1 ± 1.4 29.6 ± 1.4 
K2 (GnRH-III-Dau) 3.9 ± 0.7 3.0 ± 1.1 
 
The novel conjugates were compared to the lead compound K2 
(<EHWK(Bu)HDWK(Aoa=Dau)PG-NH2, synthesized by Sabine Schuster) that was recently 
reported to have a high affinity in low nM range towards GnRH-I receptors. [54] The results 
illustrated in Table 3 are very promising: even if control K2 displays better results, the binding 
affinity of the hybrid-conjugates is slightly reduced, but still in low nM range, underlining that 
the attachment of the CPP does not substantially alter the overall receptor binding. In fact, one 
could think that the CPP would be too large to preserve the selectivity of the GnRH peptide 
but, as already demonstrated in many studies, the Lys8 of GnRH-III, is a very good attachment 
point in order to maintain the structure of the targeting moiety and subsequently the high 
affinity. Another important remark that can be made after analyzing the data is connected with 
the size of the whole conjugate: the larger the dimension, the lower is the affinity to the receptor 
leading to almost a 10-fold decrease for GnRH-III-sC18(GFLG-Dau) in prostate cancer tissue 
compared to K2. Furthermore, as expected, no significant selectivity between pituitary gland 
and cancer cells could be detected and this is valid also for K2. The GnRH-III-Dau conjugate 
cannot easily cross the blood-brain barrier (BBB); therefore, it has only moderate toxic side 
effects at the level of the hypophysis. The remaining question is how the CPP would influence 
the crossing of the BBB. A recent study demonstrated that this ability is not directly connected 
with the cell-penetrating property of the CPP, but that arginine rich cationic amphipathic CPPs 
show a better internalization. [240] This circumstance was evaluated for sC18 in more detail and 
a recent in vivo study shows that sC18 is not accumulating in the brain but only in the ventricles, 
which would circumvent the possible generation of side effects in pituitary gland.  [241] 
3.1.3. Cell viability assays 
Since the results from the receptor binding studies were very encouraging, we decided to 
investigate the cytotoxicity of the compounds on GnRH-IR positive and negative cell lines. The 
expression of the receptor on the surface of different cell lines was evaluated by Sabine 
Schuster by western blot analysis. The western blot was performed on whole cell lysates using 
an anti-GnRH-receptor antibody (Proteintech) and various cell lines were analyzed. As 
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depicted in Figure 19, PANC-1 showed a very low signal together with Ovcar-3 and MRC-5 
cells while good positive controls were represented by A549 and U87 cells.  
 
Figure 19. Western blot studies on cell lysates of A549, U87, PANC-1, Ovcar-3, M24, MRC-5 and HT-29 cells. 
Actin expression was evaluated as loading control. 
The cytotoxicity of K2 was already evaluated by Sabine Schuster on all these cell lines after 
24 h incubation (data not shown). While in U87 and A549 cells the drug conjugate showed 
almost the same median effective concentration EC50 (around 10 µM), a remarkable difference 
was detected in the case of the other cell lines. In particular, the results obtained from MRC-5 
and Ovcar-3 cells showed a 4- to 5-fold higher value of EC50 and this value was doubled in the 
case of PANC-1 (>100 µM). This was a further confirmation of the results of the western blot. 
For this reason, PANC-1 and U87 cells were chosen as negative and positive control cell lines, 
respectively. 
In the case of our novel constructs, we decided to adopt the strategy of a short treatment time 
to ideally simulate the in vivo situation, where the drug, after administration of the therapeutic 
molecule, should easily and selectively penetrate cancer cells as soon as it is in their proximity. 
In order to choose the right contact time of the novel conjugates, the uptake of CF-labelled 
sC18 in U87 cells was analyzed via flow cytometry at different incubation times (Figure 20). 
The cellular uptake of CF-sC18 was evaluated after 5, 15 and 30 minutes, as we reasoned 
that these intervals could highlight the importance of the CPP for a quick and efficient 
penetration and at the same time emphasize the relevance of the ligand targeting ability for a 
selective approach. A 15 minutes incubation time was chosen as optimal compromise between 
5 minutes (too much stress to the cells and poor reproducibility of results) and 30 minutes (too 
long, since the cell-penetrating activity could be too high and cause a negative influence on 
the selectivity of the system and the conjugates could interact with the receptors on the surface 
of the negative control cell lines, even if expressed at lower level).  
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Figure 20. Quantification of the cellular uptake of the CF-labeled sC18 after 5, 15 and 30 min incubation with 
U87 cells. U87 cells were incubated for 5, 15 and 30 minutes with 10 µM peptide solution. The value corresponding 
to the untreated cells was used as negative control and subtracted from the other values. The experiment was 
performed in triplicate with n=1. 
Before analyzing the activity of the drug conjugates, GnRH-III-sC18 needed to be tested to 
prove that the targeted CPP could be considered as a good drug delivery system without 
showing any conspicuous toxicity. The CPP and the targeting moiety alone were also analyzed 
as controls. 
 
Figure 21. MTT-based antiproliferative activity of the targeted conjugate GnRH-III-sC18 and the controls 
sC18 and GnRH-III. The assay was performed incubating U87 and PANC-1 cells for 72 h with washout of the 
peptide solution after 15 min. Values from the positive control (DMSO/EtOH; 1:1) were substracted from all data 
and the untreated cells were set to 100%. The experiment was performed in triplicate with n=2. 
As depicted in Figure 21, only sC18 showed a slight toxicity but just at the highest 
concentration of 100 µM, which is in line with previous studies. [186] In general we can affirm 
that the targeted CPP could be used as safe and selective carrier, showing a high binding 
affinity to the receptor and no antiproliferative activity on both cell lines tested. 
Afterwards, the drug conjugates GnRH-III-sC18(Dau) and GnRH-III-sC18(GFLG-Dau) were 
analyzed under the same conditions (Figure 22 and Table 4). In particular, we were interested 
to observe if the selectivity of the ligand detected by Sabine Schuster could still be preserved 
and how the toxicity changed in comparison to the free drug and the control peptides containing 
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exclusively the targeting sequence, GnRH-III-Dau, or the CPP, sC18(Dau) and sC18(GFLG-
Dau). 
 
Figure 22. MTT-based antiproliferative activity of the targeted conjugates GnRH-III-sC18(Dau) and GnRH-III-
sC18(GFLG-Dau), the controls sC18(Dau) and sC18(GFLG-Dau), the reference K2 (GnRH-III-Dau) and the 
free drug. The assay was performed incubating U87 and PANC-1 cells for 72 h incubation with washout of the 
peptide solution after 15 min. Values from the positive control (DMSO/EtOH; 1:1) were substracted from all data 
and the untreated cells were set to 100%. The experiment was performed in triplicate with n=2. 
Table 4. EC50 values from the antiproliferative assay depicted in Figure 22 (washout after 15 minutes and 
further incubation for 72h). 
EC50 (µM) 
 
GnRH-III-
sC18(Dau) 
sC18(Dau) 
GnRH-III-
sC18(GFLG-
Dau) 
sC18(GFLG-
Dau) 
GnRH-III-
Dau (K2) 
Dau 
U87 >100 42.2 ± 19.2 62.9 ± 20.3 9.6 ± 3.2 >100 0.078 ± 0.008 
PANC-1 78.8 ± 23.1 79.9 ± 56.4 32.13 ± 5.8 9.4 ±0.9 >140 >10 
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Considering the results of the free daunorubicin, we directly notice an outstanding difference 
between the two cell lines, whereby the EC50 in PANC-1 cells is around 50 times higher than 
in U87 cells which is not correlated with the receptor expression since the free drug directly 
penetrates through the cell membrane. This result could be explained by literature data 
indicating PANC-1 as a MDR cell line expressing the Multidrug Resistance associated Protein1 
(MRP1). [242] Daunorubicin typically enters cells via passive diffusion and is thus an easy target 
for the drug efflux pumps on the inner side of the plasma membrane. Thus, we can also 
correlate in a very rational way the results obtained by Sabine Schuster, in particular the much 
lower toxicity of GnRH-III-Dau (K2) shown in PANC-1 cells after 24h incubation in comparison 
to other negative control cell lines and the more than 10-fold lower EC50 compared to U87 cells 
(data not shown). A different pattern was observed when K2 was tested under the short contact 
time conditions: in this case, the discrepancy between the two cell lines was not as evident as 
for the free drug. If we consider that the difference is not significant, we could conclude that 15 
minutes are probably not enough time for the ligand to bind to the receptor and subsequently 
internalize at high efficiency. In contrast to this hypothesis, in previous works GnRH-gold 
conjugates were detected in the lysosomes of gonadotrophs already after 30 minutes [243] and 
the time-dependent uptake of K2 was described with CLSM pictures by Schuster et al., 
displaying a colocalization with endosomes and lysosomes after 5 minutes incubation in MCF-
7 cells. [54] Probably, after 15 minutes there could be a moderate but not sufficient uptake and 
the selectivity towards positive cell lines would be detected only after a longer incubation time. 
This highly interesting aspect was explored by Sedgley et al., who indicated that the absence 
of a cytosolic C-tail in GnRH receptors could penalize the plasma membrane localization. 
GnRH-R was found to be primarily an intracellular protein that traffics to the membrane surface 
from the endoplasmic reticulum and from cryptic receptor pools in the cytosol. [244] Extracellular 
signaling would recruit these intracellular receptors but this is a slow process pointing out that 
maybe the 15 minutes incubation are not enough. Additionally, the reason for the lower 
cytotoxicity of K2 in U87 cells compared to the free drug, a part from the different uptake 
mechanism followed (receptor-mediated endocytosis and passive diffusion, respectively), was 
presumably attributed to the already described inability of releasing the free daunorubicin due 
to the high stability of the oxime bond and this is also true for all the other conjugates. The 
cleavage sites after incubation with rat liver lysosomal homogenate have been identified by 
Sabine Schuster [54] and H-Lys(Dau=Aoa)-OH was recognized as the smallest metabolite. 
Referring to the new synthesized compounds we could suppose that the release of the drug 
would occur after proteolysis at the level of the amino acid lysine, in the case of GnRH-III-
sC18(Dau) and sC18(Dau), and glycine in the compounds containing the cathepsin B 
cleavage site, GnRH-III-sC18(GFLG-Dau) and sC18(GFLG-Dau). These metabolites 
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(Figure 23) are still able to intercalate to DNA but with a weaker activity leading to lower EC50 
values than the free toxin. 
 
Figure 23. Structure of the smallest Dau-containing metabolites obtained after lysosomal degradation of 
the peptide sequence. 
If we analyze the conjugates containing the CPP sequence, we were very pleased to observe 
that the resistance in PANC-1 cells seemed to be overcome with the use of the CPP. The EC50 
measured for sC18(GFLG-Dau) in PANC-1 cells was surprisingly lower than the value of the 
free drug and comparable to the EC50 measured for U87 cells. The ability of the drug to directly 
internalize in the cell is decreased but at the same time the intracellular accumulation of the 
drug was enhanced reducing the drug efflux, as already described by Zheng et al. [245] This 
emphasizes once more the potential of CPP for drug delivery. In this context, Lelle et al. in 
2017 published a work about this aspect: utilizing a CPP carrier they could successfully bypass 
the activity of membrane proteins such as P-glycoprotein, effectively increase the intracellular 
concentration and enhance efficacy of the drug in anthracycline resistant cells. [246] Observing 
the EC50 values of the CPP controls, we can notice that their activity is stronger than for K2 in 
both cell lines, presupposing an efficient internalization mechanism guided by direct 
translocation or endocytosis with subsequent lysosomal cleavage. This demonstrates that 
sC18 can be used as very proficient carrier. In general, the compounds containing the GFLG 
cleavage site displayed a stronger activity and sC18(GFLG-Dau) could be identified as the 
most powerful compound of these series. The higher toxicity can be explained with the 
overexpression of cathepsin B inside the cells, which is able to cleave the peptide sequence 
at the level of the GFLG cleavable linker. We could think that the smaller metabolite Dau=Aoa-
Gly-OH would favor the intercalation of the DNA but Orban et al. already demonstrated that 
the two metabolites (including glycine and lysine) show the same DNA binding characteristics. 
[132] On the contrary, the GFLG spacer is probably cleaved faster than the CPP sequence in 
the lysosomes. This would mean that Dau=Aoa-Gly-OH would be more rapidly released than 
H-Lys(Dau=Aoa)-OH. Since the drug is released in a much faster and more efficient way, this 
could also favor a further internalization of the peptide in the cytosol. Furthermore, the increase 
of hydrophobicity of the peptide sequence by addition of the linker could promote the 
penetration of the CPP leading to a subsequent higher toxicity. The comparison of the retention 
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time of compounds sC18(Dau) and sC18(GFLG-Dau) is illustrated in Figure 88 in the 
attachment. Other considerations should be done by comparing the conjugates containing the 
GnRH-III ligand, GnRH-III-sC18(Dau) and GnRH-III-sC18(GFLG-Dau). The EC50 of the full 
conjugates are always higher if correlated to the CPPs and this could be explained by the 
addition of the targeting sequence, which is probably influencing the uptake ability of the CPP. 
We could in fact imagine that if the CPP alone could be taken up by direct translocation and 
endocytosis, the CPP bound to the ligand presumably internalize in a less efficient way. This 
hypothesis could be verified by secondary structure analysis of the conjugate (e.g. CD 
spectroscopy) to detect if the tendency of the CPP to form an α-helix would be hindered. 
Anyway, already by simple observation of the structure, we could imagine that such a branched 
system would not be inserted so easily inside the cell membrane. Unfortunately, the reduced 
cell-penetrating ability did not even favor selectivity: the conjugates containing the targeting 
moiety GnRH-III-sC18(Dau) and GnRH-III-sC18(GFLG-Dau) show a better activity in PANC-
1 cells differently from U87 cells. This was unexpected, since the affinity shown by the 
triptorelin binding assay was pretty high but again this could be explained with the short 
incubation time as already described for K2.  
In general, we could improve an efficient synthetic strategy to develop conjugates that involve 
a GnRH targeting unit and a CPP showing a very high binding affinity to receptors and 
demonstrating that the presence of CPP does not invalidate the ability to bind the receptor and 
the cytotoxicity of the drug. Unfortunately in vitro studies were not so decisive to show 
selectivity but these results could be justified by the unlucky choice of many factors, in 
particular the model used and the conditions of the experiment. First of all PANC-1 cells were 
chosen as negative control, since they express the receptor at a low level but during the 
experiments we could recognize that they were also resistant to the drug. This of course did 
not facilitate the evaluation of the data because it is a further factor to take into consideration. 
The other unfortunate condition was the choice of the incubation time. Even K2 did not show 
a strong selectivity towards U87 cells after 15 min and this of course negatively influenced also 
the results for the CPP conjugates. It is possible that these selectivity issues could be 
overcome in vivo and this could be proven also by choosing other in vitro cell models and more 
ideal conditions. For example the choice of the short contact time was a very astute idea but 
maybe 30 minutes or one hour incubation could be also tested and would maybe lead to more 
consistent outcomes. A part from that, a positive result could be reached in the context of drug 
resistance and for this reason these conjugates, particularly sC18(GFLG-Dau), are worth for 
a further investigation in this direction.  
3.2. DKP3RGD as targeting moiety 
Since the GnRH system did not show the expected results in terms of selectivity, we 
concentrated on another model using as targeting unit the previously introduced c[DKP3RGD] 
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synthesized in the research group of Prof. Gennari and Prof. Piarulli, which shows a high 
binding affinity towards αvβ3 integrin receptors. [153, 156] Various works where this ligand was 
conjugated to anticancer drugs have been already published showing a favorable targeting 
index when monomeric or multimeric RGD-paclitaxel conjugates were tested on different cell 
lines expressing the integrin receptors at different extent. [157, 235] However, contrasting results 
have been described in recent publications related to the possible interaction of this ligand with 
different integrins and subsequent loss of selectivity. [166, 247] Until now, no study has been done 
with the insertion of CPPs, thus we wanted to investigate how the activity and selectivity of 
these conjugates could be influenced by the presence of this carrier peptide. 
3.2.1. Synthesis and biological evaluation of the drug delivery system 
The functionalized integrin targeting ligand c[DKPf3RGD] was prepared as previously 
described [156] by the PhD students Silvia Panzeri and Sara Parente (research group of Prof. 
Piarulli). This was then functionalized with a commercially available bifunctional azido 
carboxylic PEG4-spacer by a pH-sensitive reaction in ACN/phosphate buffer. The maintenance 
of a specific pH at 7.3-7.5 was necessary to allow the binding between the nucleophilic benzylic 
amine of the ligand and the carboxylic group of the spacer. The conditions were the same as 
described in Zanella et al. [159] and 88% yield was obtained. Afterwards, sC18 was connected 
to the ligand by CuAAC via its N-terminal propargylglycine leading to compound 1. To study 
the cellular uptake, an additional modification was introduced at the side chain of lysine at 
position 8 within the sC18 sequence: labeling with 5(6)-carboxyfluorescein (CF) resulted in 
compound 1a. The synthetic strategy, depicted in Figure 24, worked straightforward and, after 
optimizing the conditions, good yields could be obtained (see Table 20 in the attachment). At 
the beginning, the reaction was performed in t-BuOH:H2O but the best results were achieved 
with DMF and H2O, following the procedure described in Raposo Moreira Dias et al. [235]. 
Contrary to the GnRH-III-conjugates, the use of an excess of the azido compound led to better 
yields since the retention time of the CPP and the final conjugate would be otherwise too similar 
and problems during the purification would occur. The unlabeled and labeled CPPs (2 and 2a) 
were also synthesized as control to allow a direct comparison with the novel targeted drug 
delivery system. The synthesized compounds are listed in Table 5. 
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Figure 24. Synthetic strategy of the full conjugates 1 and 1a. A: Synthesis of the CF-labeled sequence by 
SPPS. B: pH-sensitive reaction for the attachment of the PEG4-linker to the functionalized ligand and “click” reaction 
between the azido group of the linker and the alkyne group at the N-terminus of the CPP. Reagents and conditions: 
a: 5 eq. Fmoc-L-Pra-OH (B), 5 eq. Oxyma, 5 eq. DIC in DMF, overnight; b: 30% piperidine in DMF (20 min x 2); c: 
10 eq. Boc2O, 1 eq. DIPEA in DCM for 2 h (2x); d: 2% hydrazine in DMF (10x); e: 2 eq. CF, 2 eq. HATU, 2 eq. 
DIPEA in DMF for 2 h, then 5 eq. CF, 5 eq. Oxyma, 5 eq. DIC in DMF overnight; f: 20% piperidine in DMF, 45 min; 
g: TFA/TIS/H2O (95:2,5:2,5), 3 h, rt; h: 1 eq. c[DKPf3RGD]-NH2, 2 eq. HOOC-PEG4-N3, PBS/MeCN, pH 7.3-7.5, 
overnight; i: 1 eq. III, 1.3 eq. c[DKPf3RGD]-PEG4-N3, 0.5 eq. CuSO4 5H2O, 0.6 eq. Na ascorbate, H2O: DMF 1:1, 
10 mM, 40 °C, N2, 24 h 
Table 5. List of the synthesized compounds with their codes, names and MW (calculated and experimental). 
Code Conjugate 
MW 
(g/mol) 
MWexp 
(g/mol) 
1 c[DKPf3RGD]-sC18 2998.2 2998.3 
1a c[DKPf3RGD]-sC18(Lys8-CF) 3355.9 3356.6 
2 sC18 2069.6 2069.9 
2a sC18(Lys8-CF) 2427.9 2428.9 
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Next, we measured the binding affinity of the new conjugates towards the isolated integrin 
receptors v3 and v5, which are both tumor-associated integrins (Table 6). The assay was 
performed by Dr. Daniela Arosio (Istituto di Scienze e Tecnologie Molecolari in Milan). 
Compounds 1 and 1a were both able to inhibit biotinylated vitronectin binding to v3 with low 
nanomolar affinity, indicating that the presence of the CPP as well as the fluorophore did not 
interfere with the receptor binding. The free functionalized ligand c[DKPf3RGD] is added in the 
table as reference and it was already reported to be up to 200-fold more selective to v3. [156, 
159] Interestingly, the selectivity was even more pronounced for the conjugate 1 (up to 1.500-
fold) within this assay. If we compare these results with the binding values obtained for the 
dual-action ligand VEGFR-integrin targeting conjugate synthesized in the group of Prof. 
Gennari, we can observe a significant difference. [159] Overall, our results indicated a stronger 
affinity and selectivity even if the size and characteristics of the molecules attached to the RGD 
ligand are comparable (both α-helical peptides, 15 and 16 amino acids for VEGFR ligand and 
sC18, respectively). One explanation for this effect might be the choice of the PEG spacer. For 
the dual action ligand a PEG8 linker was employed in order to create enough distance between 
the two ligands in accordance with a previous work of Papo et al. [248]. Contrarily, we based our 
approach on a work of Penco and co-workers, which pointed out the crucial role of the spacer 
between the targeting device and the drug in small molecule drug conjugates. [249] The spacer, 
in fact, should be able to adequately separate the two moieties in order to prevent a negative 
impact on the receptor binding but also maintain the individual features of each component. 
Short-length PEG spacers were selected to enhance solubility and minimize the formation of 
bulky loops that can interfere with the binding. As a demonstration, to connect the 
c[DKPf3RGD] ligands to a multimeric scaffold, tetraethylene glycol spacers were employed by 
Raposo Moreira Dias et al. in order to render the conjugates more water‐soluble and flexible, 
reaching a very high selectivity. [235] 
Table 6. Inhibition of biotinylated vitronectin binding to αvβ3 and αvβ5 receptors. IC50 values were calculated 
as the concentration of compound required for 50% inhibition of biotinylated vitronectin binding as estimated by 
GraphPad Prism software; all values are the arithmetic mean SD of triplicate determinations. The values 
corresponding to the free functionalized ligand were previously described and are added here as reference. [156] 
Code 
IC50[nM]  
αvβ3 
IC50[µM]  
αvβ5 
1 16.7 ± 0.6 24.9 ± 2.7 
1a 15.3 ± 5.2 2.5 ± 0.2 
c[DKPf3RGD]-NH2 26.4 ± 3.7 >5 
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For further in vitro cell studies, we first investigated which cell lines could be used as positive 
and negative control. From literature data, U87 cells have been reported to display an 
enhanced expression of αvβ3 integrins; on the contrary, HT-29 cells are documented to express 
αvβ5 but not αvβ3 receptors, while MCF-7 cells showed controversial results. [250-252] We verified 
the integrin receptor expression for these cell lines by flow cytometry using for this purpose a 
FITC-labeled anti-integrin αvβ3 monoclonal antibody. The assay was run following a protocol 
developed by the PhD student Ivan Randelovic, in the research group of Dr. József Tóvári at 
the National Institute of Oncology in Budapest. After fixation, the cells were incubated with a 
BSA solution to occupy all the unspecific binding sites on the surface and then incubated with 
the antibody for 1 h. Afterwards, the fluorescence intensity was measured by flow cytometry 
and the value obtained from the measurement of the untreated cells was subtracted. All cell 
lines were tested in the same day to better compare the flow cytometry results. 
From our assay (Figure 25), U87 cells confirmed the literature data expressing αvβ3 integrins 
at higher level compared to HT-29 and MCF-7 cells (7.5 and 5 times higher value, 
respectively), which were therefore used as negative controls. Since in vitro experiments were 
performed in two different laboratories (OOI in Budapest and University of Cologne) using the 
correspondent cell lines (same type but different stocks), the integrin expression was evaluated 
in both cases and showed comparable results (data not shown). This was an essential 
demonstration to assure that the results from different labs could be correlated. 
 
Figure 25. αvβ3 integrin expression level measured by flow cytometry analysis using FITC-conjugated anti-
integrin antibody clone LM609. This is an allosteric inhibitor of integrin αvβ3, which binds to a conformational 
epitope resulting from the post-translational association of the αv and β3 subunits. The experiment was performed 
in duplicate with n=2. 
In a next step, we investigated the cytotoxic profiles of the drug-free peptides, 1 and 2. Thus, 
U87 cells as positive control and HT-29 and MCF-7 cells as negative controls, were incubated 
for 72h with different concentrations of the conjugates (Figure 26). 
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Figure 26. MTT-based antiproliferative study with compounds 1 and 2 on U87, HT-29 cells and MCF-7 cells. 
The peptides were incubated for 72 h without washout. Values from the positive control (DMSO/EtOH; 1:1) were 
substracted from all data and the untreated cells were set to 100%. The experiment was performed in triplicate with 
n=2. 
In U87 and MCF-7 cells, at the highest concentration of 100 µM, compound 1 showed minor 
toxicity whereas the free peptide sC18 (2) significantly harmed the cells. Differently, both 
compounds showed nearly no influence on cell viability when applied to HT-29 cells, even if a 
slightly higher activity of peptide 2 could be recognized also in this case. The lower cytotoxicity 
in HT-29 cells probably directly reflects the reduced sensitivity of this cell line. The high toxicity 
of 2 has not been verified by previous results, but this is maybe related to the fact that the 
cytotoxicity profile has never been tested for 72h. In fact, when the toxicity was tested after 
24h, no effect could be detected even at the highest concentration, showing a very similar 
profile between the different cells (figure 89 in attachment).  
In a 72h experiment, too many factors are playing with each other and the binding affinity 
features of the conjugates could be definitely annulled after such a long incubation time by the 
internalization ability of the CPP and the presence, even if at lower level, of αvβ3 integrin 
receptors also in the control cell lines. For this reason, the distinctive activities of the two 
compounds in the different cell lines should be related to the peculiar biological characteristics 
of each cell type and no theory about selectivity could be drawn. A much more interesting 
investigation to corroborate our hypothesis would be to examine the uptake profiles of 
compounds 1a and 2a, taking into consideration not only different incubation times but also 
the internalization behavior in presence of binding competitors or inhibitors of peculiar transport 
pathways. This was considered as decisive to let us understand the underlying mechanisms 
that influence the cell penetration of the construct, in particular evaluating the dependence on 
receptor-binding. 
First, the time-dependence of peptide uptake was quantified in U87, HT-29 and MCF-7 cells 
(Figure 27A). The three cell lines were incubated with the fluorescently labeled conjugates 1a 
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and 2a for 30 and 60 min and the fluorescence intensity was quantitatively measured by flow 
cytometry. All the results were normalized within the different cell lines to better compare the 
outcomes, not only between the peptides but also between the different systems.  
 
Figure 27. Cellular uptake of 1a and 2a in U87, HT-29 and MCF-7 cells. A: Cellular uptake was quantified by 
flow cytometry. Cells were incubated with 10 µM peptide solution for 30 or 60 min at 37°C. The results are 
normalized to the value of sC18 in U87 cells that is set to 1. The experiment was performed in triplicate with n=2. 
(**: p ≤ 0.01; ***: p ≤ 0.001; ****: p ≤ 0.0001). B: Cellular uptake was analyzed by CLSM. Cells were incubated for 
30 min with 10 µM of CF-labeled peptide solution at 37°C. External fluorescence was quenched by treatment with 
150 µM trypan blue for 15 sec. Green: CF-labeled peptide; blue: Hoechst 33342 nuclear stain; scale bar is 10 µm.  
Interestingly, in all the cell lines the uptake of 1a was time-dependent, differently from 2a where 
such a tendency could not be recognized. A general remark about these results is that, as 
already stated for the cytotoxicity, differences in the uptake are sometimes merely influenced 
by the biological characteristics that distinguish a particular cell line from the others. 
Nevertheless, if we compare the two compounds we can notice different behaviors that are 
worth to be described in details for every cell line. What we can observe is that, differently from 
the negative control cell lines, in U87 the internalization of 2a after 30 minutes was stronger 
than 1a. This reduced uptake can be explained with the different uptake modalities 
distinguishing these two peptides. We already showed that the conjugate 1a displays a high 
affinity towards integrin αvβ3. For this reason, we can imagine that, when in contact with the 
cell surface, the compound would tend to bind to the receptor and afterwards internalize by 
receptor- or by CPP-mediated uptake. This important interaction would definitely shorten the 
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time available for internalization leading to an overall reduced penetration. Indeed, since within 
this experiment we washed out the solution and trypsinized the cells, the conjugate, still bound 
to the receptor or interacting at the level of the outer membrane, would detach from the cell 
evolving in a lower cellular uptake. In addition, 1a would be probably taken up at lower extent 
because of the different structure. It has been already demonstrated that the insertion of a 
PEG spacer would enhance the hydrophilicity of the molecule leading to a lower internalization 
rate, since the direct translocation through the lipid phase of the membrane would be limited. 
[253] After 60 min incubation more peptide was able to internalize and for this reason the 
fluorescence intensity measured for 1a and 2a are leveled. Other considerations should be 
made in case of MCF-7 and HT-29 cells since in this case the receptors are present at a lower 
level and should not exert any role in the internalization. In these cell lines, after 30 min the 
uptake levels of the two compounds are comparable while after 60 min incubation, the situation 
is completely overturned in relation to U87 cells, which is a good sign because it means that 
this behavior is dependent on the different integrin expression. What we can presume is that 
1a is probably more stable than 2a, therefore it would not be rapidly degraded so that, after 60 
minutes, 1a would internalize at higher extent. Another hypothesis could be connected with a 
possible receptor-mediated uptake, which could play an important role after longer incubation 
time. As I already illustrated, our control cell lines do not completely lack of integrin receptors 
and their presence should be taken into consideration in the evaluation of the experimental 
results. To clearly understand this phenomenon and concretely imagine what could happen on 
the surface of the cell, the structure of the conjugate 1a was calculated using the Phenix 
software and illustrated with Pymol (Figure 28). 
  
Figure 28. Structure calculation of conjugate 1a illustrated with Pymol. Calculation was performed by the PhD 
student Dirk Lindenblatt (research group of Prof. Niefind, University of Cologne). 
This picture is quite significant for our study since we can directly observe how the helix 
generated by the CPP forms a 90° angle with the targeting moiety and this could allow an 
efficient insertion through the two receptor subunits and effective binding, as already 
demonstrated by the binding studies.  
The cellular uptake was also qualitatively examined by CLSM (Figure 27B): the cells were 
incubated for 30 minutes with the peptide solutions, nuclei were stained with Hoechst 44432 
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and the external fluorescence was quenched with trypan blue. While MCF-7 and HT-29 cells 
were pretty easy to handle, many problems have been met with U87 cells. This cell line is very 
sensitive to every treatment, in particular when many steps are performed in a short time 
interval as it happens for microscopy measurements (treatment, quenching, washout). Indeed, 
the cells rapidly detach from the well surface, become round and cannot be visualized so well. 
For this reason, the outcomes are also difficult to compare within different cell lines. 
Nevertheless, all the cell lines have been tested and from the pictures, we notice a quite similar 
internalization pattern between 1a and 2a. The quantitative difference in uptake shown in the 
FACS results for U87 cells between the two compounds is not clearly visible here but 2a 
displays a high standard deviation, what would explain this result. In the case of MCF-7 and 
HT-29 cells, the FACS results are here validated since the uptake of the two compounds is 
comparable. As already described in the introduction, different entry pathways can be followed 
by CPPs and these could be influenced, a part from the size of the cargo and the concentration 
of the peptide, also by the different cell lines tested. [254] In fact, regard to the uptake pattern, 
we can detect a distinctive vesicular distribution in HT-29 cells, opposed to a more diffuse 
dispersion in the cytosol of U87 and MCF-7 cells, indicating a possible explanation for the 
higher toxicity of 2 in these cell lines observed in the previous antiproliferative assay (Figure 
26). Since the microscope investigation did not offer us more relevant information than the 
quantitative assay by flow cytometry, it would be interesting to perform the same experiment 
after 60 minutes incubation to observe if some variations in the internalization pattern could be 
detected in particular for 1a. 
To better understand this important mechanism of internalization into U87 cells we decided to 
perform more experiments using flow cytometry starting with a competition assay (Figure 29). 
To do so, the competitor used was the free unfunctionalized ligand c[DKP3RGD] synthesized 
by the PhD student Clémence Robert, in the group of Prof. Piarulli. The assay was based on 
the addition of this molecule to the 1a peptide solution followed by incubation with U87 cells 
for 30 or 60 min for a better comparison with the previous results obtained from the cellular 
uptake studies.  
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Figure 29. Competition experiment. Co-incubation of the peptide 1a (10 µM) with a 10-fold excess of the free 
ligand c[DKP3RGD] for 30 and 60 min. The cellular uptake was quantified by flow cytometry. (*: p ≤ 0.05; **: p ≤ 
0.01). The experiment was performed in triplicate with n=2. 
A maximal 10-fold excess of the ligand (100 µM) was used because as soon as we increased 
its concentration, we encountered many problems by handling the cells. This was a further 
demonstration that U87 cells overexpress integrin receptors and that these receptors are very 
important for the adhesion on the surface of the plate. In fact, when RGD was added in excess, 
the cells started to detach even if high care was taken while treating them as already described 
by Russo et al. [255] In the presence of a 100-fold excess of the ligand, in fact, after 30 min 
incubation the cells were completely detached so that a significant number of cells could not 
be counted. Starting from the 30 min incubation, we can see a slight inhibition in the uptake of 
conjugate 1a. After 60 min the effect is higher, corroborating that, after longer incubation, the 
integrin-mediated internalization could have a stronger effect. Since the influence is not 
substantial, we could state that integrin-receptor mediated uptake may have a slight relevance 
on the internalization of 1a but assumedly not as meaningful as the CPP-mediated uptake. An 
additional theory could be that the conjugate recognizes the receptor but does not bind to it 
following a “kiss and run model” being then quickly taken up by CPP-mediated uptake. This 
hypothesis was already described by Reina and coworkers, who proved that the internalization 
of a cRGD ligand was not integrin-dependent but that, after binding the receptors, it would 
follow a fluid-phase endocytosis pathway to lysosomes. [165] 
This assumption could be exemplified by the model depicted in Figure 30 where two 
mechanisms are present at the same time: a receptor-mediated uptake and a CPP-mediated 
uptake. Probably in our case the CPP-mediated uptake is stronger but the recognition of the 
receptor is very important and allows the conjugates to target the cell. 
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Figure 30. Graphic model describing the hypothetical internalization mechanism of the new drug delivery 
system. The selective targeting to receptor-overexpressing cells is allowed by the integrin ligand and the good 
permeability of the CPP improves drug cellular uptake. The CPP-mediated uptake plays a big role: the peptide-drug 
conjugate is first recognized by the receptor and then internalized by CPP-mediated mechanisms (endocytosis or 
direct penetration). Next to this, the peptide drug-conjugate could also internalize inside the cell by receptor-
mediated endocytosis. In the endosomes the conjugates are degraded and the drug released. 
Since we could not demonstrate that only integrin-dependent uptake plays a role in the 
internalization of the constructs, we performed a blocking experiment that would be useful to 
understand the whole mechanism (Figure 31). In this case, the cells were pretreated for 30 
minutes with the correspondent inhibitors, afterwards the blocking solution was removed and 
the cells were incubated for further 30 min with 1a. Additionally to the free ligand c[DKP3RGD], 
other reagents have been used to block some entry pathways typical of CPP internalization. 
Poly-L-lysine (PLL) was used to inhibit the direct membrane translocation of the peptide: this 
inhibitor is meant to interact with the negative charges of the cell membrane and inhibit the 
interaction of the positively charged CPP helix blocking its penetration. The other reagent used 
was methyl-β-cyclodextrin (mβ-cd), responsible for depleting the membrane from cholesterol 
and blocking any cholesterol-dependent endocytic uptake.  
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Figure 31. Blocking experiment. 30 min pre-incubation with c[DKP3RGD] (10 µM), PLL or mβ-cd (1 mM) followed 
by 30 min incubation with 10 µM 1a solution. The experiment was performed in triplicate with n=1. 
It seems from these results that the integrin receptor-mediated uptake has practically no 
influence in the internalization of the conjugate 1a while the CPP-mediated uptake plays a 
crucial role. In fact after treatment with PLL and mβ-cd, the uptake is reduced to the half, 
respect to the control. This does not happen for the free ligand, where we can surprisingly see 
an increase of the uptake probably due to the increment of other ways of penetration mediated 
by the CPP. 
In general, the results achieved so far proved that the ligand chosen to increase the selectivity 
of the CPP could actually lead to crucial differences in the uptake of the conjugate 1 compared 
to the CPP 2 but that the internalization is probably influenced by the CPP while the ligand 
could play an important role in targeting the conjugates towards the cells overexpressing the 
receptors. Since our final goal is connected with the improvement of the traditional 
chemotherapy, especially concerning the reduction of side effects by increasing selectivity, 
new research directions have been undertaken, starting with the development of synthetic 
strategies to accomplish the conjugation to various cytotoxic payloads.  
3.2.2. Development of cryptophycin conjugates 
The first drug to be conjugated with the drug delivery system was cryptophycin-55. The 
molecule was synthesized by the PhD student Eduard Figueras Agustì (research group of Prof. 
Norbert Sewald, University of Bielefeld) and functionalized as glycinate ester of the hydroxyl 
group of the chlorohydrin (Cry-55 glycinate) in order to allow the attachment of a linker. The 
synthetic strategy followed for the preparation of the conjugates, listed in Table 7, is depicted 
in Figure 32. 
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Figure 32. Synthetic strategy for the synthesis of c[DKPf3RGD]-sC18-S-S-Cry. Reagents and conditions: a: 5 
eq. Fmoc-L-Pra-OH (B), 5 eq. Oxyma, 5 eq. DIC in DMF, overnight; b: 30% piperidine in DMF (20minx2); c: 10 eq. 
Boc2O, 1 eq. DIPEA in DCM for 2 h (2x) d: 2% hydrazine in DMF (10x); e: 5 eq. Fmoc-β-Alanine-OH, 5 eq. Oxyma, 
5 eq. DIC in DMF, overnight; f: 5 eq. Fmoc-Pen(Trt)-OH, 5 eq. Oxyma, 5 eq. DIC in DMF, overnight; g: 
TFA/thioanisole/EDT (90:7:3), 3 h; h: 1 eq. 3-mercaptopropionic acid, 2.3 eq. dithiopiridine, MeOH, 3 h, rt; i: 1 eq. 
Cry-55-gly, 4 eq. V, 4 eq. PyBOP, 4.5 eq. HOBt, 5 eq. DIPEA in dry DMF, N2, 5 h, rt; j: 1 eq. VI, 1 eq. IV, dry DMF; 
k: 1 eq. VII, 1.3 eq. c[DKPf3RGD]-PEG4-N3, 0.5 eq. CuSO4 5H2O, 0.6 eq. Na ascorbate, H2O: DMF 1:1, 10 mM, 40 
°C, N2, 24 h. 
The synthesis of the CPP moiety IV was performed as already described but at the side chain 
of Lys8 a β-alanine was attached functioning as spacer and a penicillamine residue was bound 
to it. The penicillamine was chosen because of the branched side chain that could protect the 
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disulfide bridge from the cleavage in biological fluids, thus improving the stability of the 
conjugate and hindering the premature release of the drug causing an off-target effect. [256] For 
the preparation of the drug-linker molecule VI, dithiopyridine was reacted with a thiol acid [257] 
to allow the formation of a peptide bond with the amino group of the glycine residue attached 
to the drug. Particular care had to be taken during all these steps because of the sensitivity of 
the drug. In fact, the maximum temperature that could be used was 40 °C in order to prevent 
the hydrolysis of the chlorine atom. The synthetic strategy until the formation of the CPP-drug 
conjugate VII, easily obtained in DMF solution, [258] worked successfully in optimal yields. The 
critical step during the synthesis turned out to be the “click” reaction. The previously described 
conditions were used but we directly understood that the linker would not be stable in presence 
of the reductive agent sodium ascorbate. The reaction was followed by LC-MS and samples 
were taken at regular intervals. Already after 10 minutes, the peak corresponding to the final 
product was detectable almost at the same retention time of the educt. After 1.5 h the situation 
did not change and there was still the same educt/product ratio. The reaction was left overnight 
and the next day new peaks were detectable corresponding to the oxidized CPP and the 
oxidized CPP conjugated to the ligand (Figure 33).  
 
Figure 33. ESI-MS mass spectrum of the “click” reaction between VII and c[DKPf3RGD]-PEG4-N3 after 24 h 
at rt. 1: oxidized IV; 2: oxidized c[DKPf3RGD]-IV conjugate (without Cry-linker); 3: c[DKPf3RGD]-PEG4-N3; 4+5: 
VII and c[DKPf3RGD]-sC18-S-S-Cry 
The product could be obtained in only very low amounts, the yield was very low and the starting 
material could not be recovered (Table 20 in the attachment). Alternative conditions have been 
considered in order to avoid the presence of reductive agents. In this sense, a publication from 
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Prof. Sewald showed the optimal alternative, where copper powder was used and the yields 
were quite satisfactory. [259] Unfortunately, because of the few amounts available of the 
c[DKPf3RGD] ligand and the cryptophycin variant, it was not possible to optimize the reaction 
with the right solvents and right equivalents and some work still has to be done in this direction. 
Since the compound obtained until now was not sufficient to start biological studies, we 
considered changing the cytotoxic payload but taking into consideration that the synthesis of 
these constructs should be further investigated because of the very promising activity of the 
highly active cryptophycin. 
Table 7. List of Cry-55-glycinate conjugates with their names, structures and MW (calculated and 
experimental) 
Name Structure 
MW 
(g/mol) 
MWexp 
(g/mol) 
c[DKPf3RGD]-
sC18-S-S-Cry 
 
4050.7 4049.7 
sC18-S-S-Cry 
 
3121.7 3121.4 
 
3.2.3. Development of chlorambucil conjugates and their biological evaluation 
Because of the easier way of conjugation, chlorambucil was considered as new cytotoxic 
payload. This project was in collaboration with the PhD student Clémence Robert, who 
synthesized these novel conjugates during her secondment at the University of Cologne. The 
synthetic strategy is not shown but followed the same steps as for the other conjugates. In this 
case, the drug was coupled following the traditional SPPS strategy. The synthesis seemed to 
be easy and straightforward but as soon as the peptide was cleaved from the resin, lyophilized 
and purified, a lot of problems were encountered connected with the high tendency of 
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chlorambucil to hydrolyze when in contact with water, in particular at acidic pH. This hydrolysis 
had been previously described and it could be limited by shortening the time between one 
synthesis step and the other. [260] For this reason, after purification, the dissolved peptide was 
put on ice or directly frozen for freeze-drying and the peptides were preserved at -20 °C or -80 
°C. Stock solutions were prepared in DMSO. Despite these problems, the CPP-conjugates 
could be successfully synthesized and analyzed by LC-MS (Table 8). 
Table 8. List of Chlorambucil conjugates with their names, structures and MW (calculated and 
experimental). 
Name 
Structure MW 
(g/mol) 
MWexp 
(g/mol) 
c[DKPf3RGD]-
sC18(Cbl) 
 
3297.8 3298.4 
Cbl-sC18 
 
2356.8 2356.4 
 
The cytotoxicity of the conjugates could be finally evaluated by MTT-based assay and short 
incubation times were used, for the same reasons as for the GnRH conjugates (Figure 34). As 
we can see, the free cytostatic agent was not active in both cell lines. This outcome is in strong 
relation with the weak internalization of the drug; the CPP in this case would improve a lot its 
efficacy. In fact, if we analyze the graph of Cbl-sC18 we can see that the measured EC50 value 
is much lower in particular for U87 cells and we could improve the cytotoxicity of the drug. In 
the context of selectivity, the results, were not as expected. The conjugate c[DKPf3RGD]-
sC18(Cbl) was slightly more toxic in U87 than in HT-29 cells but the activity compared to the 
free drug was pretty the same if not worse and anyway much less active than Cbl-sC18 (almost 
4-fold higher EC50 for U87 cells). We tried to figure out which could be the reason for that and, 
we realized that this could be connected with the problem of hydrolysis in the cell culture 
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medium. Also in this case we could think about the internalization pathway of the conjugate. 
As already hypothesized before, the conjugate 1 was not internalized so well as 2 because of 
the presence of PEG that could disturb the direct translocation of the peptide. Additionally, in 
U87 cells the targeted conjugate could bind to the receptors hindering a fast CPP-mediated 
penetration. In fact, the same theories shown before could be validated also in this case. 
Therefore, in HT-29 cells the conjugate is simply washed out after 15 min while for U87 cells 
the conjugate is still binding outside on the surface of the cell but, before and after being 
internalized, hydrolysis would occur hampering the alkylating activity when the conjugate finally 
reaches the site of action inside the nucleus.  
 
Figure 34. MTT-based antiproliferative study with compounds c[DKPf3RGD]-sC18(Cbl), Cbl-sC18 and Cbl 
on U87 and HT-29 cells. After 15 min incubation, the peptide solution was removed and the cells were incubated 
for additional 72 h with fresh medium. Values from the positive control (DMSO/EtOH; 1:1) were substracted from 
all data and the untreated cells were set to 100%. The experiment was performed in triplicate with n=2. 
Table 9. EC50 values of the compounds c[DKPf3RGD]-sC18(Cbl), Cbl-sC18 and Cbl referred to figure 34. 
EC50 (µM) 
 U87 HT-29 
c[DKPf3RGD]-sC18(Cbl) >110 >170 
Cbl-sC18 31.6 ± 3.3 78.6 ± 7.1 
Cbl >140 >140 
 
Since the hydrolysis of the compounds would add a further factor to take into consideration in 
this already complex system, we reasoned that chlorambucil was not the ideal drug to be used 
to investigate the selectivity of these conjugates.  
3.2.4. Development of daunorubicin conjugates and their biological evaluation 
Since the conjugation to the previous drugs caused some problems, due to the difficult 
synthesis or the instability of the molecules, we decided to use the same strategy described 
for the GnRH-III-conjugates: daunorubicin was used again for the conjugation to the CPP via 
oxime bond. In the case of GnRH-III conjugates, the main problem was the resistance in 
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PANC-1 cells and the lack of efficacy of the GnRH receptor binding after the short incubation 
time, but the drug showed a relatively good activity and an efficient conjugation strategy. 
Furthermore, the CPP clearly improved the internalization of the homing peptide playing a very 
important role in the delivery of the drug. The CPPs I and II were synthesized as already 
described for the GnRH-III conjugates (Figure 18). The “click” reaction with the ligand worked 
pretty well reaching yields from 75% to 90% (Table 20 in the attachment). In this case, in 
addition to the controls including only the CPP sequence (2b and 2c, previously named 
sC18(Dau) and sC18(GFLG-Dau)), two other determinant controls (Figure 35B) were 
synthesized by the PhD student Sara Parente from the research group of Prof. Piarulli. The 
first one 3b, containing the c[DKPf3RGD] moiety separated from the drug by a PEG4 chain, 
the second one 3c, where the two elements were outdistanced by a GFLG cleavable linker. 
For the last compound, the PEG4 linker was not inserted in order to keep more or less the 
same distance between the targeting moiety and the drug, so that the binding would not be 
influenced. These two controls were synthesized in order to strictly analyze the contribution of 
the RGD moiety to the activity of the drug and compare this to the other conjugates containing 
the CPP as carrier moiety or both the CPP and the c[DKPf3RGD]. The general synthetic 
strategy for the full conjugates is depicted in Figure 35A and all the synthesized compounds 
are listed in Table 10. 
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Figure 35. Synthetic strategy for the synthesis of 1b, 1c (A) and structure of the controls 3b and 3c (B). See 
figure 18 for the synthesis of I and II. Reagents and conditions: a: 1 eq. I or II, 1.3 eq. c[DKPf3RGD]-PEG4-N3, 0.5 
eq. CuSO4 5H2O, 0.6 eq. Na ascorbate, H2O: DMF 1:1, 10 mM, 40 °C, N2, 24 h. 
Table 10. List of synthesized c[DKPf3RGD] conjugates and controls with their codes, names and MW 
(calculated and experimental). 
Code Name 
MW 
(g/mol) 
MWexp 
(g/mol) 
1b c[DKPf3RGD]-sC18(Dau=Aoa-Lys8) 3580.1 3581.1 
2b sC18(Dau=Aoa-Lys8) 2652.2 2653.2 
3b c[DKPf3RGD]-PEG4-Aoa=Dau  1584.2 1585.0 
1c c[DKPf3RGD]-sC18(Dau=Aoa-GFLG-Lys8) 3954.6 3955.6 
2c sC18(Dau=Aoa-GFLG-Lys8) 3027.0 3027.9 
3c Dau=Aoa-GFLG-c[DKPf3RGD] 1587.4 1587.9 
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The same binding assay as for the drug-free conjugates was performed by Dr. Arosio with the 
drug conjugates and the results were quite promising and similar to the previous ones (Table 
11). 
Table 11. Inhibition of biotinylated vitronectin binding to αvβ3 and αvβ5 receptors. IC50 values were calculated 
as the concentration of compound required for 50% inhibition of biotinylated vitronectin binding as estimated by 
GraphPad Prism software; all values are the arithmetic mean SD of triplicate determinations. The values 
corresponding to the free ligand were previously described and are added here as reference. [156] 
Code 
IC50[nM]  
αvβ3 
IC50[µM]  
αvβ5 
1b 31.7 ± 4.2 >10 
1c 9.7 ± 4.0 >10 
3b 14.0 ± 1.6 6.3 ± 0.4 
3c 5.8 ± 0.6 2.1 ± 0.1 
c[DKPf3RGD]-NH2 26.4 ± 3.7 >5 
 
The presence of daunorubicin did not influence the binding to the receptors, contrarily the 
affinity, compared to the free functionalized ligand c[DKPf3RGD], was in some cases even 
improved (1c, 3b, 3c). Furthermore, the selectivity towards the two integrin types was 
maintained. Especially, we can recognize a difference between 1b and 1c but also 3b and 3c. 
It seems that a better binding is connected with the presence of the hydrophobic cleavable 
linker GFLG. An explanation for this result could be only demonstrated by docking studies 
where we could effectively see how the construct is positioned inside the receptor and which 
interactions are feasible to stabilize the complex.  
After these encouraging results, we were interested to see how the secondary structure of the 
CPP-bearing conjugates would change with the addition of the drug and/or the ligand. The 
amphipathic helix is a common motif encountered in various proteins and peptides. 
Amphipathicity induces the partition of hydrophobic and polar residues between the two 
opposite faces of the α-helix, favoring membrane binding and penetration. [261] Previous works 
already demonstrated that sC18 assumes an amphipathic α-helical conformation when in 
contact with artificial lipid membranes, [183] therefore the tendency of the novel conjugates to 
form an α-helix was analyzed by CD spectroscopy.  
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Figure 36. CD spectra of 1b, 1c, 2b and 2c in 10 mM phosphate buffer (left) and 10 mM phosphate buffer/TFE 
1:1 (right). Peptide concentration was 20 µM. 
The conjugates were dissolved in phosphate buffer but also in a 1:1 mixture of phosphate 
buffer and the secondary structure inducer TFE. The α-helical content can be quantitatively 
expressed through the R-value determined by the ratio between the ellipticity values at 220 
nm and 208 nm, [262] where R=1 corresponds to an ideal α-helix. [263] While in phosphate buffer 
only a random-coil structure could be recognized, in the presence of TFE all the conjugates 
displayed the typical curve of an α helix (Figure 36). The first important observation that can 
be evidenced is the higher tendency of the c[DKPf3RGD] conjugates 1b and 1c to form a helix. 
This can be explained by the presence of the cyclic rigid construct at the N-terminus of the 
complex that could stabilize and elongate the whole structure. On the other hand it is possible 
that the c[DKPf3RGD]-linker is well inserted in the amphipathic sequence reinforcing the helix. 
This last theory would not be consistent with the calculated structure of the conjugate 
represented in Figure 28. In fact, in that case, the illustrated construct does not seem so 
homogeneous and it looks like the ligand is not embedded so well in the helical arrangement. 
Conversely, this structure was only calculated and the behavior in presence of a membrane 
could change the resulting organization. The corresponding GFLG variants 1c and 2c always 
display lower R values indicating that the helix is somehow hindered by the presence of this 
linker located in the middle of the sequence. Surprisingly, these results are exactly the opposite 
as for the binding studies: it seems that the presence of a better helix could somehow disturb 
the binding to the receptor. To demonstrate this, we should prove that during the cell-free 
binding assay in the presence of the receptors, an α-helix is also built. 
Like for the GnRH-III conjugates, the coupling to daunorubicin proved to be very effective and 
the compounds could be obtained in a sufficient amount to perform further studies. In 
particular, the binding studies demonstrated that the coupling to daunorubicin did not affect the 
affinity to the receptor, indicating that Lys8 in the sequence of the CPP was an ideal conjugation 
site. Furthermore, the secondary structure of the CPP was not disturbed by the presence of 
the drug in the central part of the sequence, since the R-value for 2b is comparable to the one 
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of 2, as already illustrated in previous works. [186] As a further improvement, the ligand even 
seemed to favor the formation of the helix and subsequently also a possibly interaction with 
the cell membrane. Based on these results, we thought that it was worth to continue 
investigating these conjugates starting with the examination of their cytotoxic effect on the 
already introduced cell lines U87, HT-29 and MCF-7. 
First, the cytotoxic activity of the full-conjugates (1b and 1c) and controls (2b, 3b and 2c, 3c) 
was tested after 72h incubation in presence of the three cell lines. In Figure 37, the EC50 curves 
of every compound are depicted. For a more schematic summary, Table 12 shows the EC50 
values for every cell line. The outstanding difference between the cytotoxic activity of the 
synthesized compounds (low micromolar range) and the EC50 of Dau (low nanomolar range) 
after 72h incubation had been already observed for the GnRH-III conjugates and, as previously 
outlined, it depends from the release of a metabolite that intercalates DNA with lower efficiency 
than the free drug (see Figure 23). Anyway, the lower activity of daunorubicin was not 
considered as a big problem as long as selectivity would be reached and a directed transport 
towards a specific cell line would be achieved. The different activity of the free drug observed 
in the three cell lines is purely depending on the different cellular uptake and not from a targeted 
transport as we want to achieve for our conjugates. These differences can be seen also in the 
case of the CPP controls and are purely connected to the different characteristics of every cell 
line. As already foreseen for the GnRH-III conjugates, after this long incubation time, we could 
not demonstrate any selectivity towards the integrin-overexpressing cell line U87. This is not 
valid for the controls 3b and 3c, where the lowest EC50 value is always exhibited by U87 cells, 
followed by HT-29 and MCF-7 cells. In this case, in fact, the CPP portion is missing and the 
internalization should be totally dependent on the presence of the receptor. Anyway, as already 
described by Bodero et al., within the 72h incubation a different uptake could be preferred 
mediated for example by other integrin receptors and this would explain why the EC50 values 
are not so divergent. [247] The best control to demonstrate this, would be to use isogenic 
knocked-out cells where the αv subunit is not present to definitely confirm that the uptake is 
completely integrin-dependent.  
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Figure 37. Antiproliferative assay with compounds 1b, 2b, 3b, 1c, 2c, 3c on U87, HT-29 and MCF-7 cells (72 h 
incubation). The peptides were incubated for 72 h without washout. Values from the positive control (DMSO/EtOH; 
1:1) were subtracted from all data and the untreated cells were set to 100%. The experiment was performed in 
triplicate with n=2. 
Table 12. EC50 values referred to the antiproliferative assays showed in Figure 37. 
EC50 [µM] EC50 [nM] 
 1b 2b 3b 1c 2c 3c Dau 
U87 5.6 ± 1.1 5.8 ± 1.5 3.0 ± 0.7 3.9 ± 3.9 1.1 ± 0.2 2.5 ± 0.7 7.8 ± 2.4 
HT-29 2.9 ± 0.2 9.2 ± 0.1 9.2 ± 0.9 11.0 ± 1.1 2.8 ± 0.2 5.4 ± 1.3 37.9 ± 7.7 
MCF-7 9.1 ± 2.11 5.0 ± 1.1 21.7 ± 8.3 2.7 ± 0.8 3.5 ± 0.4 14.7 ± 6.5 65.1 ± 18.3 
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We imagined that, since conjugates 1b and 1c showed a noteworthy binding affinity to αvβ3, 
they would selectively bind to the surface of U87 cells. In the case of MCF-7 and HT-29 cells 
this would also occur since they also express integrins but in a limited grade. If the incubation 
time is too long, the role of the ligand for the selective targeting would be surely annulled and 
the CPP internalization would not bring so many advantages in the activity of the drug. As we 
can see, after 72 h, the EC50 values of 3b and 3c are comparable to the outcomes of 1b, 2b 
and 1c, 2c at least for U87 and HT-29 cells. In general, as we already introduced for the GnRH-
III conjugates, we thought that the incubation time should be shortened if we wanted to achieve 
the best results in terms of targeting since otherwise the different activities of each single 
conjugate would be leveled to the others after such a long interval. Our suggestion was in fact 
to demonstrate the consistent contribution of the CPP in the internalization of the CPP-bearing 
molecules meanwhile restricting the relevance of the ligand in the uptake process. 
Nevertheless, the binding should be efficient even in this short incubation and allow the 
conjugates to target the surface of the cell and subsequently improve the CPP-mediated 
uptake in the cell line displaying the integrin receptors, following the previously described “kiss 
and run” process. In fact we wanted to establish a model where we could visualize the in vivo 
condition where, after the therapeutics are administrated, they are only shortly in contact with 
the tissue and should exert their action very fast. By this strategy, we wanted to show that our 
novel compounds, in such a short time would be able to get in contact to the receptors, bind 
to them, but then be internalized through CPP-mediated uptake as we could infer from the 
results of the flow cytometry. With the intention to find better conditions to explore the biological 
activity of this drug-delivery system, we decided to perform the next experiments using shorter 
incubation times. The same strategy as for the GnRH-III conjugates was used, but before 
studying their cytotoxic effect, a deeper inspection in the internalization of the conjugates was 
carried out. The impact of the ligand and the CPP on the cellular uptake of all the conjugates 
and controls was analyzed by flow cytometry after 15 min incubation (Figure 38) and by CLSM 
after 30 min incubation (Figure 39) with the three cell lines. The choice of the different 
incubation time was due to the peculiar experimental conditions of the two assays. For CLSM, 
15 minutes would be in fact too short to easily handle the cells and this would perturbate their 
condition complicating the entire experiment. 
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Figure 38. Cellular uptake of 1b, 2b, 3b and 1c, 2c, 3c in U87, MCF-7 and HT-29 cells quantified by flow 
cytometry. Cells were incubated with 10 µM peptide solution for 15 min at 37 °C. (*: p ≤ 0.05; ***: p ≤ 0.001). The 
results were normalized to the value of 1b in U87 cells that is set to 1. The experiment was performed in triplicate 
with n=2. 
A first general glance at the results starting from the conjugates without cleavable linker (1b-
3b) shows us that the uptake of the compounds containing the ligand (1b, 3b) is reduced if 
compared to the CPP (2b). 3b shows a lower uptake compared to the CPP-containing 
counterpart since in this case the ligand is directly connected to the drug without the 
interposition of the CPP molecule. The internalization, being just receptor dependent, would 
be therefore reduced and slowed down. As for the other conjugate 1b, in case of U87 cells it 
follows the same internalization tendency like for the CF-labeled compounds 1a and 2a 
(Figure 27, uptake after 30 min incubation) suggesting that the c[DKPf3RGD] containing 
conjugate would bind to the receptors and for this reason the uptake would be decreased, at 
least at the beginning. Since the incubation time in this case is even lower (15 min) this 
supposition would be even more justified. In the case of HT-29 and MCF-7 cells, this tendency 
could be explained by the worse internalization of these conjugates because of the presence 
of the ligand and the PEG linker, which somehow hinder the transport inside the cell as we 
previously discussed. This observation does not fit with the results obtained with the CF-
labeled compounds where for HT-29 and MCF-7 cells no significant difference between 1a and 
2a after 30 minutes could be recognized. It is important to notice that in this case the incubation 
time was different (15 minutes instead of 30 minutes) and that the uptake of 1a, differently from 
2a, was previously recognized to be time-dependent. Therefore, it is possible that after 
15 minutes 1b is still taken up at a lower level. Furthermore, the labeling with a different 
molecule could also lead to discrepancies in uptake. In fact if we compare the uptake of 2b in 
the three cell lines we also notice an outstanding contrast with the CF-compounds where U87 
was the favored cell line. In this case the behavior is dissimilar and highly probably it is also 
connected with the different physicochemical properties of the two attached groups. In Figure 
87 in the attachment the retention time of 1a and 2a is compared. 
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If we correlate the higher inclination of 1b to generate a helix, we would expect that the full 
conjugate 1b would be taken up at higher extent in every cell line, or at least in the negative 
controls since there, the uptake is not dependent on the receptor. On the contrary, the uptake 
of 1b is always lower than 2b. We could explain this contradictory result, changing the 
prospective from CD measurement to a real interaction with the cell membrane. At the 
beginning, the unfolded peptide is laying in parallel with the membrane interacting with the 
phospholipid heads. Afterwards, the peptide spontaneously moves to the core of the 
membrane interacting with the hydrophobic tails (hydrophobic effect) and the sequences 
rearrange to form a helix that reduces the exposition of the peptide bonds. In the case of 1b 
we demonstrated that the helix could be also formed but the initial transfer and insertion inside 
the membrane could be limited by the presence of the highly hydrophilic ligand-linker construct. 
For this reason, these two characteristics (α-helix formation and better cellular uptake) cannot 
be directly correlated without considering other important factors. 
Anyway, most importantly, if we compare the three cell lines we can observe a significant 
selectivity for the conjugates 1b and 3b towards U87 cells that is not present for 2b (lacking 
the targeting moiety). This is a very good result because we can see that at the extent of better 
cellular uptake, a targeting could be favored. The internalization of 3b in U87, being just 
receptor dependent, is reduced compared to the CPP but anyway consistent because of the 
over-expression of the receptors on the surface of these cells, in contrast to the control cell 
lines. In this context, contrasting observations were done in the group of Prof. Gennari where 
RGD-camptothecin conjugates labeled with a naphtalimide fluorophore were tested on U87 
cells and the β3-KO isogenic cells. In this case, after 3 h incubation, no correlation between 
the integrin expression and the cellular uptake could be determined because an observed 
reduction of fluorescence intensity between 7 and 12% could be measured while in our case 
the uptake in the control cell lines HT-29 and MCF-7 was reduced to around 50%. An 
explanation of this behavior was explained by Pina et al. with a possible role of other integrins 
in the uptake of the conjugates in this longer incubation time as we already described for the 
previous cytotoxicity assays. [166] In our case the minimal uptake observed in HT-29 and MCF-
7 cells could be explained by the choice of the control cell lines, which seems to be a crucial 
problem in many works. In fact it would be highly desirable to have αv-KO cells for this purpose. 
In the case of 1b we can say that we could succeed in synthesizing a compound that is taken 
up better than the homing peptide alone and more selectively than the CPP where in fact the 
selectivity is completely lost. We could demonstrate here that the ligand is slightly hindering 
the ability of the CPP to translocate through the membrane but it is also favoring a good 
targeting. The 15 minutes incubation has been a very important model in this case because it 
could mimic the in vivo situation where the compounds come in contact with the cells for a very 
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short time interval and the binding to the receptor could ideally direct the system to interact 
with the surface.  
The microscope images underline the same tendencies observed for the first three conjugates 
by flow cytometry analysis (Figure 39). Nevertheless, in this case, a direct comparison between 
the three cell lines is not so simple since, as already mentioned before, in this kind of 
experiment the strong influence of the biological characteristics of each cellular system has to 
be taken into account, starting from the tendency of U87 cells to form clusters that easily detach 
as soon as the medium is removed and a new solution is added. Indeed, the shape of U87 
cells cannot be defined so well as for the other cell lines and this is a sign that these cells do 
not perfectly adhere to the well surface. Anyway, we can state that for all the conjugates a 
consistent uptake inside the nuclei could be determined proving that a daunorubicin-containing 
metabolite is always generated and can reach its site of action. All in all, a lysosomal 
degradation assay would be very interesting to see how each conjugate is processed after 
being internalized in the cells and which metabolite would be able to translocate through the 
nuclear membrane to reach its target. In this case we could even justify the different relocation 
of every conjugate inside the cell, observed in the CLSM pictures.  
 
Figure 39. Cellular uptake of compounds 1b, 2b, 3b and 1c, 2c, 3c analyzed by CLSM in U87, HT-29 and 
MCF-7 cells. Cells were incubated for 30 min with 10 µM of the Dau-conjugate solution at 37°C. External 
fluorescence was quenched by treatment with 150 µM trypan blue for 15 sec. Red: Dau-conjugate; blue: Hoechst 
33342 nuclear stain; scale bar is 10 µm. 
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Unfortunately, the previously observed selectivity was completely lost in the case of the 
conjugates containing the cleavable linker between the CPP and the drug molecule (1c-3c). 
In general, the GFLG linker increases the unselective uptake compared to the previously 
described conjugates. In this regard, we have to take into consideration that cathepsin B could 
play a big role by promoting the cleavage of the drug and presumably favor the further 
penetration of the conjugates and at this point, the investigation on the expression level of 
cathepsin B in the different cell lines would be crucial. In general, the GFLG conjugates are 
taken up at higher extent in every cell line but have a great influence in particular in HT-29 and 
MCF-7 cells. This is an outstanding improvement regarding the penetration ability of the CPP 
but it is of course a disadvantage in terms of selectivity. Furthermore, we should take into 
consideration also different factors connected with the physicochemical characteristics of 
these compounds. In fact, in the case of 1c and 2c the uptake improvement is maybe explained 
by the increase of the hydrophobicity introduced by the cleavage site that facilitates the 
internalization compared to 1b and 2b (see Figure 88 in the attachment for the comparison of 
the retention time of 2b and 2c). The higher uptake is verified also in the case of 3c in 
comparison to 3b, but still at a lower extent respect to the CPP-containing conjugates. Since 
in this case only the ligand should be responsible for the internalization, a hypothesis for the 
higher uptake in every cell line, leading to comparable fluorescence intensities, could be 
connected with the higher binding affinity shown by the binding assay. Furthermore, 
overexpression of cathepsin B in HT-29 and MCF-7 cells could lead to a faster degradation of 
the compound in the endosomes, a more rapid receptor recycling and promoted uptake. The 
microscopy pictures (Figure 39) are in line with the FACS studies. In particular, the higher 
uptake of 1c and 2c in HT-29 and MCF-7 cells is remarkable and a cytotoxic effect can be 
evidenced as a sign of a higher internalization.  
The results of this last experiment could finally support a significant selectivity for 1b and 3b. 
In contrast to this observation, the GFLG bearing conjugate 1c showed an enhanced uptake 
with a contemporary loss of selectivity while 3c showed comparable results in the different 
cells. These data were qualitatively and quantitatively confirmed by flow cytometry and CLSM 
data, which are in good correlation. As a further demonstration of our finding, another very 
important experiment was performed testing the cytotoxicity of all these compounds after 15 
min incubation. In order to assure the activity of the drug, the medium was removed but fresh 
medium was added for further 72 h. Notably, since we wanted to avoid a premature cell 
detachment, no washing step was performed. Especially, we wanted to correlate the results of 
the cellular uptake with the outcomes of this assay.   
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Figure 40. Antiproliferative assay with compounds 1b, 2b, 3b and 1c, 2c, 3c on U87, HT-29 and MCF-7 cells 
(15 min incubation). The peptides were incubated for 15 min and, after removing the medium, the cells were 
incubated for further 72 h.  Values from the positive control (DMSO/EtOH; 1:1) were substracted from all data and 
the untreated cells were set to 100%. The experiment was performed in triplicate with n=2. 
Table 13. EC50 values referred to the antiproliferative assays showed in Figure 40. 
EC50 [µM] EC50 [nM] 
 1b 2b 3b 1c 2c 3c Dau 
U87 12.5 ± 3 42.2 ± 12.3 56.9 ± 26.3 23.8 ± 4.4 9.6 ± 3.2 49.37 ± 16.0 78 ± 8 
HT-29 50.5 ± 14.0 >80 >180 >80 22.0 ± 7.5 >250 215 ± 105 
MCF-7 53.4 ± 15.6 25.1 ± 4.5 >140 7.8 ± 1.5 6.1 ± 1.2 >140 220 ± 89 
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The EC50 curves are depicted in figure 40 and the EC50 values are summarized in table 13. 
Essentially, we can repeat the same observations made for the FACS studies. The selectivity 
towards 1b and 3b is here clearly detectable; in particular for both compounds the curves of 
HT-29 and MCF-7 cells are overlaying leading to very similar EC50 (differences are connected 
with the standard deviations obtained for each measurement point) while U87 cells presents a 
4-fold lower EC50 compared to the control cell lines. Also in the case of 2b the cytotoxic profile 
in each cell line fits very well to the FACS data: the higher the internalization, the stronger the 
toxicity in the order MCF-7 > U87 > HT-29. For 1c, as we previously mentioned, the selectivity 
is lost but the EC50 does not exactly correlate with the previous data, as also in the case of 2c. 
In this assay, in fact, cathepsin B enzymes could have a more relevant role in the activity of 
the conjugates since, after internalization, they could exert their enzymatic activity within the 
72 hours. Surprisingly, the selectivity is also maintained for 3c. An explanation for this could 
be related with the high binding affinity of 3c to the receptors, which would allow the conjugate 
to bind to the cell surface and be internalized even after removing the medium with the peptide 
solution, since no intermediate washing step was performed. This is a good point, which would 
also explain the higher selectivity obtained in this assay for 1b and 3b compared to the FACS 
data. 
Finally, we proved that 1b could be a very efficient peptide-drug conjugate with selectivity to 
αvβ3 expressing cells. Every element of this hybrid conjugate is essential for the distinctive 
behavior of this compound, for instance the presence of the c[DKPf3RGD] ligand is necessary 
for the targeting ability (1b is selective in comparison to 2b), the CPP is enhancing the 
internalization of the construct, leading to greater toxicity even in a short treatment (1b is taken 
up at higher extent in comparison to 3b) and the PEG is fundamental to separate the two 
moieties and allow the maintenance of the distinguishing features of every component.  
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4. Head-to-tail cyclization of a cell-penetrating peptide through 
DKP scaffolds 
4.1. Novel cyclic peptides bearing a DKP scaffold 
The project presented in this part of the thesis has been developed during my secondment in 
Como, in the group of Prof. Piarulli at Università dell’Insubria. Thanks to the expertize in 
synthesizing DKP scaffolds, I was taught how to proceed with the preparation of DKP3, which 
I could successfully synthesize but, most importantly, I started a very strong collaboration with 
the PhD student Sara Parente, who provided me many times with various batches of DKP1 
and DKP3. Aside from this, we also worked in deep contact, trying to optimize the cyclization 
conditions.  
4.1.1. Synthetic strategy 
First, the scaffolds DKP1 and DKP3 were synthesized as already reported [153]. The linear 
peptide sC18* was synthesized by automated Fmoc/tBu-based SPPS. Chlorotrityl resin was 
used as solid support because of the very mild conditions required cleaving the protected 
peptide fragment from the resin prior to cyclization. We observed that loading of the chlorotrityl 
resin with Fmoc-Lys(Boc)-OH was not very effective, so we decided to use a preloaded resin. 
Afterwards, the DKP scaffold was manually coupled to the N-terminal sC18* peptide chain, still 
immobilized on the solid support, followed by reduction of the azido group with dithiotreitol 
occurring in almost quantitative yields (Figure 41). [264] 
 
Figure 41. Synthetic strategy for the synthesis of the DKP scaffold-bearing cyclic peptides cyc-DKP1 and 
cyc-DKP3. Reagents and conditions: a: 3 eq. Oxyma, 3 eq. DIC, overnight; b: DTT (2M), DIPEA (1M), DCM, 3 h; 
c: acetic acid/ TFE/ DCM 1:1:8, 2h; d: BOP (6 eq.), HOBt (6 eq.), DIPEA (12 eq.), DMF (0,2 mM), rt, overnight; e: 
full cleavage with TFA/phenol/H2O/thioanisol/EDT 82.5:5:5:5:2.5, 3h. 
Trying to obtain the best performance, using the most favorable conditions, Sara Parente 
planned to exploit the tendency of the cis-DKP1 scaffold to keep the two branched ends in the 
same direction like forming a β-hairpin. [265-267] In this case the disconnection was inserted in 
the middle of the sequence and the cyclization would not directly involve the DKP scaffold as 
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in the previous cases. Unfortunately, no improvement of the cyclization yield was obtained 
(data not shown). Comparable results were achieved by using a reverse sequence of the 
peptide: the strategy behind this was to insert the glycine residue at the C-terminus, avoiding 
racemization and allowing the cyclization with a less steric hindered amino acid instead of 
lysine (data not shown). Other expedients have been successfully investigated and actually 
led to a meaningful advancement. After cleavage of the protected linear peptide from the resin, 
the acidic solution was removed by reduced pressure and the remaining acetic acid was 
evaporated in many cycles by adding hexane, acting as azeotrope. A fundamental point in this 
process has been determined by the washing and digestion of the obtained white powder with 
a 5% NaHCO3 solution, filtration and further washing with H2O to remove the salts that could 
disturb the next steps (e.g. by acetylation of the N-terminus). Subsequently, solution-phase 
cyclization could be carried out on the crude lyophilized peptide. Use of dry DMF was not 
considered as necessary since the yields with normal DMF were comparable, but a high 
dilution was crucial to favor the intramolecular reaction at the expense of dimer formation; for 
this reason, the concentration was lowered from 0.65 mM  to 0.2 mM. [268] Another decisive 
adjustment was a second addition of BOP after 6-8 hours from the beginning of the reaction, 
since this coupling reagent is degraded after 8-10 hours, contrarily from HOBt, which is 
regenerated. Thanks to these numerous arrangements, yield of cyclization, after cleavage of 
the protecting groups and purification of the final compound, ranged from 22% for cyc-DKP1 
to 36% for cyc-DKP3. Generally, we assumed that the DKP3 scaffold allows a more efficient 
cyclization by favoring a pre-organized conformation. However, in both cases the cyclization 
remained the major yield-limiting step. The linear versions including the two DKP scaffolds at 
the N-terminus, lin-DKP3, lin-DKP1, were also synthesized (Table 14) and were important to 
better investigate, not only the role of the cyclization regarding both the spatial and the 
biological activity, but also the influence of a non-natural building block inside the peptide 
structure and how this heterocycle could interfere with the features of the CPP.  
Table 14. List of DKP-bearing synthesized compounds with their names, sequences and molecular 
weights (MW calculated and experimental). ____: amino acids involved in cyclization 
Name Sequence MW  
[g/mol] 
MWexp 
[g/mol] 
cyc-DKP3 DKP3-GLRKRLRKFRNK 1827.3 1827.7 
lin-DKP3 H2N-DKP3-GLRKRLRKFRNK-OH 1845.3 1845.7 
cyc-DKP1 DKP1-GLRKRLRKFRNK 1827.3 1827.7 
lin-DKP1 H2N-DKP1-GLRKRLRKFRNK-OH 1845.3 1845.7 
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4.1.2. Circular dichroism 
In order to generate an overall picture of the peptide structure, circular dichroism spectra of 
the synthesized compounds were measured in phosphate buffer alone or in presence of the 
α-helix inducer TFE (figure 42). In agreement with known literature data [183, 269], the linear 
compounds showed a disordered random coil structure in aqueous phosphate-buffered 
solution, while after addition of TFE preferably formed an α-helix. For lin-DKP1 we obtained 
R=0.7, while for lin-DKP3 a lower value of 0.62 was calculated. This means that this small 
DKP scaffold at the N-terminus of the sequence seems to have an influence on the tendency 
to develop a helix stabilizing the structure in a different manner depending on the cis or trans 
conformation. Probably the DKP1 follows the right arrangement to continue the helix 
framework, while the DKP3 generates a certain disorder, counterposed to the helical 
arrangement. Regarding the cyclic peptides, cyc-DKP1 appeared to be pretty flexible 
switching from random coil to helical arrangement, in particular in the presence of TFE. As 
shortly presented in the introduction, the DKP1 was often used as β-hairpin inducer to stabilize 
the formation of β-sheets: this is not the case within the cyclic organization but this is also not 
favoring the generation of a helix. In contrast, cyc-DKP3 appeared more structured displaying 
the typical spectra of slightly helical peptides even in phosphate buffer. These observations 
were made after looking at the general pattern and comparing it to the traditional schemes; 
since the minima and maxima are slightly shifted, we cannot refer to these curves as the typical 
spectra of helical peptides and the R-values were not calculated. Therefore, we considered 
that the linear and cyclic compounds should be further investigated by NMR analysis to prove 
what we could observe through these preliminary assays.  
 
 
Figure 42. Secondary structure investigation of the linear and cyclic compounds by circular dichroism. CD 
spectra of the cyclic (cyc-DKP3 and cyc-DKP1) and linear (lin-DKP3 and lin-DKP1) peptides in 10 mM phosphate 
buffer (left) and 10 mM phosphate buffer/TFE 1:1 (right). Peptide concentration was 20 µM. 
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4.1.3. NMR-based structure elucidation  
The three dimensional structures of both linear and cyclic derivatives have been investigated 
by NMR spectroscopy by Dr. Díaz and the PhD student Linda Jütten (Department of Chemistry, 
University Cologne). Although peptides were not isotopically labeled (i.e., 13C and/or 15N) and 
the availability of sample was limited, their size (12 amino acids and DKP linker, MW ca. 2 
kDa) was fortunately appropriate to carry out a full structural analysis based exclusively on 
mono- and bidimensional homonuclear proton NMR spectra. [270]   
Overall, the 2D TOCSY and 2D NOESY spectra of the linear peptides lin-DKP1 and lin-DKP3 
in aqueous buffer solution suggested a lack of secondary structure. The NMR data acquired 
at 298 K indicated a random coil structure also for the cyclic peptides. Contrarily, the 2D 
NOESY spectra of cyc-DKP3 and cyc-DKP1 acquired at lower temperatures (i.e., the lowest 
temperature allowed for aqueous NMR samples is 283 K) seemed to address specific 
conformational preferences for these peptides pointing out that the stereochemistry of the DKP 
unit is determinant for the conformational arrangement of cyclic peptides, as already described 
by Potenza and coworkers. [271] A closer inspection of all the structures suggested that not only 
one but several structural families may coexist in solution, what has been already 
demonstrated for other DKP-cyclic peptides (Figure 43). 
 
Figure 43. 2D NOESY spectra of cyc-DKP3 and cyc-DKP1 acquired at 283 K and correspondent structural 
families. (top) Amide-amide region of the 2D 1H,1H- NOESY spectra of cyclic peptides (A) cyc-DKP1 and (B) cyc-
DKP3 in solution (50 mM phosphate buffer, pH 6.08, water:D2O 9:1, 283 K, mixing time 200ms, 600MHz). (bottom) 
Overlay of the ensemble of 20 final energy-minimized CYANA structures of the peptides in solution. The main 
chains are shown in black and DKP unit at the N-terminus with color ((A) DKP1, blue; (B) DKP3, red). 
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Most importantly, according to these structure calculations, the mostly preferred conformation 
within the structural families described at 283K for cyc-DKP3 seems to exhibit hydrogen bond 
interactions including Lys8(C=O)-(HN)Asn11, Lys8(C=O)-(HN)Lys12 and Arg5(C=O)-(HN)Arg7 
residues (Figure 44).  
 
Figure 44. Line plot of the solution structure of cyc-DKP3, calculated from NMR derived data collected at 
283 K. Hydrogen bond interactions are shown as yellow dashes.  
To shed light onto a possible interaction of the peptides with cell membranes, NMR 
experiments were conducted not only in aqueous medium but also in SDS micellar medium as 
it is considered, among others, a suitable membrane mimetic agent. In Figure 45 the 1D 1H 
NMR spectra of the linear DKP-peptides in the presence of SDS micelles are displayed. 
Generally, an evident broadening of the signals was observed, what is normally taken as 
indication of an effective interaction of the peptide with the micelles. The signals in the amide 
region were also comparatively more dispersed than the equivalent ones in aqueous medium, 
what pointed out that peptide conformational changes have been induced by the presence of 
the micelles.  
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Figure 45. Structure evaluation of the linear peptides in presence of SDS micelles. (left) 1D 1H NMR spectra 
of linear peptides (A) lin-DKP1 and (B) lin-DKP3 in the presence of SDS micelles (peptide concentration ca. 1.3 
mM, peptide:SDS 1:80, 50 mM phosphate buffer, pH 6.08, water:D2O 9:1, 298 K, 600MHz). (right) Overlay of the 
ensemble of 20 final energy-minimized CYANA structures of the peptides in the presence of SDS micelles. The 
main chains are shown in black and the DKP unit at the N-terminus with color ((A) DKP1, blue; (B) DKP3, red). 
Also the ribbon diagrams of the lowest energy structures are shown in a stick model. 
This result correlates very well with the outcomes from the circular dichroism in presence of 
TFE even if in this case, the insertion of a DKP residue in the sequence does not seem to play 
an important role since no interaction between DKP and any other residue of the peptide 
sequence was observed.  
The preparation of the NMR samples containing the cyclic peptides and SDS micelles has 
been until now quite complicated. The spectra of cyclic peptides in the presence of SDS 
micelles exhibit an extraordinary broadening of the signals that could indicate a more efficient 
interaction between cyclic derivatives and micelles than the one occurring between linear 
peptides and micelles (Figure 46A). Because of the poor resolution of the spectra, the standard 
methods for assignment and structural elucidation failed systematically. As a proof of peptide-
micelle interaction, however, the diffusion coefficient values of cyc-DKP3, both in solution and 
in the presence of micelles, were measured and the results were then compared and analyzed 
(Figure 46B). Although perdeuterated SDS micelles were employed (i.e., d25-SDS), remaining 
protonated signals of the micelles were visible and could be easily identified. The experiment 
 Results and Discussion 
72 
 
provided information about the diffusion coefficients of peptide and micelles as well as about 
any other species present in the solution mixture including impurities or the chemical shift 
reference system (i.e., TSP). 
 
Figure 46. Structure evaluation of cyc-DKP3 in presence of SDS micelles. A: 1D 1H NMR spectra of cyc-DKP3 
in the presence of SDS micelles. B: Overlapped DOSY NMR spectra of the peptide free (red) and in the presence 
of SDS micelles (black) (peptide:SDS 1:80, 50 mM phosphate buffer, pH 6.08, water:D2O 9:1, 298 K, 600MHz). 
As it can be deduced from the DOSY spectra, the diffusion coefficient values of peptide and 
micelles are coincident although the molecular weight of both the micelle (theoretically ca. 60x 
SDS) and peptide are very much uneven and substantial different diffusion properties were 
expected. Since TSP does not seem to interact with the micelle, its diffusion coefficient was 
taken as diffusion reference and, from this result, one can clearly assert that cyc-DKP3 is 
effectively interacting with the micelle since its diffusion coefficient changes drastically in the 
presence of SDS micelles and has the same value as the micelle itself. 
4.1.4. Biological evaluation 
Taking advantage of the interesting results obtained from the investigation of the secondary 
structure, further examinations of the cyclic peptides in cellular systems were performed. First, 
the influence of cyclization on cell viability was determined. To this purpose, the cytotoxicity of 
all peptides on the tumor cell line HeLa was tested (figure 47). After 24 h incubation, the peptide 
solution was washed-out and the cells were further incubated for additional 48 hours. As first 
evidence, the cyclic peptides show a more significant toxicity compared to the correspondent 
linear versions. As we could already infer from the calculation of the diffusion coefficient of 
cyc-DKP3 in micellar medium, the cyclic peptides are presumably interacting with the lipid 
environment at higher extent than their linear counterpart. As a consequence, even distinct 
entry pathways could be imagined leading to a different cellular uptake level, and finally, 
cytotoxicity. However, this is not the only consideration that can be drawn from the analysis of 
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these results. In fact, a very meaningful difference can be observed in association with the use 
of cis or trans DKP scaffolds. Since preliminary studies in presence of SDS micelles were 
performed only for cyc-DKP3 we cannot directly explain this result by a concrete 
demonstration even if a strong influence of the DKP scaffold was already remarked from the 
analysis of the NOE cross peaks at lower temperature (Figure 43). Furthermore, cyc-DKP3 
also showed a higher tendency to form H-bond within the residues which could lead to a more 
rigid structure. Nonetheless, the highest toxicity corresponding to around 60% viability was 
only observed at peptide concentrations of 100 μM. Since at lower concentrations, the toxicity 
was still around 80% after 72h, we concluded that the cyclic compounds could be safely used 
for further experiments.   
 
Figure 47. Effect of the linear (lin-DKP3 and lin-DKP1) and cyclic (cyc-DKP3 and cyc-DKP1) peptides on the 
viability of HeLa cells measured by resazurin-based assay. Evaluation of the resorufin fluorescence generated 
from resazurin by viable cells after 24h incubation with the peptide solutions, washout and further incubation for 
48h. Untreated cells were used as negative control and set to 100%; positive control was represented by cells 
treated for 10 minutes with 70% EtOH and it was subtracted from the other values. (*: p≤ 0.05; p**: p ≤ 0.01; ***: p 
≤ 0.001). The experiment was performed in triplicate with n=2. 
4.2. Drug delivery with cyclic peptides 
The peculiar interplay between the cyclic peptides and the cell membrane could promote the 
cellular uptake of other molecules, such as cytostatics. To demonstrate this hypothesis, we 
investigated if the peptides were able to support and enhance the intracellular uptake of 
daunorubicin. The anticancer activity of the drug was evaluated, with and without the presence 
of the peptide. Co-incubation was performed using 10 µM of cyc-DKP3 solution and 80 nM of 
daunorubicin (concentration at which almost 40% of cells were still viable). From Figure 48, it 
can be clearly seen that the co-treatment with the peptide and the drug revealed an increased 
toxic activity in comparison with the drug alone. This was already a hint about a possible 
mechanism showing the peptide as useful promoter of penetration. 
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Figure 48. Influence of daunorubicin on the viability of HeLa cells with or without the cyclic peptide cyc-
DKP3 measured by resazurin-based assay. Evaluation of the resorufin fluorescence generated from resazurin 
by viable cells after 24h incubation with the peptide solutions, washout and further incubation for 48h. The assay 
was performed adding 10 µM of peptide solution together with 80 nM daunorubicin solution or only the free drug 
without peptide. The peptide alone was evaluated as a reference to prove the absence of toxicity at the tested 
concentration. (*: p≤ 0.05). The experiment was performed in triplicate with n=2. 
The same feature was evaluated also by CLSM (Figure 49). Co-incubation was performed 
using 10 µM of cyc-DKP3 solution and 1 µM of daunorubicin. We were interested in observing 
if, in the presence of the peptide, the uptake of the drug molecule would be stronger, thus 
corroborating the outcomes of the cytotoxicity assay. We were pleased to observe that the 
cyclic peptide could really act as efficient carrier transporting daunorubicin at much higher 
extent inside the cells if compared with the drug alone. It is known from the literature that 
daunorubicin enters the cell via direct transportation through the membrane, being a small 
molecule, able to interact with the negatively charged outer surface of the cell membrane and 
capable to insert within the lipid phase of the membrane. [272] We can imagine that the cyclic 
CPP could mediate the formation of pores through which the drug could easily enter the cells 
in a faster way than passive diffusion. The distribution is uniform but with the presence of a 
punctuate pattern that shows a coexistence of endocytic pathway and direct penetration, so 
we could also imagine that being the CPP also internalized by endocytic pathway, the drug 
could also interact with the negatively charged phospholipids and be inserted in the 
endosomes together with the peptide. 
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Figure 49. Cellular uptake after co-incubation of daunorubicin and the cyclic peptide cyc-DKP3 investigated 
by CLSM on HeLa cells. 1 µM daunorubicin alone (top) or together with 10 µM peptide solution (bottom) was 
added to HeLa cells and the uptake was evaluated after 30 minutes incubation. External fluorescence was 
quenched by treatment with 150 µM trypan blue for 15 sec. Red: daunorubicin; blue: nuclear stain with Hoechst 
33342. Scale: 10 µm. 
After these promising results with the compound cyc-DKP3, we decided to investigate a 
covalent delivery approach, too. For this purpose, a molecule of daunorubicin was covalently 
coupled to the cycle according to the synthetic strategy depicted in Figure 50. In brief, the 
peptide chain was again synthesized via SPPS, but the Lys4 of sC18* was modified with a 
protected aminooxy group. After cleavage from the resin and cyclization, which occurred as 
already described above, deprotection of the aminooxyacetic acid and coupling with 
daunorubicin by oxime bond formation was performed. This reaction has been very 
problematic since the aminooxyacetic acid, after completion of deprotection, directly reacted 
with some ketones present in the atmosphere of the laboratory or in the plastic instruments, 
so that, after purification of the deprotection reaction, the only product collected was in fact the 
protected starting peptide. This side reaction could not be avoided even if the glassware used 
was not cleaned with acetone and no plastic tubes were used. This reaction had to be repeated 
many times until I decided to add instantaneously an excess of daunorubicin to the deprotected 
product before its purification and in the tube of the collected pure fraction. By this way, I could 
obtain 1.2 mg of the final product even if the yield of the steps of deprotection and daunorubicin 
conjugation reaction was reduced from 80% (observed in general for other conjugates) to 20% 
because of the repetitive purification steps.   
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Figure 50. Synthetic strategy for the synthesis of the cyclic drug conjugate cyc-DKP3(Dau). Reagents and 
conditions: a: 3 eq. oxyma, 3 eq. DIC, overnight; b: 2% hydrazine in DMF (10x); c: 5 eq. >=Aoa, 5 eq. oxyma, 5 eq. 
DIC, overnight; d: DTT (2M), DIPEA (1M), DCM, 3 h; e: acetic acid/TFE/DCM 1:1:8, 2h; f: BOP (6 eq.), HOBt (6 
eq.), DIPEA (12 eq.), DMF (0,2 mM), rt, overnight; g: full cleavage with TFA/phenol/H2O/thioanisol/EDT 
82.5:5:5:5:2.5, 3h; h: Methoxylamine 1M, NH4OAc 0.2 M, pH 5; i: 30% excess daunorubicin, 0.2 M NH4OAc, pH 5, 
10 mg/ml. 
The product was purified using reversed-phase HPLC and identified via LC-MS. As control we 
used the Dau-modified sC18* version, namely sC18*(Dau), whose synthesis followed the 
same protocol observed for the conjugates described in the previous chapter. (Table 15). 
Table 15. List of the synthesized drug conjugates with the correspondent names, sequences and molecular 
weight (calculated and experimental). 
Name Sequence MW 
[g/mol] 
Mwexp 
[g/mol] 
cyc-DKP3(Dau) DKP3-GLRK(Aoa=Dau)RLRKFRNK 2409.8 2410.5 
sC18*(Dau) H2N-GLRK(Aoa=Dau)RLRKFRNK-OH 2154.5 2155.2 
 
The anticancer activity of the novel drug conjugates in HeLa cells was measured by resazurin-
based toxicity assay. Notably, the cyclic conjugate showed a better activity compared to the 
linear one, which would support our first hypothesis of a better cellular uptake of the cyclic 
peptide (Figure 51 and Table 16). Furthermore, since the target of the drug is the DNA located 
in the nucleus, these results could indicate a more efficient endosomal escape of the cyclic 
peptide.  
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Figure 51. Effect of the drug conjugates cyc-DKP3(Dau) and lin-DKP3(Dau) on the viability of HeLa cells 
measured by resazurin-based assay. Evaluation of the resorufin fluorescence generated from resazurin by viable 
cells after 24h incubation with the peptide solutions, washout and further incubation for 48h. Untreated cells were 
used as negative control and set to 100%; positive control was represented by cells treated for 10 minutes with 
70% EtOH and it was subtracted from the other values. The experiment was performed in triplicate with n=2. 
Table 16. EC50 values referred to the cytotoxicity assay showed in Figure 51. 
Name EC50 [µM] 
cyc-DKP3(Dau) 9.3 ± 1.7 
sC18*(Dau) 20.1 ± 3.3 
 
One could think that the lower activity of sC18*(Dau) compared to the cycle would be merely 
connected to the presence of a negative charge at the C-terminus of the sequence, since the 
peptide synthesis was performed on chlorotrytil resin, as previously described. To argue this 
hypothesis, the cellular uptake of the cyclic peptide cyc-DKP3(Dau) and the two linear 
peptides sC18*(Dau) and 2b was evaluated. Since previously published results illustrated that 
the truncated sC18* shows a weaker uptake efficiency than sC18, maybe due to the missing 
positive charged lysine residues at the C-terminus of the sequence, [184] we were interested in 
a direct correlation between the cycle and the two linear versions. Notably, a significant 
increased uptake of the cyclic peptide in comparison to both linear variants was observed 
(Figure 52), confirming that the better efficacy of the cyclic peptide could undoubtedly be 
correlated with the cyclization. All in all, these data indicate that the cyc-DKP3(Dau) appears 
to be a very efficient alternative to the original CPP 2b and correspond very well to all the 
results obtained until now. In fact, also in the cytotoxicity studies of the drug delivery system 
(drug-free peptides), the toxicity of the cyclic peptides was higher than the linear, possibly 
depending on the different interaction with the membrane clearly leading to a different cellular 
uptake. 
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Figure 52. Cellular uptake evaluation of the cyclic and linear drug conjugates cyc-DKP3(Dau), sC18*(Dau) 
and sC18(Dau) by flow cytometry. HeLa cells were incubated for 30 minutes with 10 µM peptide solution. The 
value corresponding to the untreated cells was used as negative control and subtracted from the other values. . 
(***: p ≤ 0.001; (***: p ≤ 0.0001). The experiment was performed in triplicate with n=2. 
For a further confirmation, we evaluated the cellular uptake by CLSM. From this analysis, it 
was pretty clear that both peptides were taken up to high extent after 30 minutes incubation, 
while distributing throughout the cytosol as well as the nuclei; in particular, the nuclear 
envelope is well delineated, revealing localization on the nuclear membrane in both cases 
(Figure 53). Also in this case cyc-DKP3 showed an enhanced uptake compared to sC18*(Dau) 
corroborating the flow cytometry data. 
 
Figure 53. Cellular uptake evaluation of the drug conjugates cyc-DKP3(Dau) and sC18*-Dau by CLSM. HeLa 
cells were incubated for 30 minutes with 10 µM peptide solutions, Red: Dau-conjugates; blue: nuclear stain with 
Hoechst 33342. Scale: 10 µm 
We tried to explain this behavior with the higher rigidity of the structure, translated into higher 
and more stable interaction with the membrane. As we could already infer from the NMR 
studies, since the side chains of the polar amino acids are directed towards the outside of the 
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cycle, we could imagine that there is a strong and fast interaction with the hydrophilic heads of 
the phospholipids bilayer generating a curvature that could lead to membrane destabilization 
and subsequent peptide penetration (Figure 54).  
 
Figure 54. Schematic representation of the possible interaction between cyc-DKP3 and the cell membrane. 
The ball-and-stick representation of the solution structure of cyc-DKP3 was calculated from NMR derived data 
collected at 283 K. Side chains of charged amino acids, i.e. Lys and Arg are shown in red. 
This behavior is maybe not so immediate and direct for the more flexible linear peptides 
providing a logical explanation for the enhanced activity of the cyclic peptides. 
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5. Conclusion and Outlook 
5.1. Receptor-targeted CPPs for selective delivery of anticancer 
therapeutics 
In recent years, research on new antineoplastic drugs has raised great hopes and expectations 
for more specific and less toxic treatments in the field of oncology. New targeted therapies 
have been developed using selective drugs that act on different targets (growth factors, 
receptors, enzymes) responsible for the growth and uncontrolled spread of cancer cells, for 
their resistance to traditional therapies and for the production of new blood vessels, resulting 
in less toxicity. [10-11] Peptide-drug conjugates represent novel chemical entities with a targeted 
delivery approach, where highly cytotoxic drugs are combined with peptides that are able to 
recognize tumor cells. [111] 
At the same time, cell-penetrating peptides gained special interest because they can facilitate 
cellular transfer of various molecular therapeutics, from small chemical molecules to big 
nanoparticles and large DNA fragments. [198] Because of this feature, CPPs hold great potential 
as in vitro and in vivo delivery vehicles, but at the same time they also lack selectivity, restoring 
the previously described issue. [197] 
The aim of the first part of my work was to combine these two important elements and obtain 
a drug delivery system, which would be able to efficiently deliver drugs to the cytosol (via the 
CPP) but at the same time be selective on tumor cells without damaging the healthy cells (via 
the targeting ligand). GnRH and integrin receptors have been indicated as ideal 
pharmacological targets based on their overexpression on the surface of many cancer cell 
types in comparison to healthy cells. 
 Conclusion and Outlook 
81 
 
 
Figure 55. General concept of the targeting delivery. 
As targeting ligand towards GnRH receptors a variant of the GnRH-III peptide, developed by 
the group of Prof. Mező, [131] was employed and conjugated to the CPP sC18 by “click” 
chemistry. The designed synthetic strategy worked well, and after optimization, the drug 
delivery system could be obtained in high yields. Drug conjugates have been also prepared 
where a molecule of daunorubicin was conjugated to the CPP sequence via an uncleavable 
(aminooxy) or cleavable (GFLG) linker. The GnRH-III conjugates showed a low nanomolar 
binding affinity towards GnRH receptors expressed on pituitary and prostate cancer cells and 
the CPP did not display a dramatic influence on the binding validating the choice of the 
conjugation site. The toxic effects of the compounds on cell types with varying expression 
levels of GnRH receptors were evaluated. For this purpose, a short treatment was estimated 
to be the optimal condition in order to underline the targeting ability of the ligand and 
contemporarily highlight the fast CPP-mediated penetration. Nevertheless, a lack of selectivity 
was observed for the control (GnRH-III-Dau) as well as for the full conjugates GnRH-III-
sC18(Dau) and GnRH-III-sC18(GFLG-Dau) and was attributed to the poor expression of the 
receptor at the cell surface and their slow recruitment mechanism. [244] After these 
considerations, a very interesting experiment would be to examine longer incubation times and 
the correspondent internalization mechanisms. In this sense, cellular uptake studies would be 
crucial to determine which pathways are followed and to demonstrate which role the receptor-
mediated uptake plays in this context. Nevertheless, the CPP conjugates displayed a very 
efficient activity in this short incubation time indicating the importance of the CPP for the 
penetration of the construct. In addition, a remarkable activity of daunorubicin in the resistant 
cell line PANC-1 has been recognized, in particular after treatment with sC18(GFLG-Dau) and 
should be further investigated even with other drugs to corroborate previous observations that 
MDR can be overcome by the use of CPPs. [245, 258, 273-274]  
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In the framework of integrin receptors, a recently developed cyclic peptidomimetic consisting 
of a DKP scaffold and a RGD peptide called c[DKPf3RGD] [153] was employed as tumor homing 
device after conjugation to the CPP by “click” reaction via intersection of a PEG4 linker. After 
proving that the binding affinity of the compound to the receptors was not seriously altered by 
the CPP, cells were treated with the fluorescently labeled conjugate 1a and the uptake was 
measured after co-incubation of the drug delivery system with the free ligand. A significant but 
not dramatic reduction of the uptake was measured in particular after 60 minutes incubation 
compared to 30 minutes and this observation led us to conclude that the binding to the receptor 
is essential for the targeting but that mainly the CPP is involved in the internalization of the 
construct. A blocking experiment with the free ligand led us to draw the same conclusions and 
to imagine a so called “kiss and run” process for our compound, where the ligand recognizes 
the receptor but the strong membrane interaction of the CPP and its mobility on the membrane 
surface lead to the dissociation of the ligand from its binding pocket and the subsequent 
internalization. Since the construct showed remarkable toxicity only at the highest tested 
concentration after 72 h, it could be demonstrated that the compound could be safely used as 
drug delivery system. In a first attempt, the potent drug cryptophycin was attached to the CPP 
by a disulfide bridge but since the “click” reaction for the conjugation to the ligand involved the 
use of the reducing reagent sodium ascorbate, the disulfide bridge was partially broken, and 
oxidized side products were recovered. To optimize this step new strategies should be 
investigated, among those the use of copper powder [259] but also copper-free modalities should 
be attempted. Problems connected with the stability of chlorambucil led us to favor the same 
strategy as for the GnRH-III conjugates by coupling daunorubicin to the CPP via uncleavable 
and cleavable (GFLG) linkers. In this case the synthesis was again successfully achieved and 
the selectivity between cells with different receptor expression was demonstrated by 
cytotoxicity assays and cellular uptake studies proving that the short contact time between the 
cells and the drug delivery system worked well in this case. The most promising conjugate 1b 
is depicted in figure 56.  
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Figure 56. Binding of the lead compound 1b to the integrin receptor. Every element of this hybrid conjugate is 
here highlighted.  
In conclusion, the combination of a ligand with a CPP proved to be a very promising strategy 
that is worth to be further investigated in the future. Anyhow, there is still a long way to go and 
a lot of room for improvement.  
In general, for both targeting strategies presented, to get a deeper understanding of all the 
steps occurring from the binding to the internalization, the intracellular organelles could be 
stained to perform co-localization studies with the labeled compounds and interpret their fate 
in the cytosol. Additionally, the receptors could be labeled via SNAP tag technology followed 
by CLSM in living cells in order to monitor them and study their internalization process after 
binding to the ligand. [275] This could really provide us with an important hint to discern the 
receptor and the CPP-mediated uptake. In this context, a very interesting experiment 
described by Sancey et al. involved the biotinylation of the integrin receptors on the cell 
surface, incubation with different concentrations of the peptide followed by lysis of the cells 
and subsequent quantification of the receptors internalized by endocytosis. This would be a 
definitive indication of the internalization mechanism followed. [164] Furthermore, the use of 
inhibitors like amantadine, which blocks the clathrin mediated uptake, would be also useful for 
our understanding. 
Regarding the binding to the receptor, a cell-free based competitive binding study was 
performed and showed low nanomolar binding affinity between the conjugates and the 
receptors but to increase the knowledge about this binding, docking studies with the 
crystallized receptor could be performed and in the best case a co-crystallization of the two 
elements would determine the whole structure. Another interesting experiment could be to 
measure the Kd value of our conjugates by fluorescence correlation spectroscopy in order to 
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measure an equilibrium constant that could be correlated with the binding affinity obtained by 
the competition assay with vitronectin. [164] 
To increase the selectivity, a very astute strategy published by Crisp et al., already described 
in the introduction, involved the conjugation of the CPP to a negatively charged sequence via 
a MMP-2 cleavable linker. By this approach, the penetrating capability of the CPP could be 
masked until the construct reaches the tumor environment and would be then cleaved by the 
MMP-2 enzymes overexpressed in the tumor stroma. [202] Another way to improve the targeting 
ability could be to substitute the positive charged residues in the sequence of the CPP with His 
residues, known to be negative at neutral pH but positive at the acidic pH of the tumor 
environment. [276] [277] 
To demonstrate the ability of this construct to carry even bigger and more hydrophilic 
molecules inside the cells other cargos could be also employed. In this work small therapeutics 
were conjugated to the CPP but it is known that CPPs are characterized by a great efficiency 
in carrying much bigger and complex systems. [198] For instance, the intercellular transposition 
of protein- and nucleic acid-based drugs, otherwise restricted by their size and hydrophilicity, 
could be increased and subsequently even their potency could be enhanced.  
It would be recommended before going in vivo, to test these conjugates on co-culture models. 
Some trials have been already performed using U87 cells overexpressing the receptor and the 
control cell line HT-29. Unfortunately, the results were difficult to interpret also because the 
cells were hardly distinguishable. A solution to this problem could be to use GFP-labeled U87 
cells, which would help to distinguish one cell line from the other but also the employment of 
inserts to separate the two cell lines in the same well. In the latter case, anyway, the co-culture 
would not exactly mimic the in vivo situation where the different cells are in close contact to 
each other. In general, for these further studies, it would be advisable to use αv-knock out cell 
lines to have an ideal negative control. 
Another important point to be examined is the stability of the conjugates and this should be 
done at different levels starting from the extracellular environment (plasma and blood stability) 
to the lysosomal vesicles (stability in lysosomal homogenate). This is important to see how the 
drug is released and if determinant differences can be shown between the conjugates with and 
without cleavable linker. Since the stability of the sC18 in plasma membrane has been 
determined (Figure 90 in attachment) and the peptide seemed to be highly unstable, for future 
in vivo studies the substitution of all amino acids with D-amino acids should be taken into 
consideration. [241] For the same purpose, the use of PEG shells, liposomes or nanoparticles 
would be highly favorable, leading to the generation of interesting multimodal drug delivery 
systems. These constructs could be used to enhance the stability, since the charged CPP 
sequence would be shielded until it reaches its site of action and thanks to the EPR effect, the 
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extravasation and accumulation at the tumor site would be favored, followed by a slow release 
of the drug. Furthermore, the ADME features of the drug-CPP system would be improved, 
since these molecules would be otherwise degraded very quickly. Trying to overcome the 
stability issue, some developments have been already done in this direction and cyclic variants 
of sC18* were synthesized as described in the second part of this work. 
5.2. Cyclic CPPs for cargo delivery 
By cyclization of known linear cell-penetrating peptides increased proteolytic stability, 
enhancement of cell penetration and high potential for drug delivery should be achieved. Based 
on previous studies, [183] the CAP18 (106-117) fragment of the cationic antimicrobial peptide 
sC18 was used as starting peptide and cyclized by means of a DKP scaffold, namely DKP3 
and DKP1, trans and cis, respectively. After the synthesis by SPPS of the linear sequence, the 
head-to-tail cyclization was performed in solution and the conditions were optimized to 
suppress the formation of undesired dimers and oligomers achieving the two cyclic peptides 
in satisfying yields. The two cyclic versions with their correspondent linear counterparts, were 
evaluated about their tendency to form a secondary structure. In fact, when in contact with cell 
membranes, secondary amphipathic CPPs as sC18 adopt an α-helical structure that allows 
the interaction with the phospholipidic bilayer and favors the internalization. CD spectra of the 
novel molecules have been measured and the formation of an α-helix after addition of TFE 
was corroborated in the case of the linear peptides. As for the cyclic compounds, this analysis 
showed particularly interesting results since cyc-DKP3 tended to develop a secondary 
structure even in phosphate buffer, while for cyc-DKP1 this was observed only after addition 
of TFE. Based on this preliminary information we were very curious to investigate more about 
this aspect and NMR was elected as ideal technique to do this. The NMR data in combination 
with the CD data suggest that the cyclic peptides display a higher preference to form a structure 
in aqueous buffer solution in comparison to the linear variants and that cyc-DKP3 tends to 
generate a slightly more rigid conformation in comparison with cyc-DKP1. 
A very important experiment to better understand the impact of a membrane in the 
arrangement evolution of secondary structure would be to directly test the peptides in the 
presence of artificial membranes to observe changes in their structural organization or also 
their effect on membrane destabilization. In general, interaction with artificial membrane 
systems like neutral or negatively charged large unilamellar vesicles, mimicking the specific 
composition of particular cell types, would be a possible strategy to examine the influence of 
individual membrane components on the internalization mechanisms of these cyclic peptides. 
This would be interesting even to prove a selectivity towards cancer cell lines, characterized 
by a higher negative charged distribution on their cell surface. An investigation in this direction 
has been already started since the secondary structure of the linear peptides have been 
evaluated by NMR in the presence of SDS micelles showing the formation of an α-helix as we 
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expected. The same analysis has been also performed for cyc-DKP3 and the still preliminary 
results already suggest that the cyclic peptide is deeply embedded in the micelle. Further 
examination is ongoing and will surely give us very important elements to understand these 
different interactions. 
Up to now, the cyclic and linear peptides were tested in HeLa cells where a significant cytotoxic 
effect of the cyclic peptides was shown at the highest concentration (100 μM) after 24 h 
treatment followed by washout and further 48 h incubation. This effect was not so remarkable 
in the case of the linear peptides and this could be explained with the different cellular uptake 
mechanisms involved and the possibly higher internalization rates of the cyclic peptides 
compared to the linear ones, as later demonstrated by the cellular uptake evaluation of the 
labeled compounds. If we look at the three-dimensional structure obtained with the NMR 
measurements, we could imagine that the side chains of the basic residues, in particular 
arginine residues, could effectively stick to the surface of the membrane interacting with the 
negatively charged phospholipids or proteoglycans leading to re-structuring of the double layer 
and subsequent pore formation. To validate this theory, the studies with SDS micelles would 
be in this case very useful. Since the toxic activity was observed only at the highest 
concentration, the cyclic peptides should be promising candidates for the cellular transport of 
cytotoxic payloads. Since from CD and NMR measurements, cyc-DKP3 seemed to bear ideal 
features to improve drug transport inside the cell, further biological experiments were 
performed with this variant. To prove that, the evaluation of a non-covalent daunorubicin-CPP 
complex was planned: in fact, a non-covalent drug delivery could be very desirable since the 
drug does not have to be cleaved from the peptide before reaching its site of action. Cyc-DKP3 
was co-incubated with daunorubicin and could improve the internalization of the drug, probably 
promoting the permeability to a higher number of drug molecules after pore formation, as 
previously hypothesized. A covalent link would also have an advantageous impact and for this 
reason a synthetic strategy for the conjugation of the peptide to daunorubicin was proposed 
and realized. It could be immediately noticed that the cyclization positively influenced the 
internalization. The final conjugate was directly compared to the linear version and the cellular 
uptake was quantitatively and qualitatively analyzed. As already introduced for the other 
conjugates, also in this case a lysosomal staining would be particularly relevant to describe 
the destiny of the peptides after internalization and different incubation times could be tested 
to outline a time-dependent uptake. Since we already described that the daunorubicin is not 
released as free drug, the metabolite formation after degradation in lysosomal homogenate 
could be analyzed. 
All in all, enhancement of cell penetration, absence of cytotoxicity and high potential for drug 
delivery could be actually gained. On the contrary, an improvement in the proteolytic stability 
have not been analyzed yet but it would be relevant to examine the influence of the cis and 
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trans DKP scaffold on the peptide stability against trypsin and in blood plasma and this would 
represent a very important point to be tested in the near future. 
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6. Material and Methods 
6.1. Materials 
6.1.1. Chemicals and consumables 
Unless otherwise stated, all reagents, solvents and consumables used were purchased from 
the companies Alfa Aesar (Karlsruhe, Germany), Greiner Bio-One (Kremsmünster, Austria), 
IRIS Biotech GmbH (Marktredwitz, Germany), LP Italiana SPA (Milano, Italy), Merck 
(Darmstadt, Germany), Roth (Karlsruhe, Germany), Ratiolab GmBH (Dreieich, Germany), 
Sigma-Aldrich (Taufkirchen, Germany), Sarstedt (Nümbrecht, Germany) and VWR BDH 
Prolabo (Darmstadt, Germany), and their purity fulfilled at least the specifications for synthesis 
quality. 
6.1.2. Media and solutions for cell culture 
Table 17. An overview about cell culture media and solutions used during the thesis and the correspondent 
producers. If not specified, the producer is referred to the medium/solution used at University of Cologne. 
Media and solutions Producer 
Medium for U87 cells University of Cologne 
Dulbecco's Modified Eagle's Medium (DMEM) complemented 
4500 mg/l glucose, Sigma Aldrich 
OOI 
Dulbecco's Modified Eagle's Medium (DMEM) complemented 
with 4500 mg/l glucose, Lonza (Basel, Switzerland) 
Medium for HT-29, 
MCF-7, HeLa and 
PANC-1 cells 
University of Cologne 
RPMI 1640 Medium, Sigma Aldrich 
OOI 
RPMI 1640 Medium, Lonza 
Medium for FACS RPMI 1145 Medium 
DMSO University of Cologne and OOI 
Sigma Aldrich 
Dulbecco’s Phosphate 
Buffered Saline (DPBS) 
1X 
University of Cologne 
Sigma 
OOI 
Lonza 
EtOH University of Cologne 
VWR 
OOI 
Molar Chemicals Kft. (Halásztelek, Hungary) 
FBS University of Cologne 
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Fetal Bovine Serum, sterile filtered, Sigma Aldrich 
OOI 
Biosera (Nuaillé, France) 
L-glutamine L-glutamine solution 7513, Sigma Aldrich 
Penicilline/Streptomycin OOI 
Lonza 
Trypsin-EDTA University of Cologne 
Trypsin-EDTA solution 3924, Sigma Aldrich  
OOI 
Trypsin 10X and EDTA: Lonza  
Trypsin-EDTA for FACS University of Cologne 
Trypsin-EDTA 1X in PBS, Biowest (Nuaillé, France) 
6.1.3. Equipment 
Table 18. An overview about the equipment used during the thesis and the correspondent producers. If not 
specified, the producer is referred to the instrument used at University of Cologne. 
Instrument Producer 
Balance Analytical balance: FA-210-4, Faust (Klettgau, Germany) 
CD spectrometer Jasco J-715 spectropolarimeter 
Cell culture clean bench University of Cologne 
Herasafe HS12, Thermo scientific (Waltham, Massachusetts, 
USA)  
OOI 
Holten Lamin Air HB2436 
Centrifuges University of Cologne 
Cell culture lab: Centrifuge 5417R, Eppendorf (Hamburg, 
Germany)  
Chemistry lab: Heraeus Multifuge X1R, Thermo Scientific  
OOI 
Heraeus Instruments Function Line Labofuge 400R, Thermo 
Scientific 
CO2-incubator University of Cologne 
CB Series, Binder (Tuttlingen, Germany)  
OOI 
MCO-17AIC, Sanyo (Osaka, Japan) 
Evaporator/ Concentrator XcelVap, Horizon Technology (Salem, New Hampshire, USA) 
Flow cytometer Guava® easyCyte, Merck  
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Haemocytometer Neubauer improved, superior Marienfeld (Lauda-Königshofen, 
Germany)  
Heating block Thermomixer compact, Eppendorf  
HPLC (analytical) Hewlett Packard Series 1100, Agilent (Waldbronn, Germany) 
Column: EC125/4.6 NUCLEODUR 100-5 C18ec, Macherey-
Nagel (Düren, Germany) (solvents incl. 0.1% trifluoroacetic 
acid) 
HPLC (preparative) University of Cologne 
Elite Lachrom, Hitachi (Chiyoda, Japan): Pump L-2130; 
Autosampler L-2200; Diode Array Detector L-2455 and  
Fraction Collector Foxy R1, Teledyne ISCO (Lincoln, Nebraska, 
USA) 
column:  
- VP250/16 NUCLEODUR 100-5 C18ec, Macherey-Nagel 
(preparative) 
- VP250/8 NUCLEODUR 100-5 C18ec, Macherey-Nagel (semi-
preparative) 
ELTE University 
KNAUER 2501 HPLC system (H.Knauer, Bad Homburg, 
Germany)  
column: Jupiter® 10 µm C18 300 Å, 250 x 10 mm, Phenomenex 
(Torrance, California, USA) 
LC-MS University of Cologne 
LC: 1100 Series and 1200 Series, Agilent (Santa Clara, 
California, USA) 
MS: LTQ-XL, Thermo Scientific  
column:  
- Chromolith®Performance RP-18e, 100–4.6 mm, Merck 
- Eclipse Plus C18, 3,5 µm, 4.6 x 100 mm, Agilent  
- EC 125/4.6 NUCLEODUR 100-5 C18ec, Macherey Nagel 
(solvents incl. 0.1% formic acid) 
ELTE University 
LC: Agilent 1100  
MS: Esquire 3000+ ion trap, Bruker Daltonics (Bremen, 
Germany) 
column: Supelco C18 (150 mm x 2.1 mm, 3µm) (Hesperia, 
California, USA) (solvents incl. 0.1% formic acid) 
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Lyophilizer Alpha 2-4 LDplus, Christ (Osterode am Harz, Germany)  
Magnetic stirrer VMS-C7, VWR Advanced 
Microscope University of Cologne 
Inverted microscope: AE31, Motic (Wetzlar, Germany) 
Confocal laser scanning system: D-Eclipse C1, Nikon (Tokyo, 
Japan) and SP8, Leica (Wetzlar, Germany), equipped with a 
60V oil-immersion objective. 
OOI 
Inverted microscope: CK2, Olympus (Shinjuku, Japan) 
Pipettes University of Cologne 
Eppendorf (Hamburg, Germany)  
ELTE University 
Finnpipette F2, Thermo Fisher Scientific (Waltham, 
Massachusetts, USA) 
Plate reader University of Cologne 
Infinite M200, Tecan (Männedorf, Switzerland)  
OOI 
Bio-Rad microplate reader model 550 
Robot for automated 
SPPS 
SyroI, MultiSynTech (Bochum, Germany) 
Rotary evaporator Labo Rota S300, Resona Technics 
Rotary shaker KL-2, Edmund Bühler GmbH (Bodelshausen, Germany) 
Speed-Vac Speedvac  Concentrator  Savant  SC210A and 
RVT5105 Refrigerated Vapor Trap VLP80 Vacuum Pump, 
Thermo Scientific 
Vacuum pump VWR 
Vortex Vortex Genie 2, Scientific industries (Bohemia, USA) 
Water bath SW22, Julabo (Seelbach, Germany) 
 
6.2. Methods 
6.2.1. Automated Solid Phase Peptide Synthesis 
The peptide synthesis was usually carried out on a polymeric, swellable but insoluble support 
material (resin) of divinylbenzene cross-linked polystyrene, modified with Fmoc-Rink amide 
aminomethyl for the anchoring of the first amino acid (Fmoc-Rink amide AM resin, 100-200 
mesh, 75-150 μm, loading 0.48 mmol/g). For the synthesis of the cyclic peptides a preloaded 
2-chlorotrytil chloride resin (H-L-Lys(Boc)-2CT, loading 0.74mmol/g) was used. In both cases, 
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the resin (15 μmol) was loaded in 2 ml propylene syringes, equipped with matching teflon frits. 
The automated synthesis was carried out using a multiple synthesizer robot according to the 
Fmoc/tBu strategy. All used amino acids (aa) were N-terminally Fmoc-protected, while the side 
chains of trifunctional aa were protected with orthogonal, acid labile groups. The following side 
chain protecting groups were used: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
(Pbf)for Arg; Trityl (Trt) for Asn, His, Gln and Pen; tert-Butyl (tBu) for Asp and Glu and tert-
butyloxycarbonyl (Boc) for Lys. For the selective deprotection of side chains also Fmoc-
Lys(Dde)-OH was used. During the automated synthesis, the resin was first pre-swollen for 10 
min in 800 µl of DMF, the solvent was then filtered off and afterwards the Fmoc protecting 
group on the resin was cleaved with 40% piperidine in DMF (400 µl, 3 min) and 20% piperidine 
in DMF (400 µl, 10 min), followed by 4 washing steps with 600 µl DMF each. The aa were 
dissolved to 0.4 M in DMF (Fmoc-Phe-OH: 0.4 M in NMP) and 300 µl (0.12 mmol) of the aa 
solution together with 50 µl (0.12 mmol) Oxyma (2.4 M in DMF) were pipetted to the resin and 
pre-incubated for 3 minutes. After addition of 50 µl (0.12 mmol) of DIC (2.4 M in DMF) the resin 
was left 40 min at rt, shaking occasionally. To improve the coupling yield, after a washing step 
with 800 µl DMF, the reaction was repeated once again (double coupling strategy) and finally 
washed twice with 800 µl of DMF. Consequently, the N-terminal Fmoc protecting group was 
cleaved as already described. All other aa were coupled analogously, with each cycle including 
a double coupling followed by Fmoc-cleavage. Finally, the resin was washed manually with 
DMF, DCM, MeOH and Et2O five times respectively and dried under reduced pressure in a 
vacuum concentrator for 10 min. 
6.2.2. Fmoc-cleavage 
The resin (15 µmol) was initially pre-swollen for at least 10 minutes in 1 ml of DMF. After 
removing the solvent, 500 μl of 30% piperidine in DMF were added and left 20 min shaking at 
rt; the procedure was repeated twice. The resin was then washed with DMF, DCM, MeOH and 
Et2O five times each and dried under reduced pressure in a vacuum concentrator. 
6.2.3. Manual coupling 
The resin (15 µmol) was initially pre-swollen for at least 10 minutes in 1 ml of DMF. Afterwards, 
the solvent was filtered off and the Fmoc-protected aa (45 μmol or 75 μmol) and Oxyma (45 
µmol or 75 μmol) were dissolved in 300 µl DMF. DIC (45 µmol or 75 μmol) was added to the 
mixture that was then loaded to the resin and left shaking at rt, overnight. Alternatively, the 
coupling was carried out with HATU (45 μmol) and DIPEA (45 μmol) for 2 h at rt. The resin 
was then washed with DMF, DCM, MeOH and Et2O five times each and dried under reduced 
pressure. To check the completeness of the coupling a Kaiser test was performed. Manual 
coupling was performed for particularly expensive aa and difficult couplings like for 
Fmoc-Lys(Dde)-OH, Fmoc-Propargylglycine-OH, Fmoc-Penicillamine(Trt)-OH, 
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Bis-Boc-aminooxyacetic acid, fluorophores like 5(6)-carboxyfluorescein (CF) and acid 
functionalized azido DKP scaffolds. 
6.2.4. Coupling of 5(6)-carboxyfluorescein (CF) and polymer cleavage 
The manual coupling was performed as already described. Particular care had to be taken to 
avoid the exposure to direct light and the reaction vessels were therefore precautionary 
covered with aluminium foil. After having verified by Kaiser test that the reaction was 
completed, a polymer cleavage was performed. The resin was swollen in 1 ml DMF for at least 
10 min, the solvent was filtered off and 1 ml of 20% piperidine in DMF was added to the resin 
and left shaking 45 min at rt. The resin was then washed as usual and dried. 
6.2.5. Kaiser test 
With the Kaiser test, any primary and secondary amine can be detected through a colorimetric 
reaction with ninhydrin, thus the completion of a coupling or deprotection reaction can be 
demonstrated. Some dry resin beads were transferred in a closable 1.5 ml tube and one drop 
of each of the following solutions was added in this order: 
- solution I: 1 g of ninhydrin in 20 ml of ethanol (absolute); 
- solution II: 80 g of phenol in 20 ml of ethanol (absolute); 
 - solution III: 0.4 ml of 1 mM aqueous KCN solution in 20 ml of pyridine. 
The reaction mixture was incubated for 5 min at 95 °C in a thermomixer. A blue color of the 
solution or the resin beads suggested the presence of amines, indicating the incompleteness 
of the coupling reaction (positive test). On the contrary, a yellow color implied the absence of 
free amino groups (negative test). Positive control was ethanolamine, as negative control only 
the solutions were added to the vial. 
6.2.6. Boc protection 
The resin (15 μmol) was first pre-swollen for at least 10 minutes in 1 ml DCM. After that, the 
solvent was filtered off and Boc2O (150 μmol) and DIPEA (15 μmol) were dissolved in 500 μl 
DCM, added to the resin and shaken for at least 2 h at rt. Particular attention had to be paid 
handling the Boc2O, since this substance is very dangerous. Scaling was performed under the 
hood to avoid inhalation of poisoning fumes. Subsequently, the resin was washed five times 
with DCM, MeOH and Et2O and then dried under reduced pressure. To check the 
completeness of the protection, a Kaiser test was carried out. 
6.2.7. Dde-cleavage 
The resin (15 μmol) was initially pre-swollen for at least 10 minutes in 1 ml of DMF. The solvent 
was removed and 1 ml of a hydrazine solution (2% in DMF) was added to the resin and shaken 
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for 10 min at rt. The solution was then filtered off while collecting the flow-through, the resin 
was washed twice with 1 ml of DMF and the reaction repeated at least ten times. The 
absorption at 301 nm of the collected solutions after the first and last cleavage were measured 
photometrically. The Dde cleavage was considered complete when the absorption of the first 
solution >1 and of the last solution was <0.1. If the cleavage after 10 repetitions was not 
complete, the hydrazine content was increased to 3% and the reaction repeated till completion. 
Subsequently, the resin was washed five times with DCM, MeOH and Et2O and then dried 
under reduced pressure. 
6.2.8. Sample cleavage 
To monitor the synthesis, in particular after critical steps, the peptide was cleaved from a small 
amount of resin with the simultaneous removal of all acid-labile protective groups. A small 
amount of dry resin beads were transferred into a 1.5 ml closable reaction tube; first 
scavengers (2.5 μl water, 2.5 μl TIS) and then 95 μl TFA were added. For peptides containing 
Pen, 7 μl thioanisole and 3 μl EDT were used instead and filled up with 90 μl TFA. The reaction 
was left 3h shaking at rt and then 1 ml of ice-cold, dried Et2O was added. For very short peptidic 
sequences a mixture of Et2O/n-hexane (3:1) was used. To complete the precipitation of the 
peptide, the reaction vessel was stored at -20 °C for at least 30 min. Afterwards, it was 
centrifuged (4 °C, 10000 g, 5 min), the supernatant was discarded and the pellet of the peptide 
washed at least five times with ice-cold Et2O. The pellet was dried under reduced pressure 
and the peptide was dissolved in 100 μl of H2O or H2O/t-BuOH (3:1) and centrifuged to allow 
the precipitation of the resin beads. For the LC-MS analysis 10 µl of the supernatant were 
diluted with 10 µl of the starting gradient ACN/H2O/0.1% FA. 
6.2.9.  Full cleavage 
To cleave the peptide from the resin with simultaneous removal of all acid labile protecting 
groups, first scavenger (25 μl water, 25 μl TIS) and then 950 μl of TFA were added to the dry 
resin directly in the reactor. In presence of thiol groups (Pen residue), a mixture of 
thioanisole/EDT/TFA (7:3:90) has been used instead, in order to avoid undesired oxidation. 
The solution was shaken for 3 h at rt and afterwards the reaction solution was filtered through 
the teflon frit from the syringe into a 15 ml centrifuge tube containing 10 ml of ice-cold, dry 
Et2O. Residual resin was washed with 200 μl of TFA and the solution was added to the Et2O 
too. For very short peptides instead of Et2O, a mixture of Et2O/n-hexane (3:1) was used. For 
complete precipitation of the peptide, the tube was stored at -20 °C for at least 30 min. Then, 
the solution was centrifuged off (4 °C, 5000 g, 5 min), the supernatant discarded and the 
peptide pellet washed at least five times with ice-cold Et2O by iterative resuspension and 
centrifugation. The pellet was dried under reduced pressure and then dissolved in 2-3 ml of 
H2O or H2O/t-BuOH (3:1). For LC-MS analysis, 5 μl of the solution were mixed with 15 μl 
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ACN/H2O/0.1% FA at different ratios according to the HPLC gradient used. As last step, the 
peptide was freeze-dried. 
6.2.10. Coupling of daunorubicin 
For the conjugation of daunorubicin to the peptide by oxime binding, a molecule of Bis-Boc 
aminooxyacetic acid was coupled to the side chain of a Lys (3 eq. with oxyma and DIC 
overnight). The success of the coupling was checked by Kaiser test. The cleavage from the 
resin occurred with the standard scavenger but, as already described by Mezö et al.44, 10 eq. 
of Boc-aminooxyacetic acid were added in the cleavage cocktail in order to avoid the formation 
of acetone adducts with a delta mass of +40. To circumvent the generation of formaldehyde 
adducts, glas tubes were preferably used to collect the pure fractions and for the washing 
steps. After precipitation, washing and purification, the peptide was freeze-dried and then 
dissolved in ammonium acetate buffer 0.2 M at pH 5 reaching a concentration of around 10 
mg peptide/ml or less. Daunorubicin was added in excess of about 30% and the reaction was 
stirred overnight. In order to remove unreacted daunorubicin, the reaction solution was directly 
injected into the HPLC on a semipreparative RP18 column. ACN/H2O with 0.1% TFA were 
used as eluents changing gradient as needed. The collected fractions were evaporated to 
remove the ACN, analyzed with LC-MS and lyophilized to obtain the purified peptides with 
purities >95%.  
6.2.11. Copper(I)-catalyzed azide alkyne cycloaddition (CuAAC) 
The c[DKPf3RGD]-PEG4-N3 or the azido functionalized GnRH-III were conjugated to the CPP 
by a copper (I) catalyzed azide-alkyne cycloaddition (“click” reaction) occurring between the 
azido group of the ligand and the alkyne group of the propargylglycine at the N-terminus of the 
CPP. In the case of the c[DKPf3RGD] conjugates,1.3 eq. of the azido compound were 
dissolved with 1 eq. of the alkyne-containing peptide in  a 1:1 mixture of dry DMF and degassed 
H2O in a Schlenk tube under N2 atmosphere reaching a concentration of 10mM. The same 
conditions were used also for the GnRH-III conjugates even if here the reaction was performed 
with an excess (1.3 eq.) of the alkyne-including compound. Stock solutions of CuSO4 and Na 
ascorbate in degassed H2O were prepared and 0.5 eq. and 0.6 eq. respectively were added 
to the reaction. The solution was stirred overnight under N2 atmosphere at 40 °C. The reaction 
was controlled by LC-MS till completion and then directly injected into the HPLC on a 
semipreparative RP18 column for purification obtaining final conjugates with purities >95%. 
6.2.12. Synthesis of compound V 
3-mercaptopropanoic acid (20.8 mg, 17 µl, 0.196 µmol, 1 eq.) and dithiopyridine (100 mg, 0.45 
µmol, 2.3 eq.) were dissolved in MeOH (1.2 ml, 0.2 mM) and the solution was stirred for 3 h at 
rt. After completion of the reaction, followed by HPLC, the solvent was removed by reduced 
pressure and the crude was purified by preparative RP-HPLC. The collected fractions were 
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analyzed by LC-MS and those corresponding to the pure product were freeze-dried. A 
transparent oil (26 mg, 0.14 µmol) was obtained with 62% yield and analyzed by LC-MS and 
NMR.  
6.2.13. Synthesis of compound VI 
Cry-55-gly (10.4 mg, 13.6 µmol, 1 eq.), compound V (11.7 mg, 54.5 µmol, 4 eq.), PyBOP (28 
mg, 54.5 µmol, 4 eq.) and HOBt•H2O (8.3 mg, 61.2 µmol, 4.5 eq.) were combined under inert 
atmosphere and dissolved in dry DMF (0.5 ml, 27 mM). As soon as all the reagents were 
dissolved, DIPEA was added (8.8 mg, 11.85 µl, 68 µmol, 5 eq.). The solution was stirred at rt 
and followed by HPLC; after 5 h the reaction was completed and directly purified by RP-HPLC. 
After freeze-drying, a white solid (9.2 mg, 9.6 µmol) was obtained with 70% yield. 
6.2.14. Synthesis of compound VII 
For the conjugation to the drug, the peptide (16.13 mg, 4.68 µmol, 1.5 eq.) was dissolved in 
dry DMF together with compound VI (3 mg, 3.12 µmol, 1 eq.). After overnight reaction under 
N2 atmosphere stirring at rt, the reaction was directly injected in the HPLC and purified. The 
peptide was freeze-dried from water obtaining a white solid (8.8 mg, 1.99 µmol, 64% yield). 
6.2.15. Azide reduction 
For the reduction of the azido group, the resin (15 µmol) was pre-swollen for at least 10 minutes 
in DCM and then treated with DTT (2M) in 500µL of DCM. Then, DIPEA (1 M, 87 µL) was 
added and the reaction was left shaking at rt for 2h. Afterwards, the solvent was removed and 
the resin was washed and dried. The success of the reaction was verified by Kaiser test or 
sample cleavage. 
6.2.16. Cyclization 
The synthesis followed the same steps as for the linear peptides. Since during the cyclization 
reaction the aa side chains have to be protected, the cleavage from the resin occurred in milder 
conditions. The resin was treated with a solution of DCM/TFE/AcOH (8:1:1) for 2 h at rt. The 
solution was then filtered and transferred to a flask and the resin was washed two more times 
with the same cleavage solution. The solvent was evaporated under reduced pressure and 
hexane was added to remove acetic acid as azeotrope. The crude was washed and digested 
with 5% NaHCO3, filtered and washed with ddH2O to remove all salts. After freeze-drying, the 
white solid product obtained was subjected to the next step of cyclization. 1 eq. of the fully 
protected linear peptide was dissolved in DMF (0.2 mM) and DIPEA was added till the solution 
reached pH 8 (around 12 eq.). Under these conditions, BOP (6 eq.) and HOBt (6 eq.) were 
added and the reaction was left under stirring at rt. After 6 hours, BOP was added again, the 
pH was adjusted with DIPEA (if necessary) and the reaction was left stirring overnight. For the 
treatment of the cyclization reaction, the mixture was diluted with EtOAc and extracted with 
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brine and saturated NaHCO3. The organic phase was then dried at reduced pressure, freeze-
dried and subjected to full cleavage. The crude was reacted with 1 ml of the cleavage cocktail 
K TFA/phenol/H2O/thioanisole/EDT (82.5:5:5:5:2.5) and treated as described before. After 
washing, the crude was freeze-dried, dissolved in ACN/H2O (10:90) with 0.1% TFA and purified 
on semipreparative RP-HPLC. The peptide was freeze-dried from water obtaining a white solid 
(22 to 36% yield). 
6.2.17. Synthesis of the cyclic peptide conjugated to daunorubicin 
Instead of the Bis-Boc aminooxyacetic acid as for the linear version, an isopropylidene 
protected aminooxyacetic acid was prepared by stirring for 30 minutes carboxymethoxylamine 
hemihydrochloride in acetone obtaining the protected product with quantitative yields. This was 
coupled manually to the peptide using 3 eq. of the reagent, 3 eq. Oxyma and 3 eq. DIC 
overnight. After the cyclization, deprotection of the aminooxyacetic acid was performed with a 
solution of 1 M methoxylamine containing NH4OAc-buffer (0.2 M, pH 5). To avoid undesired 
side reactions with carbonylic groups (acetone or formaldehyde), an excess of daunorubicin 
was added directly after completion of the deprotection and the purification was performed 
directly. A sample for the LC-MS analysis was taken and the fractions were immediately frozen. 
The conjugation to the drug occurred after freeze-drying as previously described. 
6.3. Peptide analysis 
All solvents and eluents used for the HPLC fulfilled the required purity with the specification 
“HPLC Gradient quality” or “LC-MS Quality”. 
6.3.1. Analytical HPLC-MS 
The characterization of the peptides during and at the end of the synthesis was carried out by 
means of reverse phase high-performance liquid chromatography electrospray ionization mass 
spectrometry (HPLC-ESI-MS). Samples were diluted with the starting gradient; the dilutions 
have been previously described for every synthetic step. The linear gradient used was typically 
10-60% B in A in 15 min with a flow rate of 0.6 ml / min (A: 0.1% FA in water, B: 0.1% FA in 
ACN). After chromatographic separation of the analytes from the column, the eluent was 
splitted into two parts (1:20). The main part was conducted to the UV detector for the 
measurement of UV absorbance at 220 or 195 nm; simultaneously the remaining part was 
ionized in the mass spectrometer and the m/z values of the pseudo-molecular ions were 
detected. Control of HPLC and ESI-MS systems as well as the evaluation of UV 
chromatograms and mass spectra were performed with the Software Xcalibur (Version 2.2, 
Thermo Scientific). Images of mass spectra were processed with Origin. The purity of the final 
compounds was determined by calculating the ratio of the product AUC to the total AUC in the 
UV-chromatogram. 
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6.3.2. Preparative HPLC 
The purification of the lyophilized peptides was carried out by preparative reverse phase HPLC. 
The lyophilized peptide (maximum 30 mg for the preparative column and 5 mg for the 
semipreparative) was dissolved in 960µl of starting gradient solution, typically H2O/ACN/TFA 
(90:10:0.1) but depending on the hydrophobicity of the peptide, vortexed and centrifuged. The 
supernatant was then transferred in a glass HPLC vial and 940 µl were automatically injected 
on the column. The elution was performed with a linear gradient, in general 10-60% B in A 
(A: 0.1% TFA in water, B: 0.08% TFA in ACN) in 45 min at a flow rate of 6 ml / min (preparative) 
or 1.5 ml/min (semipreparative). The UV absorbance was detected at 220 and 250 nm and the 
peptide containing fractions were collected in plastic tubes. Afterwards, the solution was 
concentrated using XcelVap or Speedvac for more sensitive products and then lyophilized. For 
LC-MS analysis, 2 μl of the solution were mixed with 18 μl ACN/H2O/0.1% FA at different ratio 
according to the HPLC gradient used. 
6.3.3. Circular dichroism spectroscopy 
CD spectra were recorded from 260 nm to 184 nm at 20°C using a Jasco J-715 
spectropolarimeter purged with N2 gas. For measuring CD spectra the peptides were dissolved 
to a final concentration of 20 μM. Peptide samples were diluted in 10 mM sodium phosphate 
buffer (pH 7) containing 0 or 50% (v/v) TFE. Each measurement was repeated 4 times using 
a sample cell with a path length of 0.1 cm. Instrument parameters were: response time 2 s, 
scan speed 50 nm/min, sensitivity 100 mdeg, step resolution 0.5 nm and bandwidth 1.0 nm. 
The background was removed by subtraction of the CD spectrum of the solvent. 
6.4. Biological methods 
6.4.1. Cell lines and cell culture conditions 
All the cell experiments were carried out under a laminar flow hood in sterile conditions. 
Pipettes and all consumable transferred under the hood were first autoclaved and then 
disinfected with 70% EtOH. Every working step was performed wearing a lab coat and 
disinfected gloves. Sterile Pasteur pipettes were directly connected to a vacuum pump in order 
to remove media during washing steps or by performing experiments. The temperature (37 °C) 
of the chemicals used was adjusted by a heating bath. The culturing of cells was carried out 
at 5% CO2 at 37 °C, using 100x20 mm Petri plates. The cell lines included in this work are 
listed in Table 19. 
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Table 19: Cell lines used during the thesis. 
Name Cell type 
HeLa human cervix carcinoma 
HT-29 human colon adenocarcinoma 
MCF-7 human breast adenocarcinoma 
PANC-1 human pancreas ductal adenocarcinoma 
U87 human glioma cells 
All the media for culturing the cells were supplemented with 10% FBS and adjusted with 
different contents of L-glutamine depending on the cell line (2mM for HT-29 and PANC-1 or 
4mM for U87, HeLa and MCF-7 cells). For the detachment of confluent cells culture medium 
was first removed and the cells were washed twice with DPBS. Afterwards, the cells were 
treated with 1 ml trypsin-EDTA solution for a few minutes depending on the cell line, at 37 °C. 
For U87 cells the treatment with trypsin was not necessary as this cell line was easily detached 
just by resuspending with medium. 9 ml of the appropriate culture medium with FBS were 
finally added and the cells were resuspended and completely detached. 10 µl of the cell 
suspension were taken, inserted into a counting chamber and the total number of cells was 
calculated. The desired amount of cells was subsequently diluted with fresh medium and 
transferred in new Petri plates or in 8-, 24- or 96-well plates where they could grow till reaching 
the desired confluence. 
6.4.2. Freezing and thawing cells 
To freeze the cells, after detaching them with 1 ml trypsin-EDTA solution and resuspending 
them in 9 ml of appropriate cell culture medium, they were transferred in 15 ml tubes and 
centrifuged at 1000 x g for 5 min at 4 °C. Subsequently, the cell pellet was resuspended in 1.5 
ml of freezing medium (appropriate full medium supplemented with 10% DMSO). The cell 
suspension was placed in a freezing vial and frozen in a mild, stepwise manner. The vial was 
stored inside a freezing container for 15 min at 4 °C and then for 2 h at -20 °C. The freezing 
vial was then stored overnight at -80 °C, before relocation in liquid nitrogen for long-term 
storage. 
Thawing of cells stored in liquid nitrogen was carried out by defreezing the vial at 37 °C and 
rapidly transferring it into a 15 ml tube containing 8.5 ml of the appropriate medium. After 
centrifugation, the supernatant was removed and the pellet resuspended in fresh medium. In 
this way, the DMSO could be almost completely discarded from the cell suspension and its 
toxicity could be circumvented. After 24 h at the latest the medium was exchanged to eliminate 
dead cells and the remaining DMSO. 
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6.4.3. Cell viability assays 
6.4.3.1. Resazurin-based cytotoxicity assay 
In order to test the influence of the peptides on cell viability, a resazurin-based cytotoxicity 
assay was performed. For the assay 96-well plates were used. First, a cell suspension with a 
defined concentration (HeLa: 4500 cells per well) was pipetted into the wells and filled up with 
full medium reaching a final volume of 200 μl. The next day, the culture medium was replaced 
by 100 μl of culture medium (without FBS) with a defined peptide concentration. Cells were 
incubated for 24 h with the peptide solution. After removing the solvent, 200 μl of fresh medium 
were added and the cell s were incubated for further 48h. Subsequently, the medium was 
removed, the cells washed with DPBS and then incubated with 10 μl resazurin in 90 μl medium 
(without FBS) for 1 h. As negative and positive controls untreated cells and cells treated 10 
min with 70% EtOH in H2O were used. The fluorometrical measurement was performed with a 
microplate reader at 596 nm with excitation at 550 nm.  
6.4.3.2. MTT-based cytotoxicity assay 
To investigate the antiproliferative activity of the conjugates on the human tumor cell lines U87, 
HT-29, MCF-7 and PANC-1, a MTT assay was performed. Cells were seeded in a 96-well plate 
(U87, HT-29 and MCF-7: 6000 cells per well, PANC-1: 8000 cells per well), grown for 24 h and 
incubated with various concentrations of the conjugate in appropriate serum-containing 
medium for 72 h or for 15 minutes, followed by medium removal and incubation with fresh 
medium for additional 72 h under standard growth conditions. The MTT assay was performed 
by adding 20 µL of MTT solution (5 mg/ml in DPBS) to each well and after 3 h of incubation at 
37°C, the supernatant was removed. The formazan crystals were dissolved in 100 µL of a 1:1 
solution of DMSO and EtOH and the absorbance was determined at 570 nm with a microplate 
reader. Background value (absorbance of DMSO:EtOH) was subtracted from the measured 
values and the percentage decrease in cell proliferation was determined relatively to untreated 
cells. 
6.4.4. Internalization studies 
6.4.4.1. Flow cytometry 
For uptake studies by flow cytometry, cells were seeded in a 24-well plate (Hela: 100000 cells 
per well, HT-29 and MCF-7: 120000 cells per well, U87: 150000 cells per well) and grown to 
70–80% confluency. After incubation at 37°C for 15, 30 or 60 min with the labeled peptides 
(CF or daunorubicin) in serum-free medium, the cells were washed twice with DPBS, detached 
with indicator-free trypsin and resuspended in indicator-free serum containing-RPMI medium. 
The cell suspension was transferred into a 96-well FACS plate and the fluorescence was then 
measured by a flow cytometer where 10000 viable cells were counted. Cellular 
autofluorescence was subtracted and the experiments were performed twice in triplicates. For 
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competition experiments the unfunctionalized c[DKP3RGD] ligand was added to the cells in 
10-fold excess together with the peptide. After 30 or 60 min incubation time the medium was 
removed and the cells were treated as described above. For blocking experiments the cells 
were pre-incubated with c[DKP3RGD] (10 µM), Poly-L-lysine or methyl-β-cyclodextrin (1mM) 
for 30 min followed by peptide incubation for 30 min. 
6.4.4.2. Confocal laser scanning microscopy 
For confocal microscopy uptake studies, cells were seeded in an eight-well (Ibidi) plate (U87: 
70000 cells per well; HT-29 and MCF-7: 50000 cells per well, HeLa:30000 cells per well) and 
grown to 70–80% confluency. The next day the cells were incubated with CF- or daunorubicin-
labeled peptides in serum-free medium for 30 min at 37 °C. The nuclei were stained for 10 min 
with Hoechst33342 nuclear dye (bisbenzimide  H33342, 1 mg/mL in H2O, sterile  filtered) prior 
to the end of peptide incubation. Finally, the solution was removed and cells were treated with 
200 µL trypan blue solution (150 mM in 0.1 M acetate buffer, pH 4.15) for 15 s. After washing 
once with serum-free medium and adding fresh, appropriate serum-containing medium, 
images were taken by using a Nikon Eclipse Ti or a Leica SP8 confocal laser scanning 
microscope. Images were recorded with Nikon EZ-C1 3.91 and Leica Mycrosystems software 
and adjusted with ImageJ 1.43 m and Fiji software. 
6.4.5. Integrin expression on cell surface 
Three million cells were counted for every cell line, then centrifuged in 15 ml tubes at 1000 rpm 
for 5 min at 4 °C; afterwards the supernatant was removed. To fix the cells 300 µl of 4% PFA 
were added to the pellet, which was then resuspended and left 10 minutes at rt. Afterwards, 2 
ml of DPBS were added, the 15 ml tubes vortexed and centrifuged at 1000 rpm, 5 min at 4 °C. 
The supernatant was discarded and 3 ml DPBS were added to the 15 ml tubes. The solution 
was again resuspended and divided into 3 FACS tubes (one as control and two for the 
treatment with antibody). The antibody used was an anti-integrin αvβ3 Ab clone LM609 
purchased from Merck Millipore. After addition of 2 ml of PBS to each tube, centrifugation 
followed with the same conditions as before and supernatant was removed. 50 µl of 3% BSA 
in PBS were added to each tube to block non-specific binding sites. The solution was left 10 
min at rt and moved from time to time. After this blocking step, 50 µl of antibody mixture (dilution 
1:25; 2µl antibody, 23µl DPBS and 25µl 3% BSA) were added to each FACS tube, incubated 
for 60 minutes at 37 °C and moved from time to time. After this incubation time, cells were 
washed by adding 2ml of DPBS. Centrifugation was performed, the supernatant removed and 
the pellet was then dissolved in FACS medium to proceed with the quantification of the 
fluorescence intensity.  
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6.4.6. Solid-phase integrin binding assay 
Human integrin receptors αvβ3 (R&D Systems, Minneapolis, MN, USA) and αvβ5 (EMD Millipore 
Corporation, Inc., Temecula, CA, USA) were diluted to 0.5 µg/mL in coating buffer containing 
20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MnCl2, 2 mM CaCl2, and 1 mM MgCl2. An 
aliquot of diluted receptor (100 µL/well) was added to 96-well plates (Nunc MaxiSorp, Termo 
Fisher Scientific, Roskilde, DK) and incubated overnight at 4 °C. The plates were incubated 
with blocking solution (coating buffer plus 1% BSA) for additional 2 h at rt to block nonspecific 
binding. After washing 2 times with blocking solution, plates were incubated shaking in the 
dark for 3 h at rt, with various concentrations (10-5–10-12 M) of test compounds in the presence 
of 1 µg/mL vitronectin (Molecular Innovations, Novi, MI, USA) biotinylated using an EZ-Link 
Sulfo-NHS-Biotinylation kit (Pierce, Rockford, IL, USA). After washing 3 times, the plates were 
incubated shaking for 1 h in the dark, at rt, with streptavidin-biotinylated peroxidase complex 
(Amersham Biosciences, Uppsala, Sweden). After washing 3 times with blocking solution, 
plates were incubated with 100 µL/well of Substrate Reagent Solution (R&D Systems, 
Minneapolis, MN, USA) for 30 min shaking in the dark, before stopping the reaction with the 
addition of 50 µL/well 2N H2SO4. Absorbance at 415 nm was read in a SynergyTM HT Multi-
Detection Microplate Reader (BioTek Instruments, Inc.). Each data point represents the 
average of triplicate wells; data analysis was carried out by nonlinear regression analysis with 
GraphPad Prism software. Each experiment was repeated in duplicate. 
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8.  Attachment 
8.1. List of abbreviations 
ACN acetonitrile 
AcOH acetic acid 
ADC antibody-drug conjugate 
Aoa aminooxyacetic acid 
Aoa=X aminooxyacetic acid conjugated via oxyme bond to X 
AUC area under the curve 
BBB blood-brain barrier 
Boc tert-butyloxycarbonyl 
Boc2O di-tert-butyl dicarbonate 
BOP (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium 
hexafluorophosphate 
BSA bovine serum albumin 
Bu butyryl 
Cbl chlorambucil 
CD circular dichroism 
CF 5(6)-carboxyfluorescein 
CLSM confocal laser scanning microscopy 
CPP cell-penetrating peptide 
Cry cryptophycin 
CuAAC copper-catalyzed azide-alkyne cycloaddition 
Dau daunorubicin 
ddH2O double distilled water 
DCM dichloromethane 
Dde 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl 
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DIC N,N-diisopropylcarbodiimide 
DIPEA N,N-diisopropylethylamine 
DKP diketopiperazine 
DMEM Dulbecco´s modified Eagle Medium 
DMF N,N-dimethylformamide 
DMSO dimethyl sulfoxide 
DPBS Dulbecco's Phosphate-Buffered Saline 
DTT dithiothreitol 
EC50 half maximal effective concentration 
ECM extracellular matrix 
EDT 1,2-ethanedithiol 
EDTA ethylenediaminetetraacetic acid 
ELTE Eötvös Loránd University (Budapest) 
eq. equivalent 
ESI-MS electrospray ionization mass spectrometry 
Et2O diethyl ether 
EtOAc ethyl acetate 
EtOH ethanol 
FA formic acid 
FACS Fluorescence Activated Cell Sorting 
FDA Food and Drug Administration 
FBS Fetal Bovine Serum 
FITC fluorescein isothiocyanate 
Fmoc 9-fluorenylmethyloxycarbonyl 
GnRH Gonadotropin Releasing Hormone 
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GnRH-R Gonadotropin Releasing Hormone receptor 
HATU O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
hexafluorophosphate 
HeLa human cervical carcinoma cell line 
HOBt hydroxybenzotriazole 
Hoechst bisBenzimide H 33342 trihydrochloride 
HPLC high performance liquid chromatography 
HT-29 human colon cancer cell line 
IC50 half maximal inhibitory concentration 
KCN potassium cyanide 
KO Knock-Out 
LC-MS liquid chromatography–mass spectrometry  
m/z mass-to-charge ratio 
mβ-cd methyl-β-cyclodextrin 
mAb monoclonal antibody 
MCF-7 human breast adenocarcinoma cell line 
MDR multi-drug resistant 
MeOH methanol 
MIDAS metal ion-dependent adhesion site 
MMP-2 metalloproteinase 2 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MW molecular weight 
NMP N-Methyl-2-pyrrolidone 
NMR nuclear magnetic resonance 
OOI National Institute of Oncology (Budapest) 
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PANC-1 human pancreatic cancer cell line 
PBS Phosphate-Buffered Saline 
PEG polyethylene glycol 
PFA paraformaldehyde 
PLL Poly-L-Lysine 
PyBOP benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
RP reversed phase 
RPMI 1640 Roswell Park Memorial Institute, cell culture medium 
rt room temperature 
SAR structure activity relationship 
SD standard deviation 
SMDC small molecule-drug conjugate 
SPPS solid phase peptide synthesis  
t-Bu tert-butyl 
t-BuOH tert-butyl alcohol 
TFA trifluoroacetic acid 
TFE trifluoroethanol 
TIS triisopropylsilane 
U87 human primary glioblastoma cell line 
v/v volume per volume 
VEGFR vascular endothelial growth factor receptor 
 
amino acids   
<E Glp pyroglutamic acid 
βAla  β-alanine 
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A  Ala alanine 
B  Pra propargylglycine 
D  Asp aspartic acid 
E  Glu glutamic acid 
F  Phe phenylalanine 
f D-Phe D-phenylalanine 
G  Gly glycine 
H  His histidine 
I  Ile isoleucine 
K  Lys lysine 
K(Bu)   Lys(Bu) butyrilated lysine 
L  Leu leucine 
N  Asn asparagine 
P  Pro proline 
Pen  penicillamine 
Q  Gln glutamine 
R  Arg arginine 
S  Ser serine 
V  Val valine 
Y  Tyr tyrosine 
W  Trp tryptophan 
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8.2. Attachment of supplementary data: spectra, chromatograms and 
figures 
 
 
Figure 57. LC-MS analysis of peptide GnRH-III-sC18(Dau); MW calculated: 4143.8 g/mol. Purity: 93%. UV 
chromatogram (194 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA 
in H2O; B: 0.1% FA in ACN. Red asterisks: peaks corresponding to the product without daunosamine after mass 
fragmentation. 
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Figure 58. LC-MS analysis of peptide GnRH-III-sC18(GFLG-Dau); MW calculated: 4518.2 g/mol. Purity: 95%. 
UV chromatogram (194 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% 
FA in H2O; B: 0.1% FA in ACN. Blue asterisks: peaks corresponding to the TFA adducts (delta mass +114); red 
asterisks: peaks corresponding to the product without daunosamine after mass fragmentation. 
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Figure 59. LC-MS analysis of peptide 1; MW calculated: 2998.2 g/mol. Purity: >99%. UV chromatogram (220 nm) 
and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% TFA in H2O; B: 0.1% TFA in 
ACN. Blue asterisks: peaks corresponding to the TFA adducts (delta mass +114); green asterisk: peaks 
corresponding to the TFA adducts (delta mass +228). 
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Figure 60. LC-MS analysis of peptide 1a; MW calculated: 3355.9 g/mol. Purity: >99%. UV chromatogram 
(220 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% TFA in H2O; B: 0.1% 
TFA in ACN.  
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Figure 61. LC-MS analysis of peptide 1b; MW calculated: 3580.1 g/mol. Purity: 95%. UV chromatogram (194 nm) 
and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% FA in 
ACN. Red asterisks: peaks corresponding to the product without daunosamine after mass fragmentation. 
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Figure 62. LC-MS analysis of peptide 1c; MW calculated: 3954.6 g/mol. Purity: >99%. UV chromatogram 
(194 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% 
FA in ACN. Red asterisks: peaks corresponding to the product without daunosamine after mass fragmentation. 
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Figure 63. LC-MS analysis of peptide 2a; MW calculated: 2427.9 g/mol. Purity: >99%. UV chromatogram 
(254 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% 
FA in ACN. Blue asterisks: peaks corresponding to the TFA adducts (delta mass +114). 
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Figure 64. LC-MS analysis of peptide 2b; MW calculated: 2652.2 g/mol. Purity: 97%. UV chromatogram (254 nm) 
and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% FA in 
ACN. Red asterisks: peaks corresponding to the product without daunosamine after mass fragmentation. 
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Figure 65. LC-MS analysis of peptide 2c; MW calculated: 3026.7 g/mol. Purity: >99%. UV chromatogram 
(254 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% 
FA in ACN. Red asterisks: peaks corresponding to the product without daunosamine after mass fragmentation. 
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Figure 66. LC-MS analysis of peptide 3b; MW calculated: 1584.2 g/mol. Purity: 95%. UV chromatogram (254 nm) 
and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% FA in 
ACN. Red asterisks: peaks corresponding to the product without daunosamine after mass fragmentation. 
 Attachment 
126 
 
 
Figure 67. LC-MS analysis of peptide 3c; MW calculated: 1587.4 g/mol. Purity: 98%. UV chromatogram (254 nm) 
and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% FA in 
ACN. Red asterisks: peaks corresponding to the product without daunosamine after mass fragmentation. 
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Figure 68. LC-MS analysis of peptide Cbl-sC18; MW calculated: 2356.8 g/mol. Purity: 91%. UV chromatogram 
(220 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% TFA in H2O; B: 0.1% 
TFA in ACN. Yellow asterisks: peaks corresponding to the hydrolysed product. The first peak is DMSO since the 
compound was dissolved in DMSO to avoid hydrolysis.  
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Figure 69. LC-MS analysis of peptide c[DKPf3RGD]-sC18(Cbl); MW calculated: 3296.5 g/mol. Purity: 86%. UV 
chromatogram (220 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA 
in H2O; B: 0.1% FA in ACN. Yellow asterisk: peaks corresponding to the hydrolysed product; blue asterisks: peaks 
corresponding to the TFA adducts (delta mass +114). The first peak is DMSO since the compound was dissolved 
in DMSO to avoid hydrolysis.  
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Figure 70. LC-MS analysis of peptide c[DKPf3RGD]-sC18-S-S-Cry; MW calculated: 4048.3 g/mol. Purity: 95%. 
Ion current and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% 
FA in ACN.  
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Figure 71. LC-MS analysis of peptide sC18-S-S-Cry; MW calculated: 3121.7 g/mol. Purity: 97%. UV 
chromatogram (220 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA 
in H2O; B: 0.1% FA in ACN.  
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Figure 72. LC-MS analysis of peptide c[DKPf3RGD]-PEG4-N3; MW calculated: 889.6 g/mol. Purity: >99%. UV 
chromatogram (220 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% TFA 
in H2O; B: 0.1% TFA in ACN.  
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Figure 73. LC-MS analysis of peptide I; MW calculated: 2690.2 g/mol. Purity: 98%. UV chromatogram (220 nm) 
and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% FA in 
ACN. Red asterisks: peaks corresponding to the product without daunosamine after mass fragmentation. 
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Figure 74. LC-MS analysis of peptide II; MW calculated: 3064.7 g/mol. Purity: 95%. UV chromatogram (220 nm) 
and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% FA in 
ACN. Red asterisks: peaks corresponding to the product without daunosamine after mass fragmentation. 
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Figure 75. LC-MS analysis of peptide III (R=H); MW calculated: 2107.6 g/mol. Purity: >99%. UV chromatogram 
(254 nm) and ESI-MS mass spectrum. Gradient: 5-55% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% 
FA in ACN. Blue asterisks: peaks corresponding to the TFA adducts (delta mass +114).  
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Figure 76. LC-MS analysis of peptide III (R=CF); MW calculated: 2466.0 g/mol. Purity: >99%. UV chromatogram 
(220 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% 
FA in ACN.  
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Figure 77. LC-MS analysis of peptide IV; MW calculated: 2309.92 g/mol. Purity: 95%. Ion current and ESI-MS 
mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% FA in ACN. Blue 
asterisks: peaks corresponding to the TFA adducts (delta mass +114); green asterisk: peak corresponding to the 
TFA adducts (delta mass +228). 
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Figure 78. LC-MS analysis of peptide V; MW calculated: 215.29 g/mol. Purity: >99%. UV chromatogram (220 nm) 
and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% FA in 
ACN.  
 
 
1H NMR (300 MHz, DMSO) δ 8.49 – 8.43 (m, 1H, H6), 7.86 – 7.79 (m, 1H, H4), 7.76 (d, J = 8.1 Hz, 1H, H3), 7.25 
(ddd, J = 7.1, 4.8, 1.2 Hz, 1H, H5), 3.00 (t, J = 6.9 Hz, 2H, H2), 2.63 (t, J = 6.9 Hz, 2H, H1) 
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Figure 79. LC-MS analysis of peptide VI; MW calculated: 959.0 g/mol. Purity: >99%. UV chromatogram (220 nm) 
and ESI-MS mass spectrum. Gradient: 50-90% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% FA in 
ACN.  
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Figure 80. LC-MS analysis of peptide VII; MW calculated: 3158.8 g/mol. Purity: 95%. UV chromatogram (220 nm) 
and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% FA in 
ACN.  
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Figure 81. LC-MS analysis of peptide cyc-DKP3; MW calculated: 1827.3 g/mol. Purity: >99%. UV chromatogram 
(220 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% TFA in H2O; B: 0.1% 
TFA in ACN.  
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Figure 82. LC-MS analysis of peptide cyc-DKP1; MW calculated: 1827.3 g/mol. Purity: 99%. UV chromatogram 
(194 nm) and ESI-MS mass spectrum. Gradient: 5-55% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% 
FA in ACN.  
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Figure 83. LC-MS analysis of peptide lin-DKP3; MW calculated: 1845.3 g/mol. Purity: 99%. UV chromatogram 
(220 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% TFA in H2O; B: 0.1% 
TFA in ACN.  
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Figure 84. LC-MS analysis of peptide lin-DKP1; MW calculated: 1845.3 g/mol. Purity: 97%. UV chromatogram 
(220 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% TFA in H2O; B: 0.1% 
TFA in ACN.  
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Figure 85. LC-MS analysis of peptide cyc-DKP3(Dau); MW calculated: 2409.8 g/mol. Purity: >99%. UV 
chromatogram (254 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA 
in H2O; B: 0.1% FA in ACN. Red asterisks: peaks corresponding to the product without daunosamine after mass 
fragmentation. 
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Figure 86. LC-MS analysis of peptide sC18*(Dau); MW calculated: 2154.5 g/mol. Purity: >99%. UV 
chromatogram (254 nm) and ESI-MS mass spectrum. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA 
in H2O; B: 0.1% FA in ACN. Red asterisks: peaks corresponding to the product without daunosamine after mass 
fragmentation. 
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Figure 87. UV-chromatogram (194 nm) of 1a and 1b to compare the respective retention time. Gradient: 10-
60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 0.1% FA in ACN. 
 
Figure 88. UV-chromatogram (254 nm) of sC18(Dau), namely 2b, and sC18(GFLG-Dau), namely 2c, to 
compare the respective retention time. Gradient: 10-60% B in A in 15 min, 0.6 ml/min. A: 0.1% FA in H2O; B: 
0.1% FA in ACN.  
 
 Attachment 
147 
 
Table 20. Yields obtained after the CuAAC reaction between the differently labeled CPP sequence and the 
ligands GnRH-III-N3 and c[DKPf3RGD]-PEG4-N3. 
Compound Yield of “click” reaction (%) 
GnRH-III-sC18 41 
GnRH-III-sC18(Dau) 79 
GnRH-III-sC18(GFLG-Dau) 91 
c[DKPf3RGD]-sC18-S-S-Cry 4 
1 30 
1a 90 
1b 85 
1c 75 
 
 
 
Figure 89. Effect of 1 and 2 on the cell viability measured by resazurin-based assay on U87 and MCF-7 cells. 
Evaluation of the resorufin fluorescence generated from resazurin by viable cells after 24h incubation with the 
peptide solution. Untreated cells were used as negative control and set to 100%; positive control was represented 
by cells treated for 10 minutes with 70% EtOH and it was subtracted from the other values. The experiment was 
performed in triplicate with n=2. 
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Figure 90. Plasma stability investigation. Compound 2 was dissolved in water to a concentration of 300 pmol/µl 
and then diluted with plasma (final conjugate concentration: 30 pmol/µl). The mixture was incubated at 37 °C for 
24 h. Samples of 100 µl were taken at time points of 0 min, 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 24 h. After addition of 
ACN, the solutions were centrifuged using a membrane with a nominal molecular weight limit of 10 kDa and 
afterwards monitored by RP-HPLC. 
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